2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T91b,Acne vulgaris is a common dermatological condition among young adults. It can cause psychosocial consequences that go beyond its physical effects. This study aims to assess acne prevalence and its impact on quality of life, social appearance anxiety, and treatment practices among university students in northern Bangladesh. A cross-sectional survey was conducted among 1067 students to assess acne prevalence and severity (Global Acne Grading System, GAGS). Quality of life, social appearance anxiety, and psychological distress were measured using the Dermatology Life Quality Index (DLQI), Social Appearance Anxiety Scale (SAAS), and Hospital Anxiety and Depression Scale (HADS). Sociodemographic, lifestyle, and familial factors were also evaluated. Descriptive statistics, chi-square tests, and binary logistic regression were used to identify significant associations and predictors. Acne was reported by 47.6% of participants. Among those affected (n = 465), 47.96% had mild acne, 44.95% had moderate acne, 6.02% had severe acne, and 1.08% had very severe acne. Increasing acne severity was significantly associated with poorer quality of life (p < 0.001) and higher social appearance anxiety (p = 0.013). Logistic regression identified several independent predictors of acne, including gender (p = 0.008), residence (p ≤ 0.033), middle-income status (p = 0.040), belief that diet affects acne (p < 0.001), smoking (p = 0.023), alcohol consumption (p = 0.001), and family history of acne (p < 0.001). Higher DLQI scores were also significantly associated with acne (p = 0.002), whereas SAAS and HADS were not independently associated. Among affected individuals, 33.7% consulted a dermatologist, while others relied on self-medication (29.9%), home remedies (30.8%), or combined approaches (23.7%). Acne vulgaris is highly prevalent among young adults in northern Bangladesh and substantially impacts quality of life and social appearance. Its development involves a multifactorial interplay of genetic, lifestyle, and psychosocial factors, emphasizing the need for evidence-based management, lifestyle interventions, and psychosocial support in student health programs. Future research should examine causal pathways and guide comprehensive prevention and treatment strategies.31:Tf8c,ABSTRACT Background Acne vulgaris is a common dermatological condition among young adults. It can cause psychosocial consequences that go beyond its physical effects. Aims This study aims to assess acne prevalence and its impact on quality of life, social appearance anxiety, and treatment practices among university students in northern Bangladesh. Methods A cross‐sectional survey was conducted among 1067 students to assess acne prevalence and severity (Global Acne Grading System, GAGS). Quality of life, social appearance anxiety, and psychological distress were measured using the Dermatology Life Quality Index (DLQI), Social Appearance Anxiety Scale (SAAS), and Hospital Anxiety and Depression Scale (HADS). Sociodemographic, lifestyle, and familial factors were also evaluated. Descriptive statistics, chi‐square tests, and binary logistic regression were used to identify significant associations and predictors. Results Acne was reported by 47.6% of participants. Among those affected ( n = 465), 47.96% had mild acne, 44.95% had moderate acne, 6.02% had severe acne, and 1.08% had very severe acne. Increasing acne severity was significantly associated with poorer quality of life ( p < 0.001) and higher social appearance anxiety ( p = 0.013). Logistic regression identified several independent predictors of acne, including gender ( p = 0.008), residence ( p ≤ 0.033), middle‐income status ( p = 0.040), belief that diet affects acne ( p < 0.001), smoking ( p = 0.023), alcohol consumption ( p = 0.001), and family history of acne ( p < 0.001). Higher DLQI scores were also significantly associated with acne ( p = 0.002), whereas SAAS and HADS were not independently associated. Among affected individuals, 33.7% consulted a dermatologist, while others relied on self‐medication (29.9%), home remedies (30.8%), or combined approaches (23.7%). Conclusions Acne vulgaris is highly prevalent among young adults in northern Bangladesh and substantially impacts quality of life and social appearance. Its development involves a multifactorial interplay of genetic, lifestyle, and psychosocial factors, emphasizing the need for evidence‐based management, lifestyle interventions, and psychosocial support in student health programs. Future research should examine causal pathways and guide comprehensive prevention and treatment strategies. 32:T54f,Patients treated with a 1726-nm laser showed significant improvement in moderate-to-severe acne for ≥6 months in a prospective study. One-year follow-up data are presented. In this prospective institutional review board-approved study, patients underwent 3 treatments with a 1726-nm laser, 2-5 weeks apart. Inflammatory lesion counts (ILC) and Investigator's Global Assessment (IGA) scores were assessed at baseline, 3 months, and 1 year after treatment. Adverse events, treatment satisfaction, and self-confidence were assessed. Of 104 patients with Fitzpatrick skin types II-VI and moderate-to-severe acne, 89 and 71 patients, respectively, attended 12- and 52-week visits. At 12 weeks, 79.8% demonstrated ≥50% improvement in ILC, which increased to 91.5% at 52 weeks. The proportion of patients with clear or almost clear IGA scores increased from 36.0% at 3 months to 66.2% at 52 weeks. Treatment was well tolerated: Mild erythema and edema occurred in 100% and 98.1% of patients, respectively. No blistering, crusting, or hypo- or hyperpigmentation were observed. Patient satisfaction and self-confidence improved at both follow-up timepoints. No control group; reliance on image assessment; open-label design. The seboselective 1726-nm laser is an effective and well-tolerated therapy for reducing moderate-to-severe facial acne for at least 1 year.33:T598,Dapsone (4,4'-Diamino diphenyl sulfone) has been utilized in managing a wide variety of mucocutaneous conditions, usually as a systemic product. Topical dapsone is commercially available as 5% and 7.5% gel and is FDA-approved for acne vulgaris. These topical formulations have shown less systemic absorption and fewer adverse events. Considering this, topical dapsone might benefit localized disease, immunosuppressed individuals, and those who avoid exposure to systemic therapies. Following PRISMA guidelines, a comprehensive literature search was conducted across PubMed, Web of Science, and Scopus databases for published papers up to April 2025. Then, eligible studies are included, and we summarize the findings of different clinical studies concerning the use, efficacy, and side effects of topical dapsone in various mucocutaneous conditions, excluding acne vulgaris. Finally, 56 articles were selected based on the eligibility criteria. We summarized and categorized them into two general entities, including applications of the topical dapsone and side effects of the topical dapsone. The first entity has six subheadings consisting of acne vulgaris and acneiform eruptions, Rosacea, neutrophilic dermatosis, vesiculobullous diseases, vasculitis, and others. In conclusion, topical dapsone appears to have therapeutic advantages in several mucocutaneous conditions, especially in minimal, localized, and chronic eruptions.34:T6da,ABSTRACTBackgroundDapsone (4,4′‐Diamino diphenyl sulfone) has been utilized in managing a wide variety of mucocutaneous conditions, usually as a systemic product. Topical dapsone is commercially available as 5% and 7.5% gel and is FDA‐approved for acne vulgaris. These topical formulations have shown less systemic absorption and fewer adverse events. Considering this, topical dapsone might benefit localized disease, immunosuppressed individuals, and those who avoid exposure to systemic therapies.MethodsFollowing PRISMA guidelines, a comprehensive literature search was conducted across PubMed, Web of Science, and Scopus databases for published papers up to April 2025. Then, eligible studies are included, and we summarize the findings of different clinical studies concerning the use, efficacy, and side effects of topical dapsone in various mucocutaneous conditions, excluding acne vulgaris.ResultsFinally, 56 articles were selected based on the eligibility criteria. We summarized and categorized them into two general entities, including applications of the topical dapsone and side effects of the topical dapsone. The first entity has six subheadings consisting of acne vulgaris and acneiform eruptions, Rosacea, neutrophilic dermatosis, vesiculobullous diseases, vasculitis, and others.ConclusionIn conclusion, topical dapsone appears to have therapeutic advantages in several mucocutaneous conditions, especially in minimal, localized, and chronic eruptions.35:T719,Acne pathogenesis is multifactorial, involving systemic factors including gut dysbiosis, hormones, and chronic inflammation. Probiotics, myoinositol, and plant-derived molecules may modulate acne by targeting these factors. The objective is to compare a synbiotic containing herbs against a myoinositol-based herbal supplement on how they influence acne, the gut microbiome, short chain fatty acids (SCFAs), and hormonal profiles. This was an 8-week, randomized study involving 36 male and female patients aged 12 to 45 years with non-cystic acne. Subjects received either a synbiotic or a myoinositol-based herbal supplement (MBHS). Acne lesions were counted, stool samples were collected for gut microbiome and SCFA analyses, and hormone collections were performed at baseline, 4, and 8 weeks. Several gut bacteria increased by at least threefold at both week 4 and 8 in the synbiotic (Erysipelatoclostridium merdavium, Blautia argi, Faecalibacterium prausnitzii, Prevotella copri, Streptococcus sp001556435, Blautia sp900541955) and MBHS group (Megamonas funiformis, Ligilactobacillus ruminis, Prevotella ssp015074785, Prevotella copri, Gca-900199835 sp900176495). Acne lesion counts decreased significantly in both groups at week 4 (p < 0.0001) and week 8 (synbiotic, p < 0.0001; MBHS, p < 0.0001). There were significant and trending increases in stool and plasma SCFAs in both cohorts at week 4 and 8. After 8 weeks of MBHS, 17-OHP and androstenedione significantly decreased from 27.3 to 11.3 pg/ml (p = 0.001) and 94.9 to 68.0 pg/ml (p = 0.04), respectively. Both the synbiotic and MBHS improved gut health, augmented SCFAs, and reduced lesion counts in those with non-cystic acne. The MBHS may act by reducing hormone levels of 17-OHP and androstenedione. www. gov (NCT05919810).36:T48e,A total of 19 907 patients (mean [SD] age, 20.6 [7.8] years; 10 504 females [52.8%]) were included, among whom 4482 (22.5%) had acne relapse and 1639 (8.2%) had isotretinoin retrial. Female sex (hazard ratio [HR], 1.43; 95% CI, 1.35-1.52) was significantly associated with increased rates of acne relapse, and isotretinoin cumulative dosage (mg/kg) was associated with a decreased rate of acne relapse (HR, 0.996; 95% CI, 0.995-0.997). Furthermore, daily dose was not associated with decreased risk of acne relapse or isotretinoin retrial among those with conventional and high cumulative dosages. Female sex (HR, 0.68; 95% CI, 0.62-0.76) and isotretinoin cumulative dosage (HR, 0.99; 95% CI, 0.98-0.99) were associated with decreased rates of isotretinoin retrial. Stratification by cumulative dosage indicated that higher cumulative dosage was associated with decreased rates of retrial among patients with low (<120 mg/kg) and conventional (120-220 mg/kg), but not high (>220 mg/kg) cumulative dosage. Maximum daily dose (mg/kg/d) was not negatively associated with acne relapse or isotretinoin retrial in patients with cumulative dosage of 120 mg/kg or more.37:T9da,Isotretinoin is the only medical acne treatment capable of inducing acne remission; however, some patients experience acne relapse and require retrials of isotretinoin. There is a need to understand who is most at risk and how daily dose and cumulative dosage can influence outcomes. To assess rates of acne relapse and isotretinoin retrial and to identify associated factors among patients with acne who received an isotretinoin treatment course. This cohort study used data from the MarketScan commercial claims database from January 1, 2017, to December 31, 2020, to identify patients with acne who were 12 years or older and had received isotretinoin for 4 months or longer, with at least 1 year of continuous enrollment after completion of isotretinoin. Data analyses were performed from June 30, 2024, to August 1, 2024. Multivariable Cox proportional hazards regression was used to quantify associations of patient demographic and treatment characteristics with acne relapse and isotretinoin retrial. A total of 19 907 patients (mean [SD] age, 20.6 [7.8] years; 10 504 females [52.8%]) were included, among whom 4482 (22.5%) had acne relapse and 1639 (8.2%) had isotretinoin retrial. Female sex (hazard ratio [HR], 1.43; 95% CI, 1.35-1.52) was significantly associated with increased rates of acne relapse, and isotretinoin cumulative dosage (mg/kg) was associated with a decreased rate of acne relapse (HR, 0.996; 95% CI, 0.995-0.997). Furthermore, daily dose was not associated with decreased risk of acne relapse or isotretinoin retrial among those with conventional and high cumulative dosages. Female sex (HR, 0.68; 95% CI, 0.62-0.76) and isotretinoin cumulative dosage (HR, 0.99; 95% CI, 0.98-0.99) were associated with decreased rates of isotretinoin retrial. Stratification by cumulative dosage indicated that higher cumulative dosage was associated with decreased rates of retrial among patients with low (<120 mg/kg) and conventional (120-220 mg/kg), but not high (>220 mg/kg) cumulative dosage. Maximum daily dose (mg/kg/d) was not negatively associated with acne relapse or isotretinoin retrial in patients with cumulative dosage of 120 mg/kg or more. The findings of this cohort study suggest that higher cumulative dosage may potentially reduce risk of acne relapse and isotretinoin retrial. Furthermore, daily dose was not associated with decreased risk of the outcomes for conventional and high cumulative dosage; therefore, daily dosing could be individualized to patient goals and preferences.38:Tc4b,ImportanceIsotretinoin is the only medical acne treatment capable of inducing acne remission; however, some patients experience acne relapse and require retrials of isotretinoin. There is a need to understand who is most at risk and how daily dose and cumulative dosage can influence outcomes.ObjectiveTo assess rates of acne relapse and isotretinoin retrial and to identify associated factors among patients with acne who received an isotretinoin treatment course.Design, Setting, and ParticipantsThis cohort study used data from the MarketScan commercial claims database from January 1, 2017, to December 31, 2020, to identify patients with acne who were 12 years or older and had received isotretinoin for 4 months or longer, with at least 1 year of continuous enrollment after completion of isotretinoin. Data analyses were performed from June 30, 2024, to August 1, 2024.Main Outcomes and MeasuresMultivariable Cox proportional hazards regression was used to quantify associations of patient demographic and treatment characteristics with acne relapse and isotretinoin retrial.ResultsA total of 19 907 patients (mean [SD] age, 20.6 [7.8] years; 10 504 females [52.8%]) were included, among whom 4482 (22.5%) had acne relapse and 1639 (8.2%) had isotretinoin retrial. Female sex (hazard ratio [HR], 1.43; 95% CI, 1.35-1.52) was significantly associated with increased rates of acne relapse, and isotretinoin cumulative dosage (mg/kg) was associated with a decreased rate of acne relapse (HR, 0.996; 95% CI, 0.995-0.997). Furthermore, daily dose was not associated with decreased risk of acne relapse or isotretinoin retrial among those with conventional and high cumulative dosages. Female sex (HR, 0.68; 95% CI, 0.62-0.76) and isotretinoin cumulative dosage (HR, 0.99; 95% CI, 0.98-0.99) were associated with decreased rates of isotretinoin retrial. Stratification by cumulative dosage indicated that higher cumulative dosage was associated with decreased rates of retrial among patients with low (&lt;120 mg/kg) and conventional (120-220 mg/kg), but not high (&gt;220 mg/kg) cumulative dosage. Maximum daily dose (mg/kg/d) was not negatively associated with acne relapse or isotretinoin retrial in patients with cumulative dosage of 120 mg/kg or more.Conclusions and RelevanceThe findings of this cohort study suggest that higher cumulative dosage may potentially reduce risk of acne relapse and isotretinoin retrial. Furthermore, daily dose was not associated with decreased risk of the outcomes for conventional and high cumulative dosage; therefore, daily dosing could be individualized to patient goals and preferences.39:T55c,The potent carcinogen, benzene, is a known degradation product of benzoyl peroxide (BPO) and was recently reported to form when BPO drug products, used for acne and rosacea treatment, are incubated at body temperature and elevated temperatures expected during storage and transportation. This study provides evidence for a wide range of benzene concentrations (0.16-35.30 ppm) detected by gas chromatography-mass spectrometry in 111 over-the-counter BPO drug products tested and maintained at room temperature. A prescription-encapsulated BPO drug product was stability tested at cold (2 °C) and elevated (50 °C) temperature, resulting in no apparent benzene formation at 2 °C and high levels of benzene formation at 50 °C, suggesting that encapsulation technology may not stabilize BPO drug products but that cold storage may greatly reduce benzene formation. Face model experiments where BPO drug product was applied to polymethyl methacrylate photoprotection test skin plates and benzene was detected in surrounding air by selected ion flow tube-mass spectrometry showed detectable benzene through evaporation and substantial benzene formation when exposed to UV light at levels below peak sunlight. Results suggest that potential benzene exposure from formation during BPO drug product use poses significant risks independent of the starting benzene concentration.3a:T50a,Globally, the age-standardized prevalence rate of acne vulgaris among adolescents and young adults increased from 8563.4 per 100 000 population [95% uncertainty interval (UI) 7343.5-9920.1] in 1990 to 9790.5 (95% UI 8420.9-11 287.2) per 100 000 population in 2021, with an AAPC of 0.43 [95% confidence interval (CI) 0.41-0.46]. The age-standardized incidence rate and age-standardized DALY rate also showed a similar upward trend. Regionally, Western Europe had the highest age-standardized prevalence, incidence and DALY rates, while North Africa and the Middle East had the largest increase in these rates. By SDI quintile, the high SDI region had the highest age-standardized prevalence, incidence and DALY rates from 1990 to 2021, whereas the low-middle SDI region had the lowest burden of acne vulgaris but experienced the most significant increase in these rates. Globally, the age-standardized prevalence rate of acne vulgaris in 2021 was approximately 25% higher in young women than in young men (10 911.8 per 100 000 population vs. 8727.8 per 100 000 population). Among all age groups, adolescents aged 15-19 years had the highest age-specific prevalence rate, while adolescents aged 10-14 years experienced the largest increase from 1990 to 2021 (AAPC 0.50, 95% CI 0.48-0.52).3b:Te52,Acne vulgaris is a common skin condition affecting adolescents and young adults worldwide, yet data on the burden and trends of this disease remain limited. We aimed to investigate trends in the burden of acne vulgaris among adolescents and young adults aged 10-24 years at global, regional and national levels. We retrieved data from the Global Burden of Disease Study 2021 for individuals aged 10-24 years in 204 countries and territories from 1990 to 2021. We analysed the numbers, age-standardized rates and average annual percentage changes (AAPCs) of the prevalence, incidence and disability-adjusted life years (DALYs) for acne vulgaris at the global, regional and national levels. Additionally, we examined these global trends by age, sex and Sociodemographic Index (SDI). Globally, the age-standardized prevalence rate of acne vulgaris among adolescents and young adults increased from 8563.4 per 100 000 population [95% uncertainty interval (UI) 7343.5-9920.1] in 1990 to 9790.5 (95% UI 8420.9-11 287.2) per 100 000 population in 2021, with an AAPC of 0.43 [95% confidence interval (CI) 0.41-0.46]. The age-standardized incidence rate and age-standardized DALY rate also showed a similar upward trend. Regionally, Western Europe had the highest age-standardized prevalence, incidence and DALY rates, while North Africa and the Middle East had the largest increase in these rates. By SDI quintile, the high SDI region had the highest age-standardized prevalence, incidence and DALY rates from 1990 to 2021, whereas the low-middle SDI region had the lowest burden of acne vulgaris but experienced the most significant increase in these rates. Globally, the age-standardized prevalence rate of acne vulgaris in 2021 was approximately 25% higher in young women than in young men (10 911.8 per 100 000 population vs. 8727.8 per 100 000 population). Among all age groups, adolescents aged 15-19 years had the highest age-specific prevalence rate, while adolescents aged 10-14 years experienced the largest increase from 1990 to 2021 (AAPC 0.50, 95% CI 0.48-0.52). The burden of acne vulgaris among adolescents and young adults has continued to increase in nearly all countries since the 1990s. Managing this condition remains a significant challenge, necessitating more effective and targeted interventions to control the acne burden. Acne is a skin condition that causes pimples, blackheads and cysts. The condition commonly affects teenagers and young adults and can impact self-esteem. This study aimed to understand the prevalence of acne among young people aged 10–24 years globally and track how its frequency has changed over time. We used data from the Global Burden of Disease Study 2021, which includes information from 204 countries and territories over three decades. We analysed the number of acne cases, how common it is, the number of new cases, and its impact on people’s lives. We found that the prevalence of acne increased worldwide from 1990 to 2021, with the highest rates observed in teenagers aged 15–19 years. The most significant rise in cases was among the 10–14 years age group. In 2021, acne was around 25% more common in young women than in young men. Western Europe had the highest rates, while North Africa and the Middle East saw the largest increase. We also found that more developed regions had higher rates of acne, while less developed regions experienced the largest increases. These trends identified in our study highlight the growing prevalence of acne among young people globally, and emphasize the need for better treatments and further research to understand and manage the condition effectively.3c:Tb8f,Abstract Background Acne vulgaris is a common skin condition affecting adolescents and young adults worldwide, yet data on the burden and trends of this disease remain limited. We aimed to investigate trends in the burden of acne vulgaris among adolescents and young adults aged 10–24 years at global, regional and national levels. Methods We retrieved data from the Global Burden of Disease Study 2021 for individuals aged 10–24 years in 204 countries and territories from 1990 to 2021. We analysed the numbers, age-standardized rates and average annual percentage changes (AAPCs) of the prevalence, incidence and disability-adjusted life years (DALYs) for acne vulgaris at the global, regional and national levels. Additionally, we examined these global trends by age, sex and Sociodemographic Index (SDI). Results Globally, the age-standardized prevalence rate of acne vulgaris among adolescents and young adults increased from 8563.4 per 100 000 population [95% uncertainty interval (UI) 7343.5–9920.1] in 1990 to 9790.5 (95% UI 8420.9–11 287.2) per 100 000 population in 2021, with an AAPC of 0.43 [95% confidence interval (CI) 0.41–0.46]. The age-standardized incidence rate and age-standardized DALY rate also showed a similar upward trend. Regionally, Western Europe had the highest age-standardized prevalence, incidence and DALY rates, while North Africa and the Middle East had the largest increase in these rates. By SDI quintile, the high SDI region had the highest age-standardized prevalence, incidence and DALY rates from 1990 to 2021, whereas the low-middle SDI region had the lowest burden of acne vulgaris but experienced the most significant increase in these rates. Globally, the age-standardized prevalence rate of acne vulgaris in 2021 was approximately 25% higher in young women than in young men (10 911.8 per 100 000 population vs. 8727.8 per 100 000 population). Among all age groups, adolescents aged 15–19 years had the highest age-specific prevalence rate, while adolescents aged 10–14 years experienced the largest increase from 1990 to 2021 (AAPC 0.50, 95% CI 0.48–0.52). Conclusions The burden of acne vulgaris among adolescents and young adults has continued to increase in nearly all countries since the 1990s. Managing this condition remains a significant challenge, necessitating more effective and targeted interventions to control the acne burden. 3d:T779,Omega-3 fatty acids (ω-3 FA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are essential nutrients known for their anti-inflammatory properties, which involve reducing pro-inflammatory cytokines, eicosanoids, and insulin-like growth factor-1. This suggests their potential to alleviate acne severity, especially when deficits are present. To elevate EPA/DHA levels in acne patients through dietary intervention and supplementation, observing subsequent clinical effects. Over 16 weeks, 60 patients without prescription medication (n = 23 acne comedonica [AC], n = 37 acne papulopustulosa [AP]) adhered to a Mediterranean diet, incorporating oral algae-derived ω-3 FA supplementation (600 mg DHA/300 mg EPA week 1-8, 800 mg DHA/400 mg EPA week 8-16). At four visits (V1-V4), blood EPA/DHA levels were tracked using the HS-omega 3 index® (EPA/DHA (%) of total identified fatty acids in erythrocytes; target 8%-11%, deficit <8%, severe deficit <4%), alongside clinical assessments and standardized questionnaires. At baseline, 98.3% of patients had an EPA/DHA deficit, with the mean HS-omega 3 index® rising from 4.9% at V1 to 8.3% at V4 (p < 0.001). AC showed significantly higher indices than AP at V4 (p = 0.035). Objective improvements in both inflammatory and non-inflammatory lesions were observed (p < 0.001). While self-reported appearance worsened in four patients, overall quality of life improved (p < 0.001), particularly in AP. Dietary triggers were more clearly defined than beneficial foods. Intake of cow's milk and dairy products reduced (p < 0.001). Compliance was good; no adverse events were reported. Many acne patients have a ω-3 FA deficit. The HS-omega 3 index® can be increased by a Mediterranean diet and oral supplementation with algae-derived ω-3 FA. Acne severity improved significantly in patients with target ω-3 FA levels.3e:T9f0,AbstractBackgroundOmega‐3 fatty acids (ω‐3 FA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are essential nutrients known for their anti‐inflammatory properties, which involve reducing pro‐inflammatory cytokines, eicosanoids, and insulin‐like growth factor‐1. This suggests their potential to alleviate acne severity, especially when deficits are present.AimsTo elevate EPA/DHA levels in acne patients through dietary intervention and supplementation, observing subsequent clinical effects.MethodsOver 16 weeks, 60 patients without prescription medication (n = 23 acne comedonica [AC], n = 37 acne papulopustulosa [AP]) adhered to a Mediterranean diet, incorporating oral algae‐derived ω‐3 FA supplementation (600 mg DHA/300 mg EPA week 1–8, 800 mg DHA/400 mg EPA week 8–16). At four visits (V1–V4), blood EPA/DHA levels were tracked using the HS‐omega 3 index® (EPA/DHA (%) of total identified fatty acids in erythrocytes; target 8%–11%, deficit <8%, severe deficit <4%), alongside clinical assessments and standardized questionnaires.ResultsAt baseline, 98.3% of patients had an EPA/DHA deficit, with the mean HS‐omega 3 index® rising from 4.9% at V1 to 8.3% at V4 (p < 0.001). AC showed significantly higher indices than AP at V4 (p = 0.035). Objective improvements in both inflammatory and non‐inflammatory lesions were observed (p < 0.001). While self‐reported appearance worsened in four patients, overall quality of life improved (p < 0.001), particularly in AP. Dietary triggers were more clearly defined than beneficial foods. Intake of cow's milk and dairy products reduced (p < 0.001). Compliance was good; no adverse events were reported.ConclusionMany acne patients have a ω‐3 FA deficit. The HS‐omega 3 index® can be increased by a Mediterranean diet and oral supplementation with algae‐derived ω‐3 FA. Acne severity improved significantly in patients with target ω‐3 FA levels.3f:T593,Acne vulgaris commonly affects adults, adolescents, and preadolescents aged 9 years or older. The objective of this study was to provide evidence-based recommendations for the management of acne. A work group conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of evidence and formulating and grading recommendations. This guideline presents 18 evidence-based recommendations and 5 good practice statements. Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. Oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy. Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Combining topical therapies with multiple mechanisms of action, limiting systemic antibiotic use, combining systemic antibiotics with topical therapies, and adding intralesional corticosteroid injections for larger acne lesions are recommended as good practice statements. Analysis is based on the best available evidence at the time of the systematic review. These guidelines provide evidence-based recommendations for the management of acne vulgaris.40:T49a,The survey was completed by 1357 respondents (65.7% completion rate) (mean [SD] age, 42.4 [14.3] years; 918 [67.7%] female, 439 [32.4%] male). Compared to those with no acne, for those with severe acne, participants reported less comfort being friends (adjusted coefficient [95% CI], -0.28 [-0.47 to -0.10]; P = .003), hiring (-0.33 [-0.51 to -0.15]; P < .001), having physical contact (-0.26 [-0.45 to -0.08]; P = .006), dating (-0.44 [-0.74 to -0.14]; P = .004), and posting a photograph together on social media (-0.50 [-0.70 to -0.30]; P < .001). Compared to those with no acne, participants were more likely to rate individuals with severe acne as having poor hygiene (adjusted coefficient [95% CI], -1.04 [-1.46 to -0.82]; P < .001) and being unattractive (-0.89 [-1.12 to -0.67]; P < .001), unintelligent (-0.42 [-0.63 to -0.22]; P < .001), unlikable (-0.36 [-0.56 to -0.15]; P < .001), immature (-0.52 [-0.74 to -0.30]; P < .001), and untrustworthy (-0.40 [-0.61 to -0.18]; P < .001). There was evidence that the effect size of the association of acne with desire to social distance was greater for individuals with dark skin.41:Ta1c,Little is known about the prevalence and magnitude of stigmatizing attitudes of the general public toward individuals with acne. To explore the degree of stigma toward individuals with acne and whether these attitudes vary based on characteristics of the individuals with acne or of the survey participants. In this cross-sectional internet survey study, 4 stock portraits of adults that varied in sex (male/female) and skin tone (light/dark) were digitally enhanced to have acne (mild/severe). One of these 12 images was randomly presented to survey participants, who subsequently answered questions regarding stigmatizing attitudes with respect to the pictured individual, such as desire for social distance and stereotype endorsement. The survey was administered to a convenience sample of adult respondents in the US who were volunteers on the ResearchMatch platform. Prevalence and magnitude of stigma toward individuals with acne. The survey was completed by 1357 respondents (65.7% completion rate) (mean [SD] age, 42.4 [14.3] years; 918 [67.7%] female, 439 [32.4%] male). Compared to those with no acne, for those with severe acne, participants reported less comfort being friends (adjusted coefficient [95% CI], -0.28 [-0.47 to -0.10]; P = .003), hiring (-0.33 [-0.51 to -0.15]; P < .001), having physical contact (-0.26 [-0.45 to -0.08]; P = .006), dating (-0.44 [-0.74 to -0.14]; P = .004), and posting a photograph together on social media (-0.50 [-0.70 to -0.30]; P < .001). Compared to those with no acne, participants were more likely to rate individuals with severe acne as having poor hygiene (adjusted coefficient [95% CI], -1.04 [-1.46 to -0.82]; P < .001) and being unattractive (-0.89 [-1.12 to -0.67]; P < .001), unintelligent (-0.42 [-0.63 to -0.22]; P < .001), unlikable (-0.36 [-0.56 to -0.15]; P < .001), immature (-0.52 [-0.74 to -0.30]; P < .001), and untrustworthy (-0.40 [-0.61 to -0.18]; P < .001). There was evidence that the effect size of the association of acne with desire to social distance was greater for individuals with dark skin. This survey study demonstrates that stigmatizing attitudes toward patients with acne existed across a variety of social and professional scenarios, with severe acne and acne in darker skin tone being associated with a greater degree of stigma. These findings highlight the need to identify approaches to reduce stigmatizing attitudes in the community and for adequate access to care, which might prevent negative downstream effects related to these stigmatizing attitudes.42:Te3a,ImportanceLittle is known about the prevalence and magnitude of stigmatizing attitudes of the general public toward individuals with acne.ObjectiveTo explore the degree of stigma toward individuals with acne and whether these attitudes vary based on characteristics of the individuals with acne or of the survey participants.Design, Setting, and ParticipantsIn this cross-sectional internet survey study, 4 stock portraits of adults that varied in sex (male/female) and skin tone (light/dark) were digitally enhanced to have acne (mild/severe). One of these 12 images was randomly presented to survey participants, who subsequently answered questions regarding stigmatizing attitudes with respect to the pictured individual, such as desire for social distance and stereotype endorsement. The survey was administered to a convenience sample of adult respondents in the US who were volunteers on the ResearchMatch platform.Main Outcomes and MeasuresPrevalence and magnitude of stigma toward individuals with acne.ResultsThe survey was completed by 1357 respondents (65.7% completion rate) (mean [SD] age, 42.4 [14.3] years; 918 [67.7%] female, 439 [32.4%] male). Compared to those with no acne, for those with severe acne, participants reported less comfort being friends (adjusted coefficient [95% CI], −0.28 [−0.47 to −0.10]; P = .003), hiring (−0.33 [−0.51 to −0.15]; P &lt; .001), having physical contact (−0.26 [−0.45 to −0.08]; P = .006), dating (−0.44 [−0.74 to −0.14]; P = .004), and posting a photograph together on social media (−0.50 [−0.70 to −0.30]; P &lt; .001). Compared to those with no acne, participants were more likely to rate individuals with severe acne as having poor hygiene (adjusted coefficient [95% CI], −1.04 [−1.46 to −0.82]; P &lt; .001) and being unattractive (−0.89 [−1.12 to −0.67]; P &lt; .001), unintelligent (−0.42 [−0.63 to −0.22]; P &lt; .001), unlikable (−0.36 [−0.56 to −0.15]; P &lt; .001), immature (−0.52 [−0.74 to −0.30]; P &lt; .001), and untrustworthy (−0.40 [−0.61 to −0.18]; P &lt; .001). There was evidence that the effect size of the association of acne with desire to social distance was greater for individuals with dark skin.Conclusions and RelevanceThis survey study demonstrates that stigmatizing attitudes toward patients with acne existed across a variety of social and professional scenarios, with severe acne and acne in darker skin tone being associated with a greater degree of stigma. These findings highlight the need to identify approaches to reduce stigmatizing attitudes in the community and for adequate access to care, which might prevent negative downstream effects related to these stigmatizing attitudes.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Acne Vulgaris: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Acne Vulgaris (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Acne%20Vulgaris\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Acne Vulgaris\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Acne%20Vulgaris\"}]}}"}}]],["$","$L2f",null,{"title":"Acne Vulgaris: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Acne Vulgaris with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.2340/actadv.v106.adv-2026-0642","pmid":"42640063","title":"Truncal Acne Is Independently Associated with Stigmatization, Poorer Treatment Adherence and Greater Healthcare Utilization: A 20-country Survey","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-08-25T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0642","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-28T06:25:33.325Z","updated_at":"2026-08-28T06:25:33.325Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0642","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0642","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0642","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0642","tag_type":"condition","value":"Truncal Acne","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0642","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0642","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0642","tag_type":"sample_size","value":"n=1879","value_numeric":1879},{"paper_doi":"10.2340/actadv.v106.adv-2026-0642","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0642","tag_type":"study_design","value":"Cross-Sectional Survey","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0642","tag_type":"warning","value":"Industry funding (Laboratoire Ducray) with funder involvement in project design may introduce bias, though data collection and analysis were reportedly independent.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0642","tag_type":"warning","value":"Institutional review board approval was waived due to anonymized self-reported data; clinical severity was not independently verified by physicians.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0642","tag_type":"warning","value":"No therapeutic interventions were evaluated; this study covers psychosocial and healthcare utilization outcomes only — modality/brand/generic drug tags are not applicable.","value_numeric":null}],"summaries":{"what_studied":"This cross-sectional international online survey compared 804 adults with truncal acne (TA) to 1,075 with exclusively facial acne (FA) across 20 countries, assessing stigmatization, psychosocial burden, healthcare utilization, and treatment adherence via multivariable logistic regression adjusted for age, sex, and country.","key_result":"TA was independently associated with stigmatization (aOR 1.41 [95% CI 1.16–1.71]), hospitalization (aOR 1.73 [1.25–2.38]), and poor treatment adherence (aOR 1.26 [1.03–1.53]). Stigmatization rates were nearly identical in truncal-only (49.2%) vs. combined facial-and-truncal patients (50.5%), showing the burden is intrinsic to trunk involvement. Truncal-only patients had lower dermatologist access (63.8% vs. 78.9%) but far higher hospitalization (20.3% vs. 6.0%) and surgical consultation rates (9.0% vs. 1.9%).","limitations":"- Cross-sectional design prevents causal inference.\n- No physician-assessed severity scores or lesion counts; healthcare utilization is self-reported.\n- Study was industry-funded (Laboratoire Ducray), with funder involvement in project design.","practice_takeaway":"Routinely examine the trunk in all acne patients — truncal involvement drives stigmatization and poor adherence independent of facial disease, and truncal-only patients often skip specialist care until complications arise. Screen for stigmatization and symptom burden (especially pain and burning) to support treatment engagement."}},{"doi":"10.2147/ccid.s616091","pmid":null,"title":"Preclinical Evaluation of Anti-Acne Topical Creams Containing Psorospermum Febrifugum Stem Bark Extract: Lipase Inhibition, Sebum Regulation, and Dermal Safety","journal_title":"Clinical, Cosmetic and Investigational Dermatology","journal_issn":"1178-7015","published_at":"2026-08-01T00:00:00.000Z","url":"https://doi.org/10.2147/ccid.s616091","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-08-14T13:25:06.033Z","updated_at":"2026-08-14T13:25:06.033Z","tags":[{"paper_doi":"10.2147/ccid.s616091","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"condition","value":"Seborrhoea","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"generic","value":"Psorospermum febrifugum stem bark extract","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"modality","value":"Botanical Topical Agent","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"modality","value":"Lipase Inhibitor","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"sample_size","value":"n=54","value_numeric":54},{"paper_doi":"10.2147/ccid.s616091","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"study_design","value":"Preclinical Study (In Vitro and In Vivo)","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"warning","value":"AI-generated figure enhancement (OpenAI GPT-5.5) was disclosed by authors — image integrity should be considered when interpreting visual data.","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"warning","value":"Porcine pancreatic lipase was used as a surrogate for C. acnes lipase; direct antimicrobial or anti-C. acnes activity was not evaluated.","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"warning","value":"Sample size of n=54 refers to the in vivo rat cohort (9 groups × 6 animals); a separate cohort was used for dermal irritation testing — total animal numbers across both experiments are not explicitly summed in the paper.","value_numeric":null},{"paper_doi":"10.2147/ccid.s616091","tag_type":"warning","value":"Three phthalate ester compounds detected by GC-MS were attributed to environmental/laboratory contamination and excluded from pharmacological interpretation; this assumption, while standard practice, was not independently verified.","value_numeric":null}],"summaries":{"what_studied":"Topical oil-in-water creams containing 1–5% w/w *Psorospermum febrifugum* stem bark extract were formulated and evaluated preclinically for lipase inhibitory activity (in vitro fluorometric assay), sebum suppression (oleic acid–induced seborrhoea rat model, 14-day treatment), and dermal safety (OECD Guideline 404) in Wistar rats.","key_result":"The 5% cream (C5) achieved 57% porcine pancreatic lipase inhibition (vs. 88.1% for orlistat) and 60.7% sebum reduction at day 14 (vs. 62.3% for 2% benzoyl peroxide); lipase inhibition and sebum reduction correlated strongly (Pearson r = 0.88, p < 0.01). All extract-loaded creams had irritation indices <0.2 (non-irritant), versus 0.85 (mildly irritant) for benzoyl peroxide.","limitations":"- The oleic acid rat model and porcine pancreatic lipase surrogate do not fully replicate human acne pathogenesis (no *C. acnes* colonisation, follicular hyperkeratinisation, or direct C. acnes lipase testing).\n- Only 14-day treatment was assessed; no accelerated stability, long-term safety, or histopathological data were collected.\n- No isolated compound testing was done, so mechanistic links remain associative, not causative.","practice_takeaway":"This is early-stage preclinical work only — no clinical use is yet supported. Dermatologists interested in botanical anti-acne agents should note that *P. febrifugum* cream matched benzoyl peroxide sebum suppression in a rat model with lower irritancy, warranting controlled human trials before any clinical application."}},{"doi":"10.5826/dpc.1603a7403","pmid":null,"title":"Impact of Isotretinoin Therapy on Thyroid Hormone Levels in Patients with Acne Vulgaris: A Systematic Review and Meta-Analysis","journal_title":"Dermatology Practical & Conceptual","journal_issn":"2160-9381","published_at":"2026-07-31T00:00:00.000Z","url":"https://doi.org/10.5826/dpc.1603a7403","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-08-06T13:22:17.809Z","updated_at":"2026-08-06T13:22:17.809Z","tags":[{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"condition","value":"Thyroid Dysfunction","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"generic","value":"isotretinoin","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"modality","value":"Retinoid","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"sample_size","value":"n=447","value_numeric":447},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"warning","value":"All 8 included studies were observational (prospective cohort); no RCTs were available, so causal inference is limited.","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"warning","value":"Heterogeneity was moderate to high (I²=70–89%) in most analyses; sensitivity analyses identified specific studies driving this, but full resolution was not achieved.","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"warning","value":"Hormone levels remained within normal reference ranges across all studies despite statistically significant SMD changes — clinical significance is uncertain.","value_numeric":null},{"paper_doi":"10.5826/dpc.1603a7403","tag_type":"warning","value":"The meta-analysis pooled both free (FT3, FT4) and total (T3, T4) hormone measurements across studies, which may introduce additional measurement variability despite use of SMD.","value_numeric":null}],"summaries":{"what_studied":"This systematic review and meta-analysis pooled data from 8 prospective observational studies (n=447 acne vulgaris patients) to evaluate changes in TSH, T3, and T4 levels at 3, 4, and 6 months after starting systemic isotretinoin (0.2–1 mg/kg/day).","key_result":"T3 fell significantly at all time points (3 mo: SMD −0.42, P=0.03; 4 mo: SMD −0.63, P=0.002; 6 mo: SMD −1.13, P=0.0001). T4 dropped significantly at 4 and 6 months (SMD −0.79, P=0.0001; SMD −0.87, P=0.01). TSH rose significantly only at 6 months (SMD +0.54, P=0.03). Despite statistical significance, all hormone values remained within normal ranges across studies — no patients developed overt hypothyroidism during follow-up.","limitations":"- Only 8 small studies (n=447 total) were included, limiting statistical power.\n- No study followed patients to treatment completion, so it is unknown whether thyroid changes are transient or permanent.\n- Moderate-to-high heterogeneity (I²=70–89%) in most analyses, partly explained by differences in dosage, sample characteristics, and study setting.","practice_takeaway":"Clinicians prescribing long-term isotretinoin — especially to patients with pre-existing subclinical thyroid dysfunction — should consider periodic thyroid function monitoring after 4–6 months of therapy. Current evidence does not support overt hypothyroidism risk in thyroid-normal patients, but vigilance is warranted."}},{"doi":"10.1007/s40257-026-01044-z","pmid":"42234395","title":"Practical Therapeutic Strategies for Acne-Induced Hyperpigmentation Across all Skin Types","journal_title":"American Journal of Clinical Dermatology","journal_issn":"1175-0561","published_at":"2026-06-03T00:00:00.000Z","url":"https://doi.org/10.1007/s40257-026-01044-z","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:24:05.536Z","updated_at":"2026-06-10T14:24:05.536Z","tags":[{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"condition","value":"Post-Inflammatory Erythema","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"condition","value":"Post-Inflammatory Hyperpigmentation","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"generic","value":"azelaic acid","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"generic","value":"hydroquinone","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"generic","value":"isotretinoin","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"generic","value":"tranexamic acid","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"modality","value":"Antifibrinolytic","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"modality","value":"Chemical Peel","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"modality","value":"Laser","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"modality","value":"Microneedling","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"modality","value":"Systemic Retinoid","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"modality","value":"Topical Depigmenting Agent","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"modality","value":"Topical Retinoid","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"warning","value":"Female sex is listed as a risk factor for AIH, but sex-stratified treatment outcome data are not presented; generalizability across sexes is unclear.","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"warning","value":"No sample size applies — this is a review article with no original patient cohort.","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01044-z","tag_type":"warning","value":"This is a narrative review published in 2026; no systematic search strategy or PRISMA methodology is described, so recommendations reflect expert opinion rather than pooled evidence.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates therapeutic strategies for acne-induced hyperpigmentation (AIH) and acne-induced macular erythema across all Fitzpatrick skin types, covering topical agents, systemic therapies, procedural options, and photoprotection.","key_result":"Up to 85% of patients with Fitzpatrick phototypes IV–VI develop post-inflammatory hyperpigmentation after inflammatory acne. Both AIH and macular erythema can persist months to years and may impair quality of life more than active acne itself. Treatment options include topical agents (azelaic acid, retinoids, hydroquinone, antioxidants), systemic therapies (isotretinoin, oral antibiotics, oral tranexamic acid), chemical peels, lasers, and microneedling.","limitations":"No validated patient-reported outcome measures specific to AIH or acne-induced macular erythema currently exist; the article is a narrative review without a systematic literature search or meta-analysis, limiting the strength of evidence-based recommendations.","practice_takeaway":"For patients with skin of color presenting with post-acne hyperpigmentation, prioritize strict photoprotection alongside targeted depigmenting agents (e.g., azelaic acid, retinoids, hydroquinone) and treat active acne aggressively to reduce new lesions. Oral tranexamic acid and energy-based devices are additional options, but skin phototype must guide procedural choices to minimize risk of further pigmentary change."}},{"doi":"10.1001/jamadermatol.2026.1197","pmid":"42160078","title":"Isotretinoin Treatment in Adolescence and Adult Height","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-05-20T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.1197","source_score":19,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-26T13:34:49.105Z","updated_at":"2026-05-26T13:34:49.105Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"generic","value":"isotretinoin","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"generic","value":"tetracycline","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"modality","value":"Retinoid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"sample_size","value":"n=379196","value_numeric":379196},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"warning","value":"Cross-sectional design precludes causal inference; confounding by acne severity or other factors cannot be fully excluded despite adjustment for birth cohort and education.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"warning","value":"The study population is drawn exclusively from Danish military conscription records, which may limit generalizability to non-European or non-conscription populations.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1197","tag_type":"warning","value":"Women were a small minority of the sample (10,858 out of 379,196), and only 278 were isotretinoin users, making female-specific conclusions less robust.","value_numeric":null}],"summaries":{"what_studied":"This nationwide cross-sectional study examined whether isotretinoin use during adolescence is associated with reduced adult height, using Danish military conscription records (2001–2015) linked to prescription registries for 379,196 individuals (368,338 men, 10,858 women).","key_result":"Isotretinoin was not associated with reduced adult height. Adjusted mean height difference vs. reference group was +0.31 cm (95% CI, 0.20–0.41 cm) in men and +0.25 cm (95% CI, −0.47 to 0.96 cm) in women — both well below the predefined minimal clinically important difference of 5 cm. Results held across strata of age at initiation, cumulative dose, and stunting as outcome.","limitations":"- Cross-sectional design cannot establish causation or rule out residual confounding.\n- Women were substantially underrepresented (only 278 isotretinoin users), limiting precision of female estimates.\n- Height was measured at conscription (~age 19), so later growth (if any) after treatment was not captured.","practice_takeaway":"Clinicians can reassure adolescent patients and families that isotretinoin treatment for acne is not associated with impaired linear growth. This evidence supports evidence-based prescribing decisions without concern for stunting as a treatment risk."}},{"doi":"10.1111/jocd.70654","pmid":"41486969","title":"Prevalence of Acne and Its Impact on Quality of Life, Social Appearance Anxiety and Treatment Practices Among Young Adults","journal_title":"Journal of Cosmetic Dermatology","journal_issn":"1473-2130","published_at":"2026-01-05T00:00:00.000Z","url":"https://doi.org/10.1111/jocd.70654","source_score":4,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-09","doi":"10.1111/jocd.70654","days":"7","issn":"1473-2130","rank":"9","field":"Clinical Medicine","score":"4","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jocd.70654","title":"Prevalence of Acne and Its Impact on Quality of Life, Social Appearance Anxiety and Treatment Practices Among Young Adults.","journal":"Journal of cosmetic dermatology","methods":"","results":"Acne was reported by 47.6% of participants. Among those affected (n = 465), 47.96% had mild acne, 44.95% had moderate acne, 6.02% had severe acne, and 1.08% had very severe acne. Increasing acne severity was significantly associated with poorer quality of life (p < 0.001) and higher social appearance anxiety (p = 0.013). Logistic regression identified several independent predictors of acne, including gender (p = 0.008), residence (p ≤ 0.033), middle-income status (p = 0.040), belief that diet affects acne (p < 0.001), smoking (p = 0.023), alcohol consumption (p = 0.001), and family history of acne (p < 0.001). Higher DLQI scores were also significantly associated with acne (p = 0.002), whereas SAAS and HADS were not independently associated. Among affected individuals, 33.7% consulted a dermatologist, while others relied on self-medication (29.9%), home remedies (30.8%), or combined approaches (23.7%).","abstract":"$30","keywords":["Bangladesh","acne vulgaris","prevalence","quality of life","social appearance anxiety","young adults"],"pubmed_id":"41486969","conclusions":"","publication_date":"2026-01-05T00:00:00"},"crossref":{"DOI":"10.1111/jocd.70654","URL":"https://doi.org/10.1111/jocd.70654","ISSN":["1473-2130","1473-2165"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jocd.70654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"1","score":1,"title":["Prevalence of Acne and Its Impact on Quality of Life, Social Appearance Anxiety and Treatment Practices Among Young Adults"],"author":[{"given":"Tajin Ahmed","family":"Jisa","sequence":"first","affiliation":[{"name":"Department of Statistics Hajee Mohammad Danesh Science and Technology University Dinajpur Bangladesh"}]},{"given":"Md. Tahalil Islam","family":"Rahat","sequence":"additional","affiliation":[{"name":"Department of Statistics Hajee Mohammad Danesh Science and Technology University Dinajpur Bangladesh"}]},{"given":"Most. Shermin Akter","family":"Sumi","sequence":"additional","affiliation":[{"name":"Department of Statistics Hajee Mohammad Danesh Science and Technology University Dinajpur Bangladesh"}]},{"given":"Nourin","family":"Sultana","sequence":"additional","affiliation":[{"name":"Department of Statistics Hajee Mohammad Danesh Science and Technology University Dinajpur Bangladesh"}]},{"given":"Jibon Kumar","family":"Sarker","sequence":"additional","affiliation":[{"name":"Department of Statistics Hajee Mohammad Danesh Science and Technology University Dinajpur Bangladesh"}]},{"given":"Mifta","family":"Nurejannath","sequence":"additional","affiliation":[{"name":"Department of Statistics Hajee Mohammad Danesh Science and Technology University Dinajpur Bangladesh"}]},{"given":"Md. Kaderi","family":"Kibria","sequence":"additional","affiliation":[{"name":"Department of Statistics Hajee Mohammad Danesh Science and Technology University Dinajpur Bangladesh"},{"name":"Department of Statistics University of Rajshahi Rajshahi Bangladesh"}]}],"issued":{"date-parts":[[2026,1]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"25","archive":["Portico"],"created":{"date-time":"2026-01-05T09:09:38Z","timestamp":1767604178000,"date-parts":[[2026,1,5]]},"indexed":{"date-time":"2026-01-05T09:13:43Z","timestamp":1767604423078,"date-parts":[[2026,1,5]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000,"date-parts":[[2026,1,5]]},"delay-in-days":4,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.70654"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-09-28"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-12-23"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-01-05"}],"deposited":{"date-time":"2026-01-05T09:09:41Z","timestamp":1767604181000,"date-parts":[[2026,1,5]]},"issn-type":[{"type":"print","value":"1473-2130"},{"type":"electronic","value":"1473-2165"}],"published":{"date-parts":[[2026,1]]},"publisher":"Wiley","reference":[{"DOI":null,"key":"e_1_2_15_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Reportlinker Global Acne Market Report for 2016–2026 ”(2018).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.agsy.2020.102986","key":"e_1_2_15_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.23880/cprj‐16000105","key":"e_1_2_15_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.13462","key":"e_1_2_15_5_1","year":"2015","issue":null,"author":"Tan J. K. L.","volume":"172","first-page":"3","unstructured":null,"article-title":"A Global Perspective on the Epidemiology of Acne","journal-title":"British Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0250155","key":"e_1_2_15_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_15_7_1","year":"2016","issue":null,"author":"Kumar S.","volume":"26","first-page":"35","unstructured":null,"article-title":"Psychosocial Impact of Acne on Quality of Life in North India: A Hospital‐Based Cross‐Sectional Study","journal-title":"Journal of Pakistan Association of Dermatologists","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_15_8_1","year":"2023","issue":null,"author":"Noor T.","volume":"33","first-page":"424","unstructured":null,"article-title":"Association of Depression, Anxiety and Stress in Acne Vulgaris in Bangladesh","journal-title":"Journal of Pakistan Association of Dermatologists","doi-asserted-by":null},{"DOI":"10.1046/j.1365‐2133.1997.18131897.x","key":"e_1_2_15_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598‐024‐55094‐6","key":"e_1_2_15_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2165/00128071-200809050-00001","key":"e_1_2_15_11_1","year":"2008","issue":null,"author":"Gollnick H. P. M.","volume":"9","first-page":"279","unstructured":null,"article-title":"Can we Define Acne as a Chronic Disease? If So, How and When?","journal-title":"American Journal of Clinical Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.17721","key":"e_1_2_15_12_1","year":"2019","issue":null,"author":"Common J. E. A.","volume":"181","first-page":"665","unstructured":null,"article-title":"What Does Acne Genetics Teach us About Disease Pathogenesis?","journal-title":"British Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/ijd.15280","key":"e_1_2_15_13_1","year":"2021","issue":null,"author":"Sachdeva M.","volume":"60","first-page":"792","unstructured":null,"article-title":"The Prevalence, Risk Factors, and Psychosocial Impacts of Acne Vulgaris in Medical Students: A Literature Review","journal-title":"International Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.3390/medicina59010052","key":"e_1_2_15_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1155/2014/974019","key":"e_1_2_15_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_15_16_1","year":"2022","issue":null,"author":"Huei L. T.","volume":"77","first-page":"446","unstructured":null,"article-title":"Prevalence and Psychosocial Impact of Acne Vulgaris Among High School and University Students in Sarawak, Malaysia","journal-title":"Medical Journal of Malaysia","doi-asserted-by":null},{"DOI":"10.1080/09546634.2019.1657792","key":"e_1_2_15_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.21276/ssr‐iijls.2024.10.6.24","key":"e_1_2_15_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.5812/ijpbs.113164","key":"e_1_2_15_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/1744-859X-7-4","key":"e_1_2_15_20_1","year":"2008","issue":null,"author":"Zigmond A. S.","volume":"7","first-page":"4","unstructured":null,"article-title":"Hospital Anxiety and Depression Scale (HADS): Validation in a Greek General Hospital Sample","journal-title":"Annals of General Psychiatry","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_15_21_1","year":"2002","issue":null,"author":"Asad F.","volume":"12","first-page":"69","unstructured":null,"article-title":"Anxiety and Depression in Patients With Acne Vulgaris","journal-title":"Journal of Pakistan Association of Dermatologists","doi-asserted-by":null},{"DOI":"10.7759/cureus.5722","key":"e_1_2_15_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fpsyg.2023.1153101","key":"e_1_2_15_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4103/jdrntruhs.jdrntruhs_88_22","key":"e_1_2_15_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1590/s0365‐05962012000600007","key":"e_1_2_15_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3329/medtoday.v29i2.34623","key":"e_1_2_15_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/CCID.S148499","key":"e_1_2_15_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4172/2155‐9554.1000404","key":"e_1_2_15_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdds.2017.01.001","key":"e_1_2_15_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_15_30_1","year":"2015","issue":null,"author":"Muthupalaniappen L.","volume":"10","first-page":"1","unstructured":null,"article-title":"Acne Disability, Self Management and Help‐Seeking Behaviour Among Medical Students","journal-title":"Medical & Health (Universiti Kebangsaan Malaysia)","doi-asserted-by":null},{"DOI":"10.4103/2229‐5178.126023","key":"e_1_2_15_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1468‐3083.2011.04080.x","key":"e_1_2_15_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/CM9.0000000000001292","key":"e_1_2_15_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4158/EP15748.DSCPT2","key":"e_1_2_15_34_1","year":"2015","issue":null,"author":"Goodman N. F.","volume":"21","first-page":"1415","unstructured":null,"article-title":"American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and Pcos Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome ‐ Part 2","journal-title":"Endocrine Practice","doi-asserted-by":"crossref"},{"DOI":"10.4103/0019‐5154.92672","key":"e_1_2_15_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555‐1998","key":"e_1_2_15_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2012.02.018","key":"e_1_2_15_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1468‐3083.2006.02022.x","key":"e_1_2_15_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346‐8138.12606","key":"e_1_2_15_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1523‐1747.2002.19621.x","key":"e_1_2_15_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1684/ejd.2015.2722","key":"e_1_2_15_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.13835","key":"e_1_2_15_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4236/health.2019.116052","key":"e_1_2_15_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_15_44_1","year":"2018","issue":null,"author":"Kristeen C.","volume":null,"first-page":null,"unstructured":null,"article-title":"Does Alcohol Cause Acne?","journal-title":"Health","doi-asserted-by":null},{"DOI":"10.1046/j.1365‐2133.2001.04290.x","key":"e_1_2_15_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365‐2230.2004.01646.x","key":"e_1_2_15_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/1471‐5945‐5‐2","key":"e_1_2_15_47_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/sj.jid.5700326","key":"e_1_2_15_48_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/CCID.S427648","key":"e_1_2_15_49_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/CCID.S315846","key":"e_1_2_15_50_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_15_51_1","year":"2011","issue":null,"author":"Purdy S.","volume":"2011","first-page":null,"unstructured":null,"article-title":"Acne Vulgaris","journal-title":"BMJ Clinical Evidence","doi-asserted-by":null},{"DOI":"10.1155/2010/410809","key":"e_1_2_15_52_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_15_53_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Acne Prevalence and beyond: Acne Disability and Its Predictive Factors among Chinese Late Adolescents in Hong Kong ”https://doi.org/10.1111/j.1365‐2230.2009.03340.x.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/jdv.14475","key":"e_1_2_15_54_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.25000/acem.578444","key":"e_1_2_15_55_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.7759/cureus.91820","key":"e_1_2_15_56_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/healthcare12020258","key":"e_1_2_15_57_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/archderm.143.7.912","key":"e_1_2_15_58_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/pharmacy11060183","key":"e_1_2_15_59_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jocd.70654"],"article-number":"e70654","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Cosmetic Dermatology"],"published-print":{"date-parts":[[2026,1]]},"reference-count":58,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,5]]},"references-count":58,"short-container-title":["J of Cosmetic Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jocd.70654","is_oa":true,"title":"Prevalence of Acne and Its Impact on Quality of Life, Social Appearance Anxiety and Treatment Practices Among Young Adults","updated":"2026-01-06T03:47:31+00:00","published_date":"2026-01-01","best_oa_location":{"url":"https://doi.org/10.1111/jocd.70654","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1111/jocd.70654"}}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-11T11:19:33.869Z","tags":[{"paper_doi":"10.1111/jocd.70654","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/jocd.70654","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jocd.70654","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1111/jocd.70654","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/jocd.70654","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1111/jocd.70654","tag_type":"sample_size","value":"n=1067","value_numeric":1067},{"paper_doi":"10.1111/jocd.70654","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1111/jocd.70654","tag_type":"warning","value":"Cross-sectional associations cannot establish causality.","value_numeric":null},{"paper_doi":"10.1111/jocd.70654","tag_type":"warning","value":"Findings are from university students in one region (northern Bangladesh), which may limit generalizability.","value_numeric":null},{"paper_doi":"10.1111/jocd.70654","tag_type":"warning","value":"Treatment practice percentages may overlap; denominators are not fully clear.","value_numeric":null}],"summaries":{"what_studied":"Cross-sectional survey of 1067 university students in northern Bangladesh assessing acne prevalence and severity (GAGS), quality of life (DLQI), social appearance anxiety (SAAS), psychological distress (HADS), and predictors using logistic regression.","key_result":"Acne was reported by 47.6%; among those affected (n=465), 47.96% had mild, 44.95% moderate, 6.02% severe, and 1.08% very severe disease. Greater severity correlated with worse DLQI (p<0.001) and higher SAAS (p=0.013); independent predictors included gender (p=0.008), residence (p≤0.033), middle-income status (p=0.040), belief that diet affects acne (p<0.001), smoking (p=0.023), alcohol (p=0.001), and family history (p<0.001); 33.7% consulted a dermatologist vs self-medication 29.9%, home remedies 30.8%, and combined approaches 23.7%.","limitations":"Cross-sectional design limits causal inference. Single regional university sample may restrict generalizability, and reliance on self-reported acne and behaviors can introduce misclassification.","practice_takeaway":"Expect a high acne burden in university settings with measurable DLQI impact; many students self-manage rather than seek dermatology care. Integrate evidence-based acne care with QoL screening and psychosocial support within student health programs."}},{"doi":"10.1016/j.jaad.2025.09.077","pmid":"41052654","title":"Safe and Effective Acne Treatment Across Skin Types with a 1726 nm Sebum-Selective Laser: One Year Data from a Prospective Multicenter Study","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2025-10-07T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2025.09.077","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-09","doi":"10.1016/j.jaad.2025.09.077","days":"7","issn":"0190-9622","rank":"6","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1016/j.jaad.2025.09.077","title":"Safe and Effective Acne Treatment Across Skin Types with a 1726 nm Sebum-Selective Laser: One Year Data from a Prospective Multicenter Study.","journal":"Journal of the American Academy of Dermatology","methods":"","results":"Of 104 patients with Fitzpatrick skin types II-VI and moderate-to-severe acne, 89 and 71 patients, respectively, attended 12- and 52-week visits. At 12 weeks, 79.8% demonstrated ≥50% improvement in ILC, which increased to 91.5% at 52 weeks. The proportion of patients with clear or almost clear IGA scores increased from 36.0% at 3 months to 66.2% at 52 weeks. Treatment was well tolerated: Mild erythema and edema occurred in 100% and 98.1% of patients, respectively. No blistering, crusting, or hypo- or hyperpigmentation were observed. Patient satisfaction and self-confidence improved at both follow-up timepoints.","abstract":"$32","keywords":["1726-nm laser","ILC","acne","acne severity","contact cooling","laser therapy","sebaceous glands","selective photothermolysis"],"pubmed_id":"41052654","conclusions":"The seboselective 1726-nm laser is an effective and well-tolerated therapy for reducing moderate-to-severe facial acne for at least 1 year.","publication_date":"2025-10-07T00:00:00"},"crossref":{"DOI":"10.1016/j.jaad.2025.09.077","URL":"https://doi.org/10.1016/j.jaad.2025.09.077","ISSN":["0190-9622"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0190962225029007?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0190962225029007?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Safe and Effective Acne Treatment Across Skin Types with a 1726 nm Sebum-Selective Laser: One Year Data from a Prospective Multicenter Study"],"author":[{"given":"David","family":"Goldberg","sequence":"first","affiliation":[]},{"given":"Steve","family":"Ronan","sequence":"additional","affiliation":[]},{"given":"Ashish","family":"Bhatia","sequence":"additional","affiliation":[]},{"given":"Sunil S.","family":"Dhawan","sequence":"additional","affiliation":[]},{"given":"Jeremy B.","family":"Green","sequence":"additional","affiliation":[]},{"given":"Suzanne L.","family":"Kilmer","sequence":"additional","affiliation":[]},{"given":"William","family":"Kwan","sequence":"additional","affiliation":[]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[]},{"given":"Jonathan S.","family":"Weiss","sequence":"additional","affiliation":[]},{"given":"Margot","family":"Doucette","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Karavitis","sequence":"additional","affiliation":[]},{"given":"Jeffrey S.","family":"Dover","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,10]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":null,"created":{"date-time":"2025-10-05T00:11:25Z","timestamp":1759623085000,"date-parts":[[2025,10,5]]},"indexed":{"date-time":"2025-10-05T00:46:54Z","timestamp":1759625214424,"date-parts":[[2025,10,5]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000,"date-parts":[[2025,10,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000,"date-parts":[[2025,10,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000,"date-parts":[[2025,10,1]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0190962225029007"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Safe and Effective Acne Treatment Across Skin Types with a 1726 nm Sebum-Selective Laser: One Year Data from a Prospective Multicenter Study"},{"name":"journaltitle","label":"Journal Title","value":"Journal of the American Academy of Dermatology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jaad.2025.09.077"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc."}],"deposited":{"date-time":"2025-10-05T00:11:25Z","timestamp":1759623085000,"date-parts":[[2025,10,5]]},"issn-type":[{"type":"print","value":"0190-9622"}],"published":{"date-parts":[[2025,10]]},"publisher":"Elsevier BV","reference":null,"short-title":[],"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0190962225029007"],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,10]]},"reference-count":0,"published-online":null,"references-count":0,"short-container-title":["Journal of the American Academy of Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/j.jaad.2025.09.077","is_oa":true,"title":"Safe and Effective Acne Treatment Across Skin Types with a 1726 nm Sebum-Selective Laser: One Year Data from a Prospective Multicenter Study","updated":"2025-10-06T00:09:52+00:00","published_date":"2025-10-01","best_oa_location":{"url":"https://doi.org/10.1016/j.jaad.2025.09.077","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1016/j.jaad.2025.09.077"}}},"created_at":"2025-10-11T07:13:56.506Z","updated_at":"2025-10-16T07:50:39.785Z","tags":[{"paper_doi":"10.1016/j.jaad.2025.09.077","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.09.077","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.09.077","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.09.077","tag_type":"modality","value":"Laser","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.09.077","tag_type":"sample_size","value":"n=104","value_numeric":104},{"paper_doi":"10.1016/j.jaad.2025.09.077","tag_type":"study_design","value":"Single-Arm Prospective Trial","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.09.077","tag_type":"warning","value":"Attendance fell from 104 at baseline to 71 at 52 weeks; attrition details are not provided.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.09.077","tag_type":"warning","value":"Open-label, uncontrolled design limits causal inference.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.09.077","tag_type":"warning","value":"Outcomes were judged by image assessment.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.09.077","tag_type":"warning","value":"Study design label inferred; classification may vary.","value_numeric":null}],"summaries":{"what_studied":"Prospective multicenter, open-label study of three 1726‑nm sebum‑selective laser treatments (2–5 weeks apart) for moderate-to-severe facial acne in Fitzpatrick skin types II–VI, with outcomes assessed at 12 weeks and 52 weeks.","key_result":"Of 104 enrolled, 89 and 71 attended the 12‑ and 52‑week visits. ≥50% inflammatory lesion count improvement occurred in 79.8% at 12 weeks and 91.5% at 52 weeks; clear or almost clear IGA rose from 36.0% at 3 months to 66.2% at 52 weeks. Mild erythema (100%) and edema (98.1%) were common; no blistering, crusting, or hypo-/hyperpigmentation were observed.","limitations":"No control group, reliance on image-based assessment, and open-label design.","practice_takeaway":"Three sessions of a 1726‑nm sebum‑selective laser produced sustained acne improvement through 1 year in Fitzpatrick II–VI with only transient erythema/edema and no observed pigmentary events; interpret efficacy cautiously given the uncontrolled design."}},{"doi":"10.1111/jocd.70494","pmid":"41051026","title":"Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies","journal_title":"Journal of Cosmetic Dermatology","journal_issn":"1473-2130","published_at":"2025-10-06T00:00:00.000Z","url":"https://doi.org/10.1111/jocd.70494","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-12","doi":"10.1111/jocd.70494","days":"7","issn":"1473-2130","rank":"9","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jocd.70494","title":"Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies.","journal":"Journal of cosmetic dermatology","methods":"","results":"Finally, 56 articles were selected based on the eligibility criteria. We summarized and categorized them into two general entities, including applications of the topical dapsone and side effects of the topical dapsone. The first entity has six subheadings consisting of acne vulgaris and acneiform eruptions, Rosacea, neutrophilic dermatosis, vesiculobullous diseases, vasculitis, and others.","abstract":"$33","keywords":["dapsone","dermatology","skin","sulfones","topical"],"pubmed_id":"41051026","conclusions":"In conclusion, topical dapsone appears to have therapeutic advantages in several mucocutaneous conditions, especially in minimal, localized, and chronic eruptions.","publication_date":"2025-10-06T00:00:00"},"crossref":{"DOI":"10.1111/jocd.70494","URL":"https://doi.org/10.1111/jocd.70494","ISSN":["1473-2130","1473-2165"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jocd.70494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"10","score":1,"title":["Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies"],"author":[{"given":"Bahareh","family":"Abtahi‐Naeini","sequence":"first","affiliation":[{"name":"Pediatric Dermatology Division, Department of Pediatrics Imam Hossein Children's Hospital, Isfahan University of Medical Sciences Isfahan Iran"},{"name":"Skin Diseases and Leishmaniasis Research Center Isfahan University of Medical Sciences Isfahan Iran"}]},{"given":"Hossein","family":"Sattari","sequence":"additional","affiliation":[{"name":"Clinical Research Development Center, Najafabad Branch Islamic Azad University Najafabad Iran"},{"name":"Student Research Committee Isfahan University of Medical Sciences Isfahan Iran"}]},{"given":"Kimia","family":"Afshar","sequence":"additional","affiliation":[{"name":"Student Research Committee Isfahan University of Medical Sciences Isfahan Iran"}]},{"given":"Fereshte","family":"Rastegarnasab","sequence":"additional","affiliation":[{"name":"Student Research Committee Isfahan University of Medical Sciences Isfahan Iran"}]},{"given":"Mahsa","family":"Pourmahdi‐Boroujeni","sequence":"additional","affiliation":[{"name":"Student Research Committee Isfahan University of Medical Sciences Isfahan Iran"},{"name":"Isfahan Eye Research Center Isfahan University of Medical Sciences Isfahan Iran"}]}],"issued":{"date-parts":[[2025,10]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"24","archive":["Portico"],"created":{"date-time":"2025-10-06T23:34:06Z","timestamp":1759793646000,"date-parts":[[2025,10,6]]},"indexed":{"date-time":"2025-10-16T08:40:44Z","timestamp":1760604044979,"date-parts":[[2025,10,16]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000,"date-parts":[[2025,10,6]]},"delay-in-days":5,"content-version":"vor"}],"subject":[],"abstract":"$34","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.70494"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-06-09"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-26"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-06"}],"deposited":{"date-time":"2025-10-16T08:15:38Z","timestamp":1760602538000,"date-parts":[[2025,10,16]]},"issn-type":[{"type":"print","value":"1473-2130"},{"type":"electronic","value":"1473-2165"}],"published":{"date-parts":[[2025,10]]},"publisher":"Wiley","reference":[{"DOI":"10.21037/apm-21-3935","key":"e_1_2_11_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/17425255.2019.1600670","key":"e_1_2_11_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00403-013-1409-7","key":"e_1_2_11_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.14761","key":"e_1_2_11_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/15569527.2021.2024565","key":"e_1_2_11_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/1203475416651053","key":"e_1_2_11_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ipd.12615","key":"e_1_2_11_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_9_1","year":"2012","issue":"4","author":"Handler M. Z.","volume":"6","first-page":"132","unstructured":null,"article-title":"Letter to the Editor: Application of Dapsone 5% Gel in a Patient With Dermatitis Herpetiformis","journal-title":"Journal of Dermatology Case Reports","doi-asserted-by":null},{"DOI":"10.1177/1203475418795818","key":"e_1_2_11_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_11_1","year":"2011","issue":"9","author":"Handler M. Z.","volume":"10","first-page":"1059","unstructured":null,"article-title":"Treatment of Peristomal Pyoderma Gangrenosum With Topical Crushed Dapsone","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":null},{"DOI":"10.1177/1203475418782140","key":"e_1_2_11_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.13471","key":"e_1_2_11_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.14953","key":"e_1_2_11_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2011.10.011","key":"e_1_2_11_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2021.07.004","key":"e_1_2_11_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4103/ijt.ijt_39_22","key":"e_1_2_11_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4103/ds.DS-D-24-00037","key":"e_1_2_11_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_19_1","year":"2013","issue":"4","author":"Frieling G. W.","volume":"12","first-page":"481","unstructured":null,"article-title":"Novel Use of Topical Dapsone 5% Gel for Erythema Elevatum Diutinum: Safer and Effective","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_20_1","year":"2017","issue":"6","author":"Pate D. A.","volume":"99","first-page":"426","unstructured":null,"article-title":"Leukocytoclastic Vasculitis Resolution With Topical Dapsone","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_21_1","year":"2016","issue":"4","author":"Aflatoonian M.","volume":"26","first-page":"353","unstructured":null,"article-title":"The Efficacy of Combined Topical Niosomal Dapsone Gel and Intralesional Injection of Meglumine Antimoniate in Comparison With Intralesional Meglumine Antimoniate and Cryotherapy in the Treatment of Cutaneous Leishmaniasis","journal-title":"Journal of Pakistan Association of Dermatologists","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_22_1","year":"2015","issue":"6","author":"Faghihi G.","volume":"14","first-page":"602","unstructured":null,"article-title":"Dapsone Gel in the Treatment of Papulopustular Rosacea: A Double‐Blind Randomized Clinical Trial","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":null},{"DOI":"10.1080/15569527.2024.2424932","key":"e_1_2_11_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ced.13742","key":"e_1_2_11_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_25_1","year":"2024","issue":"1","author":"Gökşin Ş.","volume":"14","first-page":"1","unstructured":null,"article-title":"Efficacy of Topical Dapsone 5% Gel for the Treatment of Erythematotelangiectatic Rosacea: New Treatment Option With Old Drug","journal-title":"Dermatology Practical & Conceptual","doi-asserted-by":null},{"DOI":"10.1159/000431171","key":"e_1_2_11_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.5070/D3208023535","key":"e_1_2_11_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_28_1","year":"2015","issue":"7","author":"Kassardjian M.","volume":"8","first-page":"48","unstructured":null,"article-title":"Management of Periocular Granuloma Annulare Using Topical Dapsone","journal-title":"Journal of Clinical and Aesthetic Dermatology","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_29_1","year":"2015","issue":"5","author":"Watton C.","volume":"372","first-page":"492","unstructured":null,"article-title":"Methemoglobinemia as a Complication of Topical Dapsone","journal-title":"New England Journal of Medicine","doi-asserted-by":null},{"DOI":"10.1542/peds.2015-3186","key":"e_1_2_11_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.14080","key":"e_1_2_11_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_32_1","year":"2022","issue":"9","author":"Cantrell C.","volume":"14","first-page":null,"unstructured":null,"article-title":"Refractory Methemoglobinemia Secondary to Topical Dapsone With Subsequent Autoimmune Hemolytic Anemia","journal-title":"Cureus Journal of Medical Science","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_33_1","year":"2015","issue":"1","author":"Del Rosso J. Q.","volume":"8","first-page":"31","unstructured":null,"article-title":"Comparative Efficacy and Tolerability of Dapsone 5% Gel in Adult Versus Adolescent Females With Acne Vulgaris","journal-title":"Journal of Clinical and Aesthetic Dermatology","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2006.10.005","key":"e_1_2_11_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jocd.70494"],"article-number":"e70494","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Cosmetic Dermatology"],"published-print":{"date-parts":[[2025,10]]},"reference-count":33,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,6]]},"references-count":33,"short-container-title":["J of Cosmetic Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jocd.70494","is_oa":true,"title":"Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies","updated":"2025-10-11T00:07:04+00:00","published_date":"2025-10-01","best_oa_location":{"url":"https://doi.org/10.1111/jocd.70494","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1111/jocd.70494"}}},"created_at":"2025-10-16T07:50:39.785Z","updated_at":"2025-10-18T07:47:19.581Z","tags":[{"paper_doi":"10.1111/jocd.70494","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Neutrophilic Dermatoses","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Rosacea","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Vasculitis","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Vesiculobullous Diseases","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"generic","value":"dapsone","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"modality","value":"Topical Sulfone","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"sample_size","value":"n=56","value_numeric":56},{"paper_doi":"10.1111/jocd.70494","tag_type":"study_design","value":"Scoping Review","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"warning","value":"Heterogeneous conditions and designs make the study type classification and generalizability uncertain.","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"warning","value":"Only abstract-level details are available; no pooled or numeric outcomes were reported here.","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"warning","value":"The abstract is inconsistent about excluding versus including acne vulgaris.","value_numeric":null}],"summaries":{"what_studied":"A PRISMA-guided scoping review searched PubMed, Web of Science, and Scopus through April 2025 and included 56 clinical articles on topical dapsone (5% or 7.5% gel) for mucocutaneous conditions, summarizing efficacy and side effects.","limitations":"The evidence is a scoping review across diverse conditions without quantified outcomes. The abstract conflicts on whether acne vulgaris was excluded or included.","practice_takeaway":"Topical dapsone (5% or 7.5% gel) may be an option for localized, chronic mucocutaneous eruptions when avoiding systemic therapy, but the support is heterogeneous and not quantified here."}},{"doi":"10.1007/s13555-025-01411-4","pmid":"40246799","title":"Prospective Comparative Study of an Oral Synbiotic and a Myoinositol-Based Herbal Supplement in Modifying Hormone Levels and the Gut Microbiome in Non-cystic Acne","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2025-04-18T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-025-01411-4","source_score":45,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-05-23","doi":"10.1007/s13555-025-01411-4","days":"30","issn":"2193-8210","rank":"5","field":"Clinical Medicine","score":"45","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1007/s13555-025-01411-4","title":"Prospective Comparative Study of an Oral Synbiotic and a Myoinositol-Based Herbal Supplement in Modifying Hormone Levels and the Gut Microbiome in Non-cystic Acne.","journal":"Dermatology and therapy","methods":"","results":"Several gut bacteria increased by at least threefold at both week 4 and 8 in the synbiotic (Erysipelatoclostridium merdavium, Blautia argi, Faecalibacterium prausnitzii, Prevotella copri, Streptococcus sp001556435, Blautia sp900541955) and MBHS group (Megamonas funiformis, Ligilactobacillus ruminis, Prevotella ssp015074785, Prevotella copri, Gca-900199835 sp900176495). Acne lesion counts decreased significantly in both groups at week 4 (p < 0.0001) and week 8 (synbiotic, p < 0.0001; MBHS, p < 0.0001). There were significant and trending increases in stool and plasma SCFAs in both cohorts at week 4 and 8. After 8 weeks of MBHS, 17-OHP and androstenedione significantly decreased from 27.3 to 11.3 pg/ml (p = 0.001) and 94.9 to 68.0 pg/ml (p = 0.04), respectively.","abstract":"$35","keywords":["EGCG","Guggul","Gut microbiome","Herbal supplement","Myoinositol","Noncystic acne","Probiotic","Short chain fatty acids","Silymarin"],"pubmed_id":"40246799","conclusions":"Both the synbiotic and MBHS improved gut health, augmented SCFAs, and reduced lesion counts in those with non-cystic acne. The MBHS may act by reducing hormone levels of 17-OHP and androstenedione.","publication_date":"2025-04-18T00:00:00"},"crossref":{"DOI":"10.1007/s13555-025-01411-4","URL":"https://doi.org/10.1007/s13555-025-01411-4","ISSN":["2193-8210","2190-9172"],"link":[{"URL":"https://link.springer.com/content/pdf/10.1007/s13555-025-01411-4.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/article/10.1007/s13555-025-01411-4/fulltext.html","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/content/pdf/10.1007/s13555-025-01411-4.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":"1331-1350","type":"journal-article","issue":"6","score":1,"title":["Prospective Comparative Study of an Oral Synbiotic and a Myoinositol-Based Herbal Supplement in Modifying Hormone Levels and the Gut Microbiome in Non-cystic Acne"],"author":[{"given":"Mildred","family":"Min","sequence":"first","affiliation":[]},{"given":"Nasima","family":"Afzal","sequence":"additional","affiliation":[]},{"given":"Jessica","family":"Maloh","sequence":"additional","affiliation":[]},{"given":"Ajay S.","family":"Dulai","sequence":"additional","affiliation":[]},{"given":"Nabeel","family":"Ahmad","sequence":"additional","affiliation":[]},{"given":"David","family":"Pinzauti","sequence":"additional","affiliation":[]},{"given":"Raja K.","family":"Sivamani","sequence":"additional","affiliation":[]}],"funder":[{"name":"Codex Labs"}],"issued":{"date-parts":[[2025,4,18]]},"member":"297","prefix":"10.1007","source":"Crossref","volume":"15","created":{"date-time":"2025-04-18T02:57:16Z","timestamp":1744945036000,"date-parts":[[2025,4,18]]},"indexed":{"date-time":"2025-09-09T22:28:37Z","timestamp":1757456917746,"date-parts":[[2025,9,9]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc/4.0","start":{"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000,"date-parts":[[2025,4,18]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://creativecommons.org/licenses/by-nc/4.0","start":{"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000,"date-parts":[[2025,4,18]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://link.springer.com/10.1007/s13555-025-01411-4"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"ArticleHistory","label":"Article History"},"label":"Received","order":1,"value":"11 February 2025"},{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":2,"value":"6 April 2025"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":3,"value":"18 April 2025"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"},"order":1},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"},"order":2,"value":"Jessica Maloh serves as a consultant and stockholder for Codex Labs. Raja K. Sivamani serves as a scientific advisor and a holder of stock options with Codex Labs, a scientific advisor to Arbonne, and as a consultant to Burt’s Bees, Novozymes, Nutrafol, Abbvie, Leo, Galderma, Pfizer, UCB, Incyte, Sanofi, Novartis, Arcutis, Amgen, Sun and Regeneron Pharmaceuticals. Mildred Min, Nasima Afzal, Ajay Dulai, Nabeel Ahmad, and David Pinzauti report no conflict of interest."},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"},"order":3,"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Allendale Institutional Review Board (CB_Acne_Supp) on June 26, 2023. Written informed consent and assent (where appropriate) was obtained from all subjects and/or guardians involved in the study."}],"deposited":{"date-time":"2025-05-20T18:02:52Z","timestamp":1747764172000,"date-parts":[[2025,5,20]]},"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"published":{"date-parts":[[2025,4,18]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.3390/molecules21081063","key":"1411_CR1","year":"2016","issue":"8","author":"L Fox","volume":"21","first-page":"1063","unstructured":"Fox L, Csongradi C, Aucamp M, du Plessis J, Gerber M. Treatment modalities for acne. Molecules. 2016;21(8):1063.","article-title":null,"journal-title":"Molecules","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.12149","key":"1411_CR2","year":"2013","issue":"3","author":"K Bhate","volume":"168","first-page":"474","unstructured":"Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168(3):474–85.","article-title":null,"journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2019.1654075","key":"1411_CR3","year":"2021","issue":"3","author":"N Hazarika","volume":"32","first-page":"277","unstructured":"Hazarika N. Acne vulgaris: new evidence in pathogenesis and future modalities of treatment. J Dermatol Treat. 2021;32(3):277–85.","article-title":null,"journal-title":"J Dermatol Treat","doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.14586","key":"1411_CR4","year":"2018","issue":"10","author":"HM Yan","volume":"45","first-page":"1166","unstructured":"Yan HM, Zhao HJ, Guo DY, Zhu PQ, Zhang CL, Jiang W. Gut microbiota alterations in moderate to severe acne vulgaris patients. J Dermatol. 2018;45(10):1166–71.","article-title":null,"journal-title":"J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.3389/fmicb.2022.1083432","key":"1411_CR5","year":"2022","issue":null,"author":"X Xiao","volume":"13","first-page":"1083432","unstructured":"Xiao X, Hu X, Yao J, et al. The role of short-chain fatty acids in inflammatory skin diseases. Front Microbiol. 2022;13:1083432.","article-title":null,"journal-title":"Front Microbiol","doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms24087053","key":"1411_CR6","year":"2023","issue":"8","author":"J Nowowiejska","volume":"24","first-page":"7053","unstructured":"Nowowiejska J, Baran A, Flisiak I. Lipid alterations and metabolism disturbances in selected inflammatory skin diseases. Int J Mol Sci. 2023;24(8):7053.","article-title":null,"journal-title":"Int J Mol Sci","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00726-023-03320-2","key":"1411_CR7","year":"2023","issue":"10","author":"Q He","volume":"55","first-page":"1417","unstructured":"He Q, Shu H, Peng Y, et al. Untargeted metabolomics analysis of plasma metabolic characteristics in patients with acne and insulin resistance. Amino Acids. 2023;55(10):1417–28.","article-title":null,"journal-title":"Amino Acids","doi-asserted-by":"publisher"},{"DOI":null,"key":"1411_CR8","year":"2017","issue":"2","author":"A Jovic","volume":"25","first-page":"1133","unstructured":"Jovic A, Marinovic B, Kostovic K, Ceovic R, Basta-Juzbasic A, Bukvic MZ. The impact of pyschological stress on acne. Acta Dermatovenerol Croat. 2017;25(2):1133–41.","article-title":null,"journal-title":"Acta Dermatovenerol Croat","doi-asserted-by":null},{"DOI":"10.2147/CCID.S148499","key":"1411_CR9","year":"2017","issue":null,"author":"S Zari","volume":"10","first-page":"503","unstructured":"Zari S, Alrahmani D. The association between stress and acne among female medical students in Jeddah, Saudi Arabia. Clin Cosmet Investig Dermatol. 2017;10:503–6.","article-title":null,"journal-title":"Clin Cosmet Investig Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/cpt1978244465","key":"1411_CR10","year":"1978","issue":"4","author":"DH Huffman","volume":"24","first-page":"465","unstructured":"Huffman DH, Kampmann JP, Hignite CE, Azarnoff DL. Gynecomastia induced in normal males by spironolactone. Clin Pharmacol Ther. 1978;24(4):465–73.","article-title":null,"journal-title":"Clin Pharmacol Ther","doi-asserted-by":"publisher"},{"DOI":"10.2310/7750.2012.12026","key":"1411_CR11","year":"2013","issue":"2","author":"GW Jung","volume":"17","first-page":"114","unstructured":"Jung GW, Tse JE, Guiha I, Rao J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. J Cutan Med Surg. 2013;17(2):114–22.","article-title":null,"journal-title":"J Cutan Med Surg","doi-asserted-by":"publisher"},{"DOI":"10.3390/microorganisms10071303","key":"1411_CR12","year":"2022","issue":"7","author":"P Sanchez-Pellicer","volume":"10","first-page":"1303","unstructured":"Sanchez-Pellicer P, Navarro-Moratalla L, Nunez-Delegido E, Ruzafa-Costas B, Aguera-Santos J, Navarro-Lopez V. Acne, microbiome, and probiotics: the gut-skin axis. Microorganisms. 2022;10(7):1303.","article-title":null,"journal-title":"Microorganisms","doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms25041984","key":"1411_CR13","year":"2024","issue":"4","author":"I Rygula","volume":"25","first-page":"1984","unstructured":"Rygula I, Pikiewicz W, Grabarek BO, Wojcik M, Kaminiow K. The role of the gut microbiome and microbial dysbiosis in common skin diseases. Int J Mol Sci. 2024;25(4):1984.","article-title":null,"journal-title":"Int J Mol Sci","doi-asserted-by":"publisher"},{"DOI":"10.3390/jcm8070987","key":"1411_CR14","year":"2019","issue":"7","author":"YB Lee","volume":"8","first-page":"987","unstructured":"Lee YB, Byun EJ, Kim HS. Potential role of the microbiome in acne: a comprehensive review. J Clin Med. 2019;8(7):987.","article-title":null,"journal-title":"J Clin Med","doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-2968","key":"1411_CR15","year":"2018","issue":"8","author":"Y Deng","volume":"98","first-page":"783","unstructured":"Deng Y, Wang H, Zhou J, Mou Y, Wang G, Xiong X. Patients with acne vulgaris have a distinct gut microbiota in comparison with healthy controls. Acta Derm Venereol. 2018;98(8):783–90.","article-title":null,"journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1411_CR16","year":"2001","issue":"6","author":"LA Volkova","volume":"79","first-page":"39","unstructured":"Volkova LA, Khalif IL, Kabanova IN. Impact of the impaired intestinal microflora on the course of acne vulgaris. Klin Med (Mosk). 2001;79(6):39–41.","article-title":null,"journal-title":"Klin Med (Mosk)","doi-asserted-by":null},{"DOI":"10.1111/jam.13349","key":"1411_CR17","year":"2017","issue":"2","author":"EG Lopes","volume":"122","first-page":"450","unstructured":"Lopes EG, Moreira DA, Gullon P, Gullon B, Cardelle-Cobas A, Tavaria FK. Topical application of probiotics in skin: adhesion, antimicrobial and antibiofilm in vitro assays. J Appl Microbiol. 2017;122(2):450–61.","article-title":null,"journal-title":"J Appl Microbiol","doi-asserted-by":"publisher"},{"DOI":"10.1097/MCG.0000000000001053","key":"1411_CR18","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Deidda F, Amoruso A, Nicola S, Graziano T, Pane M, Mogna L. New approach in acne therapy: a specific bacteriocin activity and a targeted anti IL-8 property in just 1 probiotic strain, the L. salivarius LS03. J Clin Gastroenterol. 2018 Nov/Dec;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017:S78-S81.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.3920/BM2016.0089","key":"1411_CR19","year":"2016","issue":"5","author":"G Fabbrocini","volume":"7","first-page":"625","unstructured":"Fabbrocini G, Bertona M, Picazo O, Pareja-Galeano H, Monfrecola G, Emanuele E. Supplementation with Lactobacillus rhamnosus SP1 normalises skin expression of genes implicated in insulin signalling and improves adult acne. Benef Microbes. 2016;7(5):625–30.","article-title":null,"journal-title":"Benef Microbes","doi-asserted-by":"publisher"},{"DOI":"10.1038/nri2711","key":"1411_CR20","year":"2010","issue":"3","author":"M Saraiva","volume":"10","first-page":"170","unstructured":"Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170–81.","article-title":null,"journal-title":"Nat Rev Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-021-00664-z","key":"1411_CR21","year":"2022","issue":"2","author":"F Rinaldi","volume":"12","first-page":"577","unstructured":"Rinaldi F, Marotta L, Mascolo A, et al. Facial acne: a randomized, double-blind, placebo-controlled study on the clinical efficacy of a symbiotic dietary supplement. Dermatol Ther (Heidelb). 2022;12(2):577–89.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.3390/jpm13010096","key":"1411_CR22","year":"2022","issue":"1","author":"JH Saurat","volume":"13","first-page":"96","unstructured":"Saurat JH, Reygagne P, Josse G, et al. Long-term use of silybum marianum fruit extract contributes to homeostasis in acne-prone skin—a 12-month follow-up international “real life” cohort study. J Pers Med. 2022;13(1):96.","article-title":null,"journal-title":"J Pers Med","doi-asserted-by":"publisher"},{"DOI":"10.3390/molecules25235566","key":"1411_CR23","year":"2020","issue":"23","author":"Z Kamenov","volume":"25","first-page":"5566","unstructured":"Kamenov Z, Gateva A. Inositols in PCOS. Molecules. 2020;25(23):5566.","article-title":null,"journal-title":"Molecules","doi-asserted-by":"publisher"},{"DOI":"10.1530/EC-17-0243","key":"1411_CR24","year":"2017","issue":"8","author":"V Unfer","volume":"6","first-page":"647","unstructured":"Unfer V, Facchinetti F, Orru B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647–58.","article-title":null,"journal-title":"Endocr Connect","doi-asserted-by":"publisher"},{"DOI":"10.3389/fphar.2023.1269605","key":"1411_CR25","year":"2023","issue":null,"author":"F Di Pierro","volume":"14","first-page":"1269605","unstructured":"Di Pierro F, Sultana R, Eusaph AZ, et al. Effect of berberine phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial. Front Pharmacol. 2023;14:1269605.","article-title":null,"journal-title":"Front Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1467-2494.2006.00308.x","key":"1411_CR26","year":"2006","issue":"2","author":"J Viyoch","volume":"28","first-page":"125","unstructured":"Viyoch J, Pisutthanan N, Faikreua A, Nupangta K, Wangtorpol K, Ngokkuen J. Evaluation of in vitro antimicrobial activity of Thai basil oils and their micro-emulsion formulas against Propionibacterium acnes. Int J Cosmet Sci. 2006;28(2):125–33.","article-title":null,"journal-title":"Int J Cosmet Sci","doi-asserted-by":"publisher"},{"DOI":"10.3390/nu11102362","key":"1411_CR27","year":"2019","issue":"10","author":"S Hidese","volume":"11","first-page":"2362","unstructured":"Hidese S, Ogawa S, Ota M, et al. Effects of l-theanine administration on stress-related symptoms and cognitive functions in healthy adults: a randomized controlled trial. Nutrients. 2019;11(10):2362.","article-title":null,"journal-title":"Nutrients","doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms18051070","key":"1411_CR28","year":"2017","issue":"5","author":"AK Clark","volume":"18","first-page":"1070","unstructured":"Clark AK, Haas KN, Sivamani RK. Edible plants and their influence on the gut microbiome and acne. Int J Mol Sci. 2017;18(5):1070.","article-title":null,"journal-title":"Int J Mol Sci","doi-asserted-by":"publisher"},{"DOI":"10.3390/microorganisms11030804","key":"1411_CR29","year":"2023","issue":"3","author":"M Szoboszlay","volume":"11","first-page":"804","unstructured":"Szoboszlay M, Schramm L, Pinzauti D, Scerri J, Sandionigi A, Biazzo M. Nanopore is preferable over Illumina for 16S amplicon sequencing of the gut microbiota when species-level taxonomic classification, accurate estimation of richness, or focus on rare taxa is required. Microorganisms. 2023;11(3):804.","article-title":null,"journal-title":"Microorganisms","doi-asserted-by":"publisher"},{"DOI":"10.1038/nmeth.3869","key":"1411_CR30","year":"2016","issue":"7","author":"BJ Callahan","volume":"13","first-page":"581","unstructured":"Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581–3.","article-title":null,"journal-title":"Nat Methods","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41592-022-01520-4","key":"1411_CR31","year":"2022","issue":"7","author":"KD Curry","volume":"19","first-page":"845","unstructured":"Curry KD, Wang Q, Nute MG, et al. Emu: species-level microbial community profiling of full-length 16S rRNA Oxford Nanopore sequencing data. Nat Methods. 2022;19(7):845–53.","article-title":null,"journal-title":"Nat Methods","doi-asserted-by":"publisher"},{"DOI":"10.1093/nar/gkab776","key":"1411_CR32","year":"2021","issue":"D1","author":"DH Parks","volume":"50","first-page":"D785","unstructured":"Parks DH, Chuvochina M, Rinke C, Mussig AJ, Chaumeil P-A, Hugenholtz P. GTDB: an ongoing census of bacterial and archaeal diversity through a phylogenetically consistent, rank normalized and complete genome-based taxonomy. Nucleic Acids Res. 2021;50(D1):D785–94.","article-title":null,"journal-title":"Nucleic Acids Res","doi-asserted-by":"publisher"},{"DOI":null,"key":"1411_CR33","year":"2011","issue":"11","author":"AZ Juniarto","volume":"52","first-page":"810","unstructured":"Juniarto AZ, Goossens K, Setyawati BA, Drop SL, de Jong FH, Faradz SM. Correlation between androstenedione and 17-hydroxyprogesterone levels in the saliva and plasma of patients with congenital adrenal hyperplasia. Singapore Med J. 2011;52(11):810–3.","article-title":null,"journal-title":"Singapore Med J","doi-asserted-by":null},{"DOI":"10.2340/actadv.v104.33206","key":"1411_CR34","year":"2024","issue":null,"author":"C Eguren","volume":"104","first-page":"adv33206","unstructured":"Eguren C, Navarro-Blasco A, Corral-Forteza M, et al. A randomized clinical trial to evaluate the efficacy of an oral probiotic in acne vulgaris. Acta Derm Venereol. 2024;104:adv33206.","article-title":null,"journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1346-8138.1994.tb03277.x","key":"1411_CR35","year":"1994","issue":"10","author":"DM Thappa","volume":"21","first-page":"729","unstructured":"Thappa DM, Dogra J. Nodulocystic acne: oral gugulipid versus tetracycline. J Dermatol. 1994;21(10):729–31.","article-title":null,"journal-title":"J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ctim.2016.03.004","key":"1411_CR36","year":"2016","issue":null,"author":"PH Lu","volume":"25","first-page":"159","unstructured":"Lu PH, Hsu CH. Does supplementation with green tea extract improve acne in post-adolescent women? A randomized, double-blind, and placebo-controlled clinical trial. Complement Ther Med. 2016;25:159–63.","article-title":null,"journal-title":"Complement Ther Med","doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.13095","key":"1411_CR37","year":"2019","issue":"6","author":"M Shie Morteza","volume":"32","first-page":null,"unstructured":"Shie Morteza M, Hayati Z, Namazi N, Abdollahimajd F. Efficacy and safety of oral silymarin in comparison with oral doxycycline and their combination therapy in the treatment of acne vulgaris. Dermatol Ther. 2019;32(6):e13095.","article-title":null,"journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.3389/fnut.2022.965130","key":"1411_CR38","year":"2022","issue":null,"author":"AL Lopresti","volume":"9","first-page":null,"unstructured":"Lopresti AL, Smith SJ, Metse AP, Drummond PD. A randomized, double-blind, placebo-controlled trial investigating the effects of an Ocimum tenuiflorum (Holy Basil) extract (Holixer™) on stress, mood, and sleep in adults experiencing stress. Front Nutr. 2022;9: 965130.","article-title":null,"journal-title":"Front Nutr","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12964-023-01219-9","key":"1411_CR39","year":"2023","issue":"1","author":"D Zhang","volume":"21","first-page":"212","unstructured":"Zhang D, Jian YP, Zhang YN, et al. Short-chain fatty acids in diseases. Cell Commun Signal. 2023;21(1):212.","article-title":null,"journal-title":"Cell Commun Signal","doi-asserted-by":"publisher"},{"DOI":"10.3390/microorganisms10122382","key":"1411_CR40","year":"2022","issue":"12","author":"R Effendi","volume":"10","first-page":"2382","unstructured":"Effendi R, Anshory M, Kalim H, et al. Akkermansia muciniphila and Faecalibacterium prausnitzii in immune-related diseases. Microorganisms. 2022;10(12):2382.","article-title":null,"journal-title":"Microorganisms","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12272-012-0614-9","key":"1411_CR41","year":"2012","issue":"6","author":"DK Lee","volume":"35","first-page":"1065","unstructured":"Lee DK, Kim MJ, Ham JW, et al. In vitro evaluation of antibacterial activities and anti-inflammatory effects of Bifidobacterium spp. addressing acne vulgaris. Arch Pharm Res. 2012;35(6):1065–71.","article-title":null,"journal-title":"Arch Pharm Res","doi-asserted-by":"publisher"},{"DOI":"10.4049/jimmunol.1403169","key":"1411_CR42","year":"2015","issue":"9","author":"M Sassone-Corsi","volume":"194","first-page":"4081","unstructured":"Sassone-Corsi M, Raffatellu M. No vacancy: how beneficial microbes cooperate with immunity to provide colonization resistance to pathogens. J Immunol. 2015;194(9):4081–7.","article-title":null,"journal-title":"J Immunol","doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2019.00277","key":"1411_CR43","year":"2019","issue":null,"author":"D Parada Venegas","volume":"10","first-page":"277","unstructured":"Parada Venegas D, De la Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277.","article-title":null,"journal-title":"Front Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000365656","key":"1411_CR44","year":"2014","issue":"4","author":"B Wei","volume":"229","first-page":"359","unstructured":"Wei B, Qu L, Zhu H, et al. Higher 17alpha-hydroxyprogesterone levels aggravated the severity of male adolescent acne in Northeast China. Dermatology. 2014;229(4):359–62.","article-title":null,"journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.4103/0019-5154.127667","key":"1411_CR45","year":"2014","issue":"2","author":"S Ghosh","volume":"59","first-page":"107","unstructured":"Ghosh S, Chaudhuri S, Jain VK, Aggarwal K. Profiling and hormonal therapy for acne in women. Indian J Dermatol. 2014;59(2):107–15.","article-title":null,"journal-title":"Indian J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2023.2298878","key":"1411_CR46","year":"2024","issue":"1","author":"JQ Del Rosso","volume":"35","first-page":"2298878","unstructured":"Del Rosso JQ, Kircik L. The cutaneous effects of androgens and androgen-mediated sebum production and their pathophysiologic and therapeutic importance in acne vulgaris. J Dermatolog Treat. 2024;35(1):2298878.","article-title":null,"journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1155/2016/1674950","key":"1411_CR47","year":"2016","issue":null,"author":"M Montanino Oliva","volume":"2016","first-page":"1674950","unstructured":"Montanino Oliva M, Minutolo E, Lippa A, Iaconianni P, Vaiarelli A. Effect of myoinositol and antioxidants on sperm quality in men with metabolic syndrome. Int J Endocrinol. 2016;2016:1674950.","article-title":null,"journal-title":"Int J Endocrinol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1411_CR48","year":"2006","issue":"5","author":"R Agostini","volume":"10","first-page":"247","unstructured":"Agostini R, Rossi F, Pajalich R. Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled study. Eur Rev Med Pharmacol Sci. 2006;10(5):247–50.","article-title":null,"journal-title":"Eur Rev Med Pharmacol Sci","doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1411"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Dermatology and Therapy"],"published-print":{"date-parts":[[2025,6]]},"reference-count":48,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,4,18]]},"references-count":48,"clinical-trial-number":[{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct05919810"}],"short-container-title":["Dermatol Ther (Heidelb)"],"is-referenced-by-count":2},"unpaywall":{"doi":"10.1007/s13555-025-01411-4","is_oa":true,"title":"Prospective Comparative Study of an Oral Synbiotic and a Myoinositol-Based Herbal Supplement in Modifying Hormone Levels and the Gut Microbiome in Non-cystic Acne","updated":"2025-08-04T14:10:34+00:00","published_date":"2025-04-18","best_oa_location":{"url":"https://link.springer.com/content/pdf/10.1007/s13555-025-01411-4.pdf","pmh_id":null,"url_for_pdf":"https://link.springer.com/content/pdf/10.1007/s13555-025-01411-4.pdf","url_for_landing_page":"https://doi.org/10.1007/s13555-025-01411-4"}}},"created_at":"2025-09-19T21:51:03.802Z","updated_at":"2025-09-19T21:51:03.802Z","tags":[{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"generic","value":"myo-inositol","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"modality","value":"Myoinositol","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"modality","value":"Synbiotic","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"sample_size","value":"n=36","value_numeric":36},{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"warning","value":"Absolute lesion count changes were not provided.","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"warning","value":"Randomization is reported, but blinding and the nature of the control/comparator are unclear.","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01411-4","tag_type":"warning","value":"Small, short study; microbiome findings may not generalize.","value_numeric":null}],"summaries":{"what_studied":"An 8‑week randomized study of 36 males and females aged 12–45 with non‑cystic acne compared an oral synbiotic containing herbs versus a myoinositol‑based herbal supplement, measuring acne lesion counts, gut microbiome and short‑chain fatty acids (SCFAs), and hormones at baseline, 4, and 8 weeks.","key_result":"Both groups had significant reductions in acne lesion counts at week 4 (p<0.0001) and week 8 (synbiotic p<0.0001; myoinositol‑based herbal supplement p<0.0001), along with increases in stool and plasma SCFAs. After 8 weeks of the myoinositol‑based herbal supplement, 17‑OHP fell from 27.3 to 11.3 pg/ml (p=0.001) and androstenedione from 94.9 to 68.0 pg/ml (p=0.04); several gut bacteria increased ≥3‑fold in each group.","limitations":"Small sample (n=36) and short follow‑up (8 weeks). Absolute changes in lesion counts were not reported, and blinding/control details were not described in the provided text.","practice_takeaway":"Over 8 weeks, both an oral synbiotic and a myoinositol‑based herbal supplement were associated with fewer acne lesions and higher SCFAs; the myoinositol‑based product also lowered 17‑OHP and androstenedione. These findings suggest potential biologic effects in non‑cystic acne but come from a small, short trial."}},{"doi":"10.1111/jdv.20697","pmid":"40235284","title":"Acne and eating disorders: A retrospective cohort study of US adults","journal_title":"Journal of the European Academy of Dermatology and Venereology","journal_issn":"0926-9959","published_at":"2025-04-16T00:00:00.000Z","url":"https://doi.org/10.1111/jdv.20697","source_score":254,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-05-01","doi":"10.1111/jdv.20697","days":"30","issn":"0926-9959","rank":"1","field":"Clinical Medicine","score":"254","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jdv.20697","title":"Acne and eating disorders: A retrospective cohort study of US adults.","journal":"Journal of the European Academy of Dermatology and Venereology : JEADV","methods":"","results":"","abstract":"","keywords":[],"pubmed_id":"40235284","conclusions":"","publication_date":"2025-04-16T00:00:00"},"crossref":{"DOI":"10.1111/jdv.20697","URL":"https://doi.org/10.1111/jdv.20697","ISSN":["0926-9959","1468-3083"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.20697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Acne and eating disorders: A retrospective cohort study of US adults"],"author":[{"given":"Michael R.","family":"Nock","sequence":"first","affiliation":[{"name":"Department of Dermatology Yale School of Medicine New Haven Connecticut USA"}]},{"given":"Marney A.","family":"White","sequence":"additional","affiliation":[{"name":"Department of Social and Behavioral Sciences Yale School of Public Health New Haven Connecticut USA"},{"name":"Department of Psychiatry Yale School of Medicine New Haven Connecticut USA"}]},{"given":"Jeffrey M.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Dermatology Yale School of Medicine New Haven Connecticut USA"},{"name":"Department of Biomedical Informatics and Data Science Yale School of Public Health New Haven Connecticut USA"}]}],"issued":{"date-parts":[[2025,4,16]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-04-16T07:26:16Z","timestamp":1744788376000,"date-parts":[[2025,4,16]]},"indexed":{"date-time":"2025-07-30T12:36:37Z","timestamp":1753878997765,"date-parts":[[2025,7,30]]},"license":[{"URL":"http://onlinelibrary.wiley.com/termsAndConditions#vor","start":{"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000,"date-parts":[[2025,4,16]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jdv.20697"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2024-10-21"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-04-01"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-04-16"}],"deposited":{"date-time":"2025-04-16T07:26:19Z","timestamp":1744788379000,"date-parts":[[2025,4,16]]},"issn-type":[{"type":"print","value":"0926-9959"},{"type":"electronic","value":"1468-3083"}],"published":{"date-parts":[[2025,4,16]]},"publisher":"Wiley","reference":[{"DOI":null,"key":"e_1_2_2_2_1","year":"2011","issue":"1","author":"Saitta P","volume":"88","first-page":"33","unstructured":null,"article-title":"An update on the presence of psychiatric comorbidities in acne patients, part 1: overview of prevalence","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1176/appi.books.9780890425787","key":"e_1_2_2_3_1","year":"2022","issue":null,"author":"American Psychiatric Association","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1111/jocd.14330","key":"e_1_2_2_4_1","year":"2022","issue":"5","author":"Öner Ü","volume":"21","first-page":"2176","unstructured":null,"article-title":"Could acne be a risk factor for developing eating disorders? Acne vulgaris and eating disorders","journal-title":"J Cosmet Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1177/0145445503259853","key":"e_1_2_2_5_1","year":"2004","issue":"6","author":"Williamson DA","volume":"28","first-page":"711","unstructured":null,"article-title":"Cognitive‐behavioral theories of eating disorders","journal-title":"Behav Modif","doi-asserted-by":"crossref"},{"DOI":"10.3109/00048679109077729","key":"e_1_2_2_6_1","year":"1991","issue":"1","author":"Lee S","volume":"25","first-page":"134","unstructured":null,"article-title":"Acne as a risk factor for anorexia nervosa in Chinese","journal-title":"Aust N Z J Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1177/070674379203700113","key":"e_1_2_2_7_1","year":"1992","issue":"1","author":"Gupta MA","volume":"37","first-page":"58","unstructured":null,"article-title":"Bulimia nervosa and acne may be related: a case report","journal-title":"Can J Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00403-024-03349-7","key":"e_1_2_2_8_1","year":"2024","issue":"8","author":"Choe J","volume":"316","first-page":"598","unstructured":null,"article-title":"Use and cost of dietary changes, supplements, over‐the‐counter topicals, and prescriptions for acne: a cross‐sectional survey among United States adults","journal-title":"Arch Dermatol Res","doi-asserted-by":"crossref"},{"DOI":"10.3390/jpm14020133","key":"e_1_2_2_9_1","year":"2024","issue":"2","author":"Karaağaç M","volume":"14","first-page":"133","unstructured":null,"article-title":"Lack of association of acne severity with depression, anxiety, stress, and eating attitudes: a cross‐sectional study","journal-title":"J Pers Med","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.18514","key":"e_1_2_2_10_1","year":"2020","issue":"3","author":"Gaufin M","volume":"182","first-page":"786","unstructured":null,"article-title":"Practical screening for depression in dermatology: using technology to improve care","journal-title":"British Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0290763","key":"e_1_2_2_11_1","year":"2023","issue":"9","author":"Chang J","volume":"18","first-page":null,"unstructured":null,"article-title":"Acne accounts for an almost 2.5‐fold higher proportion of dermatology visits among adult females compared to adult males in the United States: a study of the national ambulatory medical care survey from 2002–2016","journal-title":"PLoS One","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jdv.20697"],"article-number":"jdv.20697","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"reference-count":10,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,4,16]]},"references-count":10,"short-container-title":["Acad Dermatol Venereol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jdv.20697","is_oa":true,"title":"Acne and eating disorders: A retrospective cohort study of US adults","updated":"2025-08-04T14:10:34+00:00","published_date":"2025-04-16","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.20697","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.20697","url_for_landing_page":"https://doi.org/10.1111/jdv.20697"}}},"created_at":"2025-09-19T22:00:18.111Z","updated_at":"2025-09-19T22:12:33.828Z","tags":[{"paper_doi":"10.1111/jdv.20697","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/jdv.20697","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jdv.20697","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1111/jdv.20697","tag_type":"condition","value":"Eating Disorders","value_numeric":null},{"paper_doi":"10.1111/jdv.20697","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/jdv.20697","tag_type":"study_design","value":"Retrospective Cohort","value_numeric":null},{"paper_doi":"10.1111/jdv.20697","tag_type":"warning","value":"Only the title, data availability note, and references were provided; no methods, sample size, or results are visible in the excerpt.","value_numeric":null},{"paper_doi":"10.1111/jdv.20697","tag_type":"warning","value":"Study design classification is inferred from the title; details could differ in the full text.","value_numeric":null},{"paper_doi":"10.1111/jdv.20697","tag_type":"warning","value":"The article is a letter to the editor and the accessible content is paywalled, limiting extraction of outcomes.","value_numeric":null}],"summaries":{"what_studied":"A retrospective cohort study of US adults examined the relationship between acne and eating disorders, with participant data available through the NIH All of Us Researcher Workbench."}},{"doi":"10.1001/jamadermatol.2025.0019","pmid":"40042878","title":"At-Home LED Devices for the Treatment of Acne Vulgaris","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-03-05T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.0019","source_score":137,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-03-11","doi":"10.1001/jamadermatol.2025.0019","days":"30","issn":"2168-6068","rank":"3","field":"Clinical Medicine","score":"137","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.0019","title":"At-Home LED Devices for the Treatment of Acne Vulgaris: A Systematic Review and Meta-Analysis.","journal":"JAMA dermatology","methods":"","results":"","abstract":"This systematic review and meta-analysis examines 6 studies to determine the safety and efficacy of different types of at-home light-emitting diode devices in reducing acne lesions.","keywords":[],"pubmed_id":"40042878","conclusions":"","publication_date":"2025-03-05T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.0019","URL":"https://doi.org/10.1001/jamadermatol.2025.0019","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2830694/jamadermatology_ershadi_2025_ld_250002_1747728370.57354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"552","type":"journal-article","issue":"5","score":1,"title":["At-Home LED Devices for the Treatment of Acne Vulgaris"],"author":[{"given":"Sherry","family":"Ershadi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"Associate Editor, JAMA Dermatology"}]}],"issued":{"date-parts":[[2025,5,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-03-05T16:02:56Z","timestamp":1741190576000,"date-parts":[[2025,3,5]]},"indexed":{"date-time":"2025-07-24T11:36:45Z","timestamp":1753357005628,"date-parts":[[2025,7,24]]},"subject":[],"abstract":"This systematic review and meta-analysis examines 6 studies to determine the safety and efficacy of different types of at-home light-emitting diode devices in reducing acne lesions.","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2830694"}},"subtitle":["A Systematic Review and Meta-Analysis"],"deposited":{"date-time":"2025-05-21T15:00:35Z","timestamp":1747839635000,"date-parts":[[2025,5,21]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,5,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1111/bjd.12186","key":"dld250002r1","year":"2013","issue":"5","author":"Kwon","volume":"168","first-page":"1088","unstructured":null,"article-title":"The clinical and histological effect of home-use, combination blue-red LED phototherapy for mild-to-moderate acne vulgaris in Korean patients: a double-blind, randomized controlled trial.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1365-2133.2000.03481.x","key":"dld250002r2","year":"2000","issue":"5","author":"Papageorgiou","volume":"142","first-page":"973","unstructured":null,"article-title":"Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"dld250002r3","year":"2016","issue":"3","author":"Nestor","volume":"9","first-page":"25","unstructured":null,"article-title":"Efficacy and tolerability of a combined 445nm and 630nm over-the-counter light therapy mask with and without topical salicylic acid versus topical benzoyl peroxide for the treatment of mild-to-moderate acne vulgaris.","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1097/00042728-200710000-00012","key":"dld250002r4","year":"2007","issue":"10","author":"Na","volume":"33","first-page":"1228","unstructured":null,"article-title":"Red light phototherapy alone is effective for acne vulgaris: randomized, single-blinded clinical trial.","journal-title":"Dermatol Surg","doi-asserted-by":"publisher"},{"DOI":"10.3109/14764172.2011.630081","key":"dld250002r5","year":"2011","issue":"6","author":"Gold","volume":"13","first-page":"308","unstructured":null,"article-title":"Clinical efficacy of home-use blue-light therapy for mild-to moderate acne.","journal-title":"J Cosmet Laser Ther","doi-asserted-by":"publisher"},{"DOI":"10.3109/14764172.2015.1007064","key":"dld250002r6","year":"2015","issue":"4","author":"Ash","volume":"17","first-page":"170","unstructured":null,"article-title":"A randomized controlled study for the treatment of acne vulgaris using high-intensity 414 nm solid state diode arrays.","journal-title":"J Cosmet Laser Ther","doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,5,1]]},"reference-count":6,"published-online":null,"references-count":6,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamadermatol.2025.0019","is_oa":false,"title":"At-Home LED Devices for the Treatment of Acne Vulgaris","updated":"2025-08-04T14:10:34+00:00","published_date":"2025-03-05","best_oa_location":null}},"created_at":"2025-09-19T18:40:43.237Z","updated_at":"2025-09-19T22:48:22.683Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.0019","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0019","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0019","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0019","tag_type":"modality","value":"LED Phototherapy","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0019","tag_type":"study_design","value":"Systematic Review and Meta-analysis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0019","tag_type":"warning","value":"Number of included studies is known (6), but total participants, device parameters, and heterogeneity are not described in the provided text.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0019","tag_type":"warning","value":"Only abstract-level information provided; no quantitative outcomes or effect sizes were reported.","value_numeric":null}],"summaries":{"what_studied":"A systematic review and meta-analysis of 6 studies evaluating the safety and efficacy of different at-home LED devices for reducing acne lesions."}},{"doi":"10.1001/jamadermatol.2024.5416","pmid":"39813053","title":"Acne Relapse and Isotretinoin Retrial in Patients With Acne","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-01-15T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2024.5416","source_score":64,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-01-22","doi":"10.1001/jamadermatol.2024.5416","days":"30","issn":"2168-6068","rank":"4","field":"Clinical Medicine","score":"64","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.5416","title":"Acne Relapse and Isotretinoin Retrial in Patients With Acne.","journal":"JAMA dermatology","methods":"","results":"$36","abstract":"$37","keywords":[],"pubmed_id":"39813053","conclusions":"","publication_date":"2025-01-15T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.5416","URL":"https://doi.org/10.1001/jamadermatol.2024.5416","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2829255/jamadermatology_lai_2025_oi_240066_1744811605.49753.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"367","type":"journal-article","issue":"4","score":1,"title":["Acne Relapse and Isotretinoin Retrial in Patients With Acne"],"author":[{"given":"Jenny","family":"Lai","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"Associate Editor and Evidence-based Practice Editor, JAMA Dermatology"}]}],"issued":{"date-parts":[[2025,4,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-01-15T16:00:43Z","timestamp":1736956843000,"date-parts":[[2025,1,15]]},"indexed":{"date-time":"2025-04-17T04:11:40Z","timestamp":1744863100932,"date-parts":[[2025,4,17]]},"subject":[],"abstract":"$38","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2829255"}},"subtitle":[],"deposited":{"date-time":"2025-04-16T15:01:06Z","timestamp":1744815666000,"date-parts":[[2025,4,16]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,4,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/j.jaad.2023.12.017","key":"doi240066r1","year":"2024","issue":"5","author":"Reynolds","volume":"90","first-page":"1006.e1","unstructured":null,"article-title":"Guidelines of care for the management of acne vulgaris.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1440-0960.2010.00657.x","key":"doi240066r2","year":"2010","issue":"4","author":"Rademaker","volume":"51","first-page":"248","unstructured":null,"article-title":"Adverse effects of isotretinoin: a retrospective review of 1743 patients started on isotretinoin.","journal-title":"Australas J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.1984.tb04030.x","key":"doi240066r3","year":"1984","issue":"1","author":"Jones","volume":"111","first-page":"123","unstructured":null,"article-title":"Remission rates in acne patients treated with various doses of 13-cis-retinoic acid (isotretinoin).","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.1993.tb11850.x","key":"doi240066r4","year":"1993","issue":"3","author":"Stainforth","volume":"129","first-page":"297","unstructured":null,"article-title":"Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course?","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.1993.tb11849.x","key":"doi240066r5","year":"1993","issue":"3","author":"Layton","volume":"129","first-page":"292","unstructured":null,"article-title":"Isotretinoin for acne vulgaris–10 years later: a safe and successful treatment.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/archderm.134.3.376","key":"doi240066r6","year":"1998","issue":"3","author":"White","volume":"134","first-page":"376","unstructured":null,"article-title":"Recurrence rates after the first course of isotretinoin.","journal-title":"Arch Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000018130","key":"doi240066r7","year":"1999","issue":"3","author":"Lehucher-Ceyrac","volume":"198","first-page":"278","unstructured":null,"article-title":"Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240066r8","year":"2005","issue":"3","author":"Al-Mutairi","volume":"4","first-page":"369","unstructured":null,"article-title":"Isotretinoin in acne vulgaris: a prospective analysis of 160 cases from Kuwait.","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1159/000090658","key":"doi240066r9","year":"2006","issue":"2","author":"Quéreux","volume":"212","first-page":"168","unstructured":null,"article-title":"Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2007.08250.x","key":"doi240066r10","year":"2007","issue":"6","author":"Azoulay","volume":"157","first-page":"1240","unstructured":null,"article-title":"Isotretinoin therapy and the incidence of acne relapse: a nested case-control study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240066r11","year":"2008","issue":"10","author":"Liu","volume":"7","first-page":"963","unstructured":null,"article-title":"Relapse of acne following isotretinoin treatment: a retrospective study of 405 patients.","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1159/000249320","key":"doi240066r12","year":"1986","issue":"3","author":"Harms","volume":"172","first-page":"148","unstructured":null,"article-title":"The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study.","journal-title":"Dermatologica","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1468-3083.2010.03933.x","key":"doi240066r13","year":"2011","issue":"9","author":"Borghi","volume":"25","first-page":"1094","unstructured":null,"article-title":"Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2010.06.025","key":"doi240066r14","year":"2011","issue":"2","author":"Coloe","volume":"65","first-page":"422","unstructured":null,"article-title":"Could higher doses of isotretinoin reduce the frequency of treatment failure in patients with acne?","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2013.6746","key":"doi240066r15","year":"2013","issue":"12","author":"Blasiak","volume":"149","first-page":"1392","unstructured":null,"article-title":"High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ad.2012.05.004","key":"doi240066r16","year":"2013","issue":"1","author":"Morales-Cardona","volume":"104","first-page":"61","unstructured":null,"article-title":"Acne relapse rate and predictors of relapse following treatment with oral isotretinoin.","journal-title":"Actas Dermosifiliogr","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.06.1293","key":"doi240066r17","year":"2020","issue":"5","author":"Fernandez","volume":"82","first-page":"1218","unstructured":null,"article-title":"Retrospective case series of isotretinoin outcomes for acne in 393 female patients at Baylor College of Medicine during 2012-2016.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.15109","key":"doi240066r18","year":"2021","issue":"6","author":"Demirci Saadet","volume":"34","first-page":null,"unstructured":null,"article-title":"Investigation of relapse rate and factors affecting relapse after oral isotretinoin treatment in patients with acne vulgaris.","journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.3389/fphar.2021.733526","key":"doi240066r19","year":"2021","issue":null,"author":"Skroza","volume":"12","first-page":null,"unstructured":null,"article-title":"Advantages of tailored isotretinoin treatment in moderate to severe acne: real-life data.","journal-title":"Front Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1055/s-0038-1673354","key":"doi240066r20","year":"2019","issue":"1","author":"Kulaylat","volume":"32","first-page":"54","unstructured":null,"article-title":"Truven Health Analytics MarketScan databases for clinical research in colon and rectal surgery.","journal-title":"Clin Colon Rectal Surg","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.04.145","key":"doi240066r21","year":"2020","issue":"5","author":"Tripathi","volume":"83","first-page":"1546","unstructured":null,"article-title":"Big data in dermatology: publicly available health care databases for population health research.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.2363","key":"doi240066r22","year":"2023","issue":"10","author":"Barbieri","volume":"159","first-page":"1135","unstructured":null,"article-title":"Temporal trends in the use of systemic medications for acne from 2017 to 2020.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240066r23","year":"2021","issue":"36","author":"Fryar","volume":null,"first-page":"1","unstructured":null,"article-title":"Anthropometric reference data for children and adults: United States, 2015-2018.","journal-title":"Vital Health Stat 3","doi-asserted-by":null},{"DOI":"10.4103/0019-5154.131455","key":"doi240066r24","year":"2014","issue":"3","author":"Rao","volume":"59","first-page":"316","unstructured":null,"article-title":"Safety and efficacy of low-dose isotretinoin in the treatment of moderate to severe acne vulgaris.","journal-title":"Indian J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1440-0960.2012.00947.x","key":"doi240066r25","year":"2013","issue":"3","author":"Rademaker","volume":"54","first-page":"157","unstructured":null,"article-title":"Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us?","journal-title":"Australas J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/jvc2.154","key":"doi240066r26","year":"2023","issue":"3","author":"Daly","volume":"2","first-page":"432","unstructured":null,"article-title":"A systematic review of isotretinoin dosing in acne vulgaris.","journal-title":"JEADV Clin Pract","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2010.10152.x","key":"doi240066r27","year":"2011","issue":"6","author":"Lee","volume":"164","first-page":"1369","unstructured":null,"article-title":"Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0210445","key":"doi240066r28","year":"2019","issue":"3","author":"Charrow","volume":"14","first-page":null,"unstructured":null,"article-title":"Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era.","journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2007.06.045","key":"doi240066r29","year":"2008","issue":"1","author":"Collier","volume":"58","first-page":"56","unstructured":null,"article-title":"The prevalence of acne in adults 20 years and older.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240066r30","year":"1997","issue":"10","author":"Lehucher-Ceyrac","volume":"124","first-page":"692","unstructured":null,"article-title":"[Acne, hyperandrogenism and oral isotretinoin resistance. 23 cases. Therapeutic implications].","journal-title":"Ann Dermatol Venereol","doi-asserted-by":null},{"DOI":"10.1111/j.1365-4632.2012.05691.x","key":"doi240066r31","year":"2013","issue":"3","author":"Cakir","volume":"52","first-page":"371","unstructured":null,"article-title":"Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0290763","key":"doi240066r32","year":"2023","issue":"9","author":"Chang","volume":"18","first-page":null,"unstructured":null,"article-title":"Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: a study of the national ambulatory medical care survey from 2002-2016.","journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.12942","key":"doi240066r33","year":"2016","issue":"5","author":"Rademaker","volume":"55","first-page":"518","unstructured":null,"article-title":"Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,4,1]]},"reference-count":33,"published-online":null,"references-count":33,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamadermatol.2024.5416","is_oa":false,"title":"Acne Relapse and Isotretinoin Retrial in Patients With Acne","updated":"2025-08-04T14:10:34+00:00","published_date":"2025-01-15","best_oa_location":null}},"created_at":"2025-09-19T22:06:30.810Z","updated_at":"2025-09-20T05:46:34.060Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"generic","value":"isotretinoin","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"modality","value":"Oral Retinoid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"sample_size","value":"n=19,907","value_numeric":19907},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"study_design","value":"Retrospective Cohort","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"warning","value":"Daily dose associations were evaluated among patients with cumulative dose ≥120 mg/kg per the abstract.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"warning","value":"Findings are from a commercial claims cohort; clinical definitions of relapse and dosing thresholds are abstract-level only.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"warning","value":"Study design classification is based on the abstract; full methodological details were not reviewed here.","value_numeric":null}],"summaries":{"what_studied":"A claims-based cohort study (MarketScan, 2017-2020) evaluated which factors were associated with acne relapse and isotretinoin retrial in patients aged 12 years or older who completed at least 4 months of isotretinoin and had at least 1 year of continuous enrollment after treatment. Multivariable Cox models examined sex, cumulative isotretinoin dose (mg/kg), and daily dose in relation to relapse and retrial.","key_result":"Of 19,907 patients, 4,482 (22.5%) relapsed and 1,639 (8.2%) underwent isotretinoin retrial. Female sex increased relapse risk (HR 1.43; 95% CI, 1.35-1.52) but decreased retrial (HR 0.68; 95% CI, 0.62-0.76); higher cumulative dose reduced relapse (HR 0.996 per mg/kg; 95% CI, 0.995-0.997) and retrial (HR 0.99 per mg/kg; 95% CI, 0.98-0.99), with lower retrial in low (<120 mg/kg) and conventional (120-220 mg/kg) but not high (>220 mg/kg) cumulative dose groups; daily or maximum daily dose was not associated with lower risk when cumulative dose was ≥120 mg/kg.","practice_takeaway":"Prioritize achieving an adequate cumulative isotretinoin dose to lower relapse and the need for retrial; increasing daily dose above conventional targets did not add protection once cumulative dose reached ≥120 mg/kg. Daily dosing can be individualized to patient preferences and tolerability without sacrificing relapse prevention at conventional or higher cumulative doses."}},{"doi":"10.1016/j.jid.2024.09.009","pmid":"39384016","title":"Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug Products","journal_title":"Journal of Investigative Dermatology","journal_issn":"0022-202X","published_at":"2024-10-10T00:00:00.000Z","url":"https://doi.org/10.1016/j.jid.2024.09.009","source_score":443,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2024-10-12","doi":"10.1016/j.jid.2024.09.009","days":"30","issn":"0022-202X","rank":"1","field":"Clinical Medicine","score":"443","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1016/j.jid.2024.09.009","title":"Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug Products.","journal":"The Journal of investigative dermatology","methods":"","results":"","abstract":"$39","keywords":["Acne","Biochemistry","Drug development","Pharmacology","UVR"],"pubmed_id":"39384016","conclusions":"","publication_date":"2024-10-10T00:00:00"},"crossref":{"DOI":"10.1016/j.jid.2024.09.009","URL":"https://doi.org/10.1016/j.jid.2024.09.009","ISSN":["0022-202X"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0022202X24021559?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0022202X24021559?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"1147-1154.e11","type":"journal-article","issue":"5","score":1,"title":["Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug Products"],"author":[{"given":"Kaury","family":"Kucera","sequence":"first","affiliation":[]},{"given":"Nicola","family":"Zenzola","sequence":"additional","affiliation":[]},{"given":"Amber","family":"Hudspeth","sequence":"additional","affiliation":[]},{"given":"Mara","family":"Dubnicka","sequence":"additional","affiliation":[]},{"given":"Wolfgang","family":"Hinz","sequence":"additional","affiliation":[]},{"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Girardi","sequence":"additional","affiliation":[]},{"given":"Arash","family":"Dabestani","sequence":"additional","affiliation":[]},{"given":"David Y.","family":"Light","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,5]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"145","created":{"date-time":"2024-10-07T05:07:28Z","timestamp":1728277648000,"date-parts":[[2024,10,7]]},"indexed":{"date-time":"2025-08-23T05:28:01Z","timestamp":1755926881173,"date-parts":[[2025,8,23]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000,"date-parts":[[2025,5,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000,"date-parts":[[2025,5,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0022202X24021559"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug Products"},{"name":"journaltitle","label":"Journal Title","value":"Journal of Investigative Dermatology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jid.2024.09.009"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2024 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology."}],"deposited":{"date-time":"2025-07-29T17:34:00Z","timestamp":1753810440000,"date-parts":[[2025,7,29]]},"issn-type":[{"type":"print","value":"0022-202X"}],"published":{"date-parts":[[2025,5]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1177/10901981211046534","key":"10.1016/j.jid.2024.09.009_bib1","year":"2022","issue":null,"author":"Allen","volume":"49","first-page":"415","unstructured":null,"article-title":"Interventions to increase sunscreen use in adults: a review of the literature","journal-title":"Health Educ Behav","doi-asserted-by":"crossref"},{"DOI":"10.1002/hlca.19710540314","key":"10.1016/j.jid.2024.09.009_bib5","year":"1971","issue":null,"author":"Blank","volume":"54","first-page":"905","unstructured":null,"article-title":"Chemically induced dynamic nuclear polarization VIII: thermal decomposition of dibenzoyl peroxides in solution [1]","journal-title":"Helv Chim Acta","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jid.2024.09.009_bib6","year":"2002","issue":null,"author":"Balasaraswathy","volume":"68","first-page":"198","unstructured":null,"article-title":"UVA and UVB in sunlight, optimal utilization of UV rays in sunlight for phototherapy","journal-title":"Indian J Dermatol Venereol Leprol","doi-asserted-by":null},{"DOI":"10.1002/jps.2600660528","key":"10.1016/j.jid.2024.09.009_bib7","year":"1977","issue":null,"author":"Bollinger","volume":"66","first-page":"718","unstructured":null,"article-title":"Benzoyl peroxide stability in pharmaceutical gel preparations","journal-title":"J Pharm Sci","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jid.2024.09.009_bib8","year":"1993","issue":null,"author":"Chang","volume":"1","first-page":"385","unstructured":null,"article-title":"Studies on benzene formation in beverages","journal-title":"J Food Drug Anal","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2023.05.093","key":"10.1016/j.jid.2024.09.009_bib9","year":"2023","issue":null,"author":"Del Rosso","volume":"89","first-page":"719","unstructured":null,"article-title":"Efficacy and safety of microencapsulated benzoyl peroxide and microencapsulated tretinoin for the treatment of acne vulgaris: results from two phase 3 double-blind, randomized, vehicle-controlled studies","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jid.2024.09.009_bib16","year":"2011","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":"Guidance for industry. Topical acne drug products for over-the-counter human use—revision of labeling and classification of benzoyl peroxide as safe and effective","journal-title":"Small Entity Compliance Guide","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jid.2024.09.009_bib28","year":null,"issue":null,"author":"Galderma Laboratories","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2024.07.011","key":"10.1016/j.jid.2024.09.009_bib29","year":"2024","issue":null,"author":"Garate","volume":null,"first-page":null,"unstructured":null,"article-title":"Benzoyl peroxide for acne treatment is not associated with an increased risk of malignancy: a retrospective cohort study [e-pub ahead of print]","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1021/jf00029a001","key":"10.1016/j.jid.2024.09.009_bib30","year":"1993","issue":null,"author":"Gardner","volume":"41","first-page":"693","unstructured":null,"article-title":"Benzene production from decarboxylation of benzoic acid in the presence of ascorbic acid and a transition-metal catalyst","journal-title":"J Agric Food Chem","doi-asserted-by":"crossref"},{"DOI":"10.1002/cber.19250580423","key":"10.1016/j.jid.2024.09.009_bib31","year":"1925","issue":null,"author":"Gelissen","volume":"58","first-page":"764","unstructured":null,"article-title":"Über neue Synthesen mittels organischer Peroxyde, IV.: die Einwirkung von Dibenzoylperoxyd auf Diphenyl","journal-title":"Ber Dtsch Chem Ges A/B","doi-asserted-by":"crossref"},{"DOI":"10.38111/ijapb.20200601004","key":"10.1016/j.jid.2024.09.009_bib32","year":"2020","issue":null,"author":"Ghimire","volume":"6","first-page":"15","unstructured":null,"article-title":"Guidelines on stability studies of pharmaceutical products and shelf life estimation","journal-title":"Int J Adv Pharm Biotechnol","doi-asserted-by":"crossref"},{"DOI":"10.1097/01.ede.0000082001.05563.e0","key":"10.1016/j.jid.2024.09.009_bib33","year":"2003","issue":null,"author":"Glass","volume":"14","first-page":"569","unstructured":null,"article-title":"Leukemia risk associated with low-level benzene exposure","journal-title":"Epidemiology","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00484-009-0211-x","key":"10.1016/j.jid.2024.09.009_bib34","year":"2009","issue":null,"author":"Grundstein","volume":"53","first-page":"255","unstructured":null,"article-title":"Maximum vehicle cabin temperatures under different meteorological conditions","journal-title":"Int J Biometeorol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0040-4039(00)90985-7","key":"10.1016/j.jid.2024.09.009_bib35","year":"1967","issue":null,"author":"Hey","volume":"8","first-page":"1477","unstructured":null,"article-title":"The effect of copper salts on the thermal decomposition of benzoyl peroxide in benzene","journal-title":"Tetrahedron Lett","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jid.2024.09.009_bib36","year":"1939","issue":null,"author":"Hunter","volume":"21","first-page":"331","unstructured":null,"article-title":"Chronic exposure to benzene (benzol). II. The clinical effects","journal-title":"J Ind Hyg Toxicol","doi-asserted-by":null},{"DOI":"10.1046/j.1523-1747.1998.00091.x","key":"10.1016/j.jid.2024.09.009_bib37","year":"1998","issue":null,"author":"Ibbotson","volume":"110","first-page":"79","unstructured":null,"article-title":"Benzoyl peroxide increases UVA-induced plasma membrane damage and lipid oxidation in murine leukemia L1210 cells","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jid.2024.09.009_bib38","year":"1987","issue":null,"author":"Jeanmougin","volume":"114","first-page":"671","unstructured":null,"article-title":"[Dosimetry of solar ultraviolet radiation. Daily and monthly changes in Paris]","journal-title":"Ann Dermatol Venereol","doi-asserted-by":null},{"DOI":"10.1002/bmc.1008","key":"10.1016/j.jid.2024.09.009_bib39","year":"2008","issue":null,"author":"Ju","volume":"22","first-page":"900","unstructured":null,"article-title":"Evaluation of headspace-gas chromatography/mass spectrometry for the analysis of benzene in vitamin C drinks; pitfalls of headspace in benzene detection","journal-title":"Biomed Chromatogr","doi-asserted-by":"crossref"},{"DOI":"10.1289/EHP13984","key":"10.1016/j.jid.2024.09.009_bib40","year":"2024","issue":null,"author":"Kucera","volume":"132","first-page":null,"unstructured":null,"article-title":"Benzoyl peroxide drug products form benzene","journal-title":"Environ Health Perspect","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jpba.2010.09.006","key":"10.1016/j.jid.2024.09.009_bib41","year":"2011","issue":null,"author":"Liu","volume":"54","first-page":"417","unstructured":null,"article-title":"A general static-headspace gas chromatographic method for determination of residual benzene in oral liquid pharmaceutical products","journal-title":"J Pharm Biomed Anal","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.tca.2015.02.008","key":"10.1016/j.jid.2024.09.009_bib42","year":"2015","issue":null,"author":"Liu","volume":"605","first-page":"68","unstructured":null,"article-title":"Thermal hazard evaluation of the autocatalytic reaction of benzoyl peroxide using DSC and TAM III","journal-title":"Thermochim Acta","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jid.2024.09.009_bib43","year":"2009","issue":null,"author":"Liu","volume":"53","first-page":"33","unstructured":null,"article-title":"Skin exposure to aliphatic polyisocyanates in the auto body repair and refinishing industry: III. A personal exposure algorithm","journal-title":"Ann Occup Hyg","doi-asserted-by":null},{"DOI":"10.1046/j.1365-4362.2002.01371.x","key":"10.1016/j.jid.2024.09.009_bib44","year":"2002","issue":null,"author":"Merker","volume":"41","first-page":"185","unstructured":null,"article-title":"Benzoyl peroxide: a history of early research and researchers","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/00984109708984036","key":"10.1016/j.jid.2024.09.009_bib45","year":"1997","issue":null,"author":"Nakai","volume":"51","first-page":"447","unstructured":null,"article-title":"Effect of environmental conditions on the penetration of benzene through human skin","journal-title":"J Toxicol Environ Health","doi-asserted-by":"crossref"},{"DOI":"10.1021/ja01213a002","key":"10.1016/j.jid.2024.09.009_bib46","year":"1946","issue":null,"author":"Nozaki","volume":"68","first-page":"1686","unstructured":null,"article-title":"The kinetics of decomposition of benzoyl peroxide in solvents","journal-title":"J Am Chem Soc","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jid.2024.09.009_bib65","year":"2022","issue":null,"author":"Oussova","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/phpp.12099","key":"10.1016/j.jid.2024.09.009_bib47","year":"2014","issue":null,"author":"Petersen","volume":"30","first-page":"96","unstructured":null,"article-title":"Application of sunscreen--theory and reality","journal-title":"Photodermatol Photoimmunol Photomed","doi-asserted-by":"crossref"},{"DOI":"10.1007/BF00209940","key":"10.1016/j.jid.2024.09.009_bib48","year":"1993","issue":null,"author":"Rastogi","volume":"50","first-page":"794","unstructured":null,"article-title":"Residues of benzene in chemical products","journal-title":"Bull Environ Contam Toxicol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2024.06.050","key":"10.1016/j.jid.2024.09.009_bib49","year":"2024","issue":null,"author":"Sadr","volume":"91","first-page":"763","unstructured":null,"article-title":"No evidence for an association between benzoyl peroxide use and increased blood benzene levels in the National Health and Nutrition Examination Survey","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1155/2015/545640","key":"10.1016/j.jid.2024.09.009_bib50","year":"2015","issue":null,"author":"Salviano Dos Santos","volume":"2015","first-page":null,"unstructured":null,"article-title":"Benzene as a chemical hazard in processed foods","journal-title":"Int J Food Sci","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jid.2024.09.009_bib51","year":"1897","issue":null,"author":"Santesson","volume":"31","first-page":"336","unstructured":null,"article-title":"Uber chronische Vergiftungen mit Steinkohlen Benzin. Vier todes falle","journal-title":"Arch Hyg","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jid.2024.09.009_bib52","year":"1997","issue":null,"author":"Schafran","volume":null,"first-page":null,"unstructured":null,"article-title":"Reduction of benzene formation in dibenzoyl peroxide formulations","journal-title":"WIPO","doi-asserted-by":null},{"DOI":"10.1146/annurev.publhealth.012809.103646","key":"10.1016/j.jid.2024.09.009_bib53","year":"2010","issue":null,"author":"Smith","volume":"31","first-page":"133","unstructured":null,"article-title":"Advances in understanding benzene health effects and susceptibility","journal-title":"Annu Rev Public Health","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jid.2024.09.009_bib55","year":"2021","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1021/jf072580q","key":"10.1016/j.jid.2024.09.009_bib60","year":"2008","issue":null,"author":"Van Poucke","volume":"56","first-page":"4504","unstructured":null,"article-title":"Monitoring the benzene contents in soft drinks using headspace gas chromatography-mass spectrometry: a survey of the situation on the Belgian market","journal-title":"J Agric Food Chem","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jid.2024.09.009_bib61","year":"2022","issue":null,"author":"Wang","volume":"19","first-page":null,"unstructured":null,"article-title":"Pharmacoepidemiological research on N-Nitrosodimethylamine-Contaminated ranitidine use and long-term cancer risk: a population-based longitudinal cohort study","journal-title":"Int J Environ Res Public Health","doi-asserted-by":null},{"DOI":"10.1001/jamanetworkopen.2023.33495","key":"10.1016/j.jid.2024.09.009_bib62","year":"2023","issue":null,"author":"You","volume":"6","first-page":null,"unstructured":null,"article-title":"Ranitidine use and incident cancer in a multinational cohort","journal-title":"JAMA Netw Open","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0022202X24021559"],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2025,5]]},"reference-count":38,"published-online":null,"references-count":38,"short-container-title":["Journal of Investigative Dermatology"],"is-referenced-by-count":8},"unpaywall":{"doi":"10.1016/j.jid.2024.09.009","is_oa":false,"title":"Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug Products","updated":"2025-05-22T18:42:22+00:00","published_date":"2024-10-07","best_oa_location":null}},"created_at":"2025-09-20T06:24:15.629Z","updated_at":"2025-09-20T06:39:36.892Z","tags":[{"paper_doi":"10.1016/j.jid.2024.09.009","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jid.2024.09.009","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1016/j.jid.2024.09.009","tag_type":"condition","value":"Rosacea","value_numeric":null},{"paper_doi":"10.1016/j.jid.2024.09.009","tag_type":"generic","value":"benzoyl peroxide","value_numeric":null},{"paper_doi":"10.1016/j.jid.2024.09.009","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1016/j.jid.2024.09.009","tag_type":"modality","value":"Topical Peroxide","value_numeric":null},{"paper_doi":"10.1016/j.jid.2024.09.009","tag_type":"sample_size","value":"n=111","value_numeric":111},{"paper_doi":"10.1016/j.jid.2024.09.009","tag_type":"study_design","value":"Cross-Sectional","value_numeric":null},{"paper_doi":"10.1016/j.jid.2024.09.009","tag_type":"warning","value":"Airborne benzene levels during simulated use were not quantified in the abstract, so clinical risk cannot be estimated from these data.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2024.09.009","tag_type":"warning","value":"Design classification is ambiguous because the work combines a cross‑sectional product survey with laboratory stability and UV‑exposure experiments.","value_numeric":null}],"summaries":{"what_studied":"Laboratory testing of benzene in 111 over‑the‑counter benzoyl peroxide (BPO) products at room temperature by GC–MS, stability of a prescription‑encapsulated BPO at 2 °C and 50 °C, and airborne benzene during simulated face application with and without sub‑peak UV.","key_result":"Benzene ranged from 0.16 to 35.30 ppm in 111 OTC BPO products kept at room temperature. An encapsulated prescription BPO showed no apparent benzene at 2 °C but high formation at 50 °C, and benzene was detectable in air during use and rose substantially under UV below peak sunlight.","limitations":"Airborne benzene concentrations and exposure durations were not quantified in the abstract, limiting exposure assessment. The face model used polymethyl methacrylate plates rather than human skin, and only one encapsulated prescription product was tested.","practice_takeaway":"BPO products can contain and generate benzene at room temperature and during use, with UV and heat boosting formation. Cold storage reduced formation in testing, while encapsulation alone may not prevent it; starting benzene content may not predict exposure."}},{"doi":"10.1093/bjd/ljae352","pmid":"39271178","title":"Global, regional and national burdens of acne vulgaris in adolescents and young adults aged 10–24 years from 1990 to 2021: a trend analysis","journal_title":"British Journal of Dermatology","journal_issn":"0007-0963","published_at":"2024-09-14T00:00:00.000Z","url":"https://doi.org/10.1093/bjd/ljae352","source_score":182,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2024-10-03","doi":"10.1093/bjd/ljae352","days":"30","issn":"0007-0963","rank":"2","field":"Clinical Medicine","score":"182","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1093/bjd/ljae352","title":"Global, regional and national burdens of acne vulgaris in adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis.","journal":"The British journal of dermatology","methods":"","results":"$3a","abstract":"$3b","keywords":[],"pubmed_id":"39271178","conclusions":"","publication_date":"2024-09-14T00:00:00"},"crossref":{"DOI":"10.1093/bjd/ljae352","URL":"https://doi.org/10.1093/bjd/ljae352","ISSN":["0007-0963","1365-2133"],"link":[{"URL":"https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljae352/59972096/ljae352.pdf","content-type":"application/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https://academic.oup.com/bjd/article-pdf/192/2/228/59972096/ljae352.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https://academic.oup.com/bjd/article-pdf/192/2/228/59972096/ljae352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"228-237","type":"journal-article","issue":"2","score":1,"title":["Global, regional and national burdens of acne vulgaris in adolescents and young adults aged 10–24 years from 1990 to 2021: a trend analysis"],"author":[{"given":"Zhou","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"},{"name":"4+4 Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"}]},{"given":"Xiaoying","family":"Zhong","sequence":"additional","affiliation":[{"name":"4+4 Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"}]},{"given":"Zhongyu","family":"Luo","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"}]},{"given":"Mingjuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"},{"name":"4+4 Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"}]},{"given":"Hanlin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"}]},{"given":"Heyi","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,"}]}],"issued":{"date-parts":[[2024,9,13]]},"member":"286","prefix":"10.1093","source":"Crossref","volume":"192","created":{"date-time":"2024-09-14T08:29:52Z","timestamp":1726302592000,"date-parts":[[2024,9,14]]},"indexed":{"date-time":"2025-09-19T08:16:12Z","timestamp":1758269772339,"date-parts":[[2025,9,19]]},"license":[{"URL":"https://academic.oup.com/pages/standard-publication-reuse-rights","start":{"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000,"date-parts":[[2024,9,13]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$3c","language":"en","relation":{},"resource":{"primary":{"URL":"https://academic.oup.com/bjd/article/192/2/228/7756775"}},"subtitle":[],"deposited":{"date-time":"2025-01-24T11:21:18Z","timestamp":1737717678000,"date-parts":[[2025,1,24]]},"issn-type":[{"type":"print","value":"0007-0963"},{"type":"electronic","value":"1365-2133"}],"published":{"date-parts":[[2024,9,13]]},"publisher":"Oxford University Press (OUP)","reference":[{"DOI":"10.1016/S0140-6736(11)60321-8","key":"2025012411205513100_ljae352-B1","year":"2012","issue":null,"author":"Williams","volume":"379","first-page":"361","unstructured":null,"article-title":"Acne vulgaris","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.19477","key":"2025012411205513100_ljae352-B2","year":"2021","issue":null,"author":"Layton","volume":"184","first-page":"219","unstructured":null,"article-title":"Reviewing the global burden of acne: how could we improve care to reduce the burden?","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMcp1702493","key":"2025012411205513100_ljae352-B3","year":"2018","issue":null,"author":"Zaenglein","volume":"379","first-page":"1343","unstructured":null,"article-title":"Acne vulgaris","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.13191","key":"2025012411205513100_ljae352-B4","year":"2015","issue":"Suppl. 4","author":"Gieler","volume":"29","first-page":"12","unstructured":null,"article-title":"Acne and quality of life –‌ impact and management","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1038/jid.2010.264","key":"2025012411205513100_ljae352-B5","year":"2011","issue":null,"author":"Halvorsen","volume":"131","first-page":"363","unstructured":null,"article-title":"Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2008.07.013","key":"2025012411205513100_ljae352-B6","year":"2008","issue":null,"author":"Dalgard","volume":"59","first-page":"746","unstructured":null,"article-title":"Holm JØ","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025012411205513100_ljae352-B7","year":"2021","issue":null,"author":"GBD","volume":"403","first-page":"2133","unstructured":null,"article-title":"Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","journal-title":"Lancet","doi-asserted-by":null},{"DOI":"10.1016/S0140-6736(20)30925-9","key":"2025012411205513100_ljae352-B8","year":"2020","issue":null,"author":"GBD","volume":"396","first-page":"1204","unstructured":null,"article-title":"Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–‌2019: a systematic analysis for the Global Burden of Disease Study 2019","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.20882","key":"2025012411205513100_ljae352-B9","year":"2022","issue":null,"author":"Chen","volume":"186","first-page":"673","unstructured":null,"article-title":"Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2023.10.062","key":"2025012411205513100_ljae352-B10","year":"2024","issue":null,"author":"Witkam","volume":"90","first-page":"552","unstructured":null,"article-title":"The epidemiology of acne vulgaris in a multiethnic adolescent population from Rotterdam, the Netherlands: a cross-sectional study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025012411205513100_ljae352-B11","year":"2021","issue":null,"author":"GBD","volume":"403","first-page":"2162","unstructured":null,"article-title":"Risk Factors Collaborators","journal-title":"Lancet","doi-asserted-by":null},{"DOI":"10.1016/S0140-6736(16)30388-9","key":"2025012411205513100_ljae352-B12","year":"2016","issue":null,"author":"Stevens","volume":"388","first-page":"e19","unstructured":null,"article-title":"Guidelines for accurate and transparent health estimates reporting: the GATHER statement","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2352-4642(18)30022-1","key":"2025012411205513100_ljae352-B13","year":"2018","issue":null,"author":"Sawyer","volume":"2","first-page":"223","unstructured":null,"article-title":"The age of adolescence","journal-title":"Lancet Child Adolesc Health","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2352-4642(22)00219-X","key":"2025012411205513100_ljae352-B14","year":"2022","issue":null,"author":"Zhang","volume":"6","first-page":"763","unstructured":null,"article-title":"Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–‌24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019","journal-title":"Lancet Child Adolesc Health","doi-asserted-by":"crossref"},{"DOI":"10.1002/(SICI)1097-0258(19970415)16:7<791::AID-SIM500>3.0.CO;2-#","key":"2025012411205513100_ljae352-B15","year":"1997","issue":null,"author":"Fay","volume":"16","first-page":"791","unstructured":null,"article-title":"Confidence intervals for directly standardized rates: a method based on the gamma distribution","journal-title":"Stat Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.autrev.2023.103450","key":"2025012411205513100_ljae352-B16","year":"2023","issue":null,"author":"Cao","volume":"22","first-page":"103450","unstructured":null,"article-title":"Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in women of childbearing age from 1990 to 2019","journal-title":"Autoimmun Rev","doi-asserted-by":"crossref"},{"DOI":"10.1002/sim.3733","key":"2025012411205513100_ljae352-B17","year":"2009","issue":null,"author":"Clegg","volume":"28","first-page":"3670","unstructured":null,"article-title":"Estimating average annual per cent change in trend analysis","journal-title":"Stat Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025012411205513100_ljae352-B18","year":"2021","issue":null,"author":"Hu","volume":"19","first-page":"509","unstructured":null,"article-title":"Sex hormones and acne: state of the art","journal-title":"J Dtsch Dermatol Ges","doi-asserted-by":null},{"DOI":"10.1016/j.clindermatol.2016.10.004","key":"2025012411205513100_ljae352-B19","year":"2017","issue":null,"author":"Ju","volume":"35","first-page":"130","unstructured":null,"article-title":"Sex hormones and acne","journal-title":"Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.14998","key":"2025012411205513100_ljae352-B20","year":"2018","issue":null,"author":"Claudel","volume":"32","first-page":"1631","unstructured":null,"article-title":"Acne and nutrition: hypotheses, myths and facts","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.13462","key":"2025012411205513100_ljae352-B21","year":"2015","issue":"Suppl. 1","author":"Tan","volume":"172","first-page":"3","unstructured":null,"article-title":"A global perspective on the epidemiology of acne","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.12149","key":"2025012411205513100_ljae352-B22","year":"2013","issue":null,"author":"Bhate","volume":"168","first-page":"474","unstructured":null,"article-title":"Epidemiology of acne vulgaris","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41598-020-62715-3","key":"2025012411205513100_ljae352-B23","year":"2020","issue":null,"author":"Heng","volume":"10","first-page":null,"unstructured":null,"article-title":"Systematic review of the epidemiology of acne vulgaris","journal-title":"Sci Rep","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2020.1602","key":"2025012411205513100_ljae352-B24","year":"2020","issue":null,"author":"Penso","volume":"156","first-page":"854","unstructured":null,"article-title":"Association between adult acne and dietary behaviors: findings from the Nutrinet-Santé Prospective Cohort Study","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.clnu.2018.04.015","key":"2025012411205513100_ljae352-B25","year":"2019","issue":null,"author":"Aghasi","volume":"38","first-page":"1067","unstructured":null,"article-title":"Dairy intake and acne development: a meta-analysis of observational studies","journal-title":"Clin Nutr","doi-asserted-by":"crossref"},{"DOI":"10.3390/nu10081049","key":"2025012411205513100_ljae352-B26","year":"2018","issue":null,"author":"Juhl","volume":"10","first-page":"1049","unstructured":null,"article-title":"Dairy intake and acne vulgaris: a systematic review and meta-analysis of 78,529 children, adolescents, and young adults","journal-title":"Nutrients","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ecoenv.2024.116429","key":"2025012411205513100_ljae352-B27","year":"2024","issue":null,"author":"Gu","volume":"278","first-page":"116429","unstructured":null,"article-title":"Air pollution and skin diseases: a comprehensive evaluation of the associated mechanism","journal-title":"Ecotoxicol Environ Saf","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jdin.2020.10.006","key":"2025012411205513100_ljae352-B28","year":"2020","issue":null,"author":"Urban","volume":"2","first-page":"40","unstructured":null,"article-title":"Burden of skin disease and associated socioeconomic status in Asia: a cross-sectional analysis from the Global Burden of Disease Study 1990–‌2017","journal-title":"JAAD Int","doi-asserted-by":"crossref"},{"DOI":"10.4103/ijd.IJD_27_20","key":"2025012411205513100_ljae352-B29","year":"2021","issue":null,"author":"Palanivel","volume":"66","first-page":"352","unstructured":null,"article-title":"A cross sectional survey for dermatoses in children and adolescents residing in orphanages in urban Tirunelveli, Tamil Nadu, India","journal-title":"Indian J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00105-022-05096-0","key":"2025012411205513100_ljae352-B30","year":"2023","issue":null,"author":"Ludwig","volume":"74","first-page":"84","unstructured":null,"article-title":"[Inflammatory dermatoses in skin of color]","journal-title":"Dermatologie (Heidelb","doi-asserted-by":"crossref"},{"DOI":"10.3389/fmed.2022.939584","key":"2025012411205513100_ljae352-B31","year":"2022","issue":null,"author":"Wang","volume":"9","first-page":"939584","unstructured":null,"article-title":"Analysis of the epidemiological burden of acne vulgaris in China based on the data of global burden of disease 2019","journal-title":"Front Med (Lausanne","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.lungcan.2020.12.007","key":"2025012411205513100_ljae352-B32","year":"2021","issue":null,"author":"Yang","volume":"152","first-page":"49","unstructured":null,"article-title":"Temporal trends of the lung cancer mortality attributable to smoking from 1990 to 2017: a global, regional and national analysis","journal-title":"Lung Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.14475","key":"2025012411205513100_ljae352-B33","year":"2018","issue":null,"author":"Wolkenstein","volume":"32","first-page":"298","unstructured":null,"article-title":"Acne prevalence and associations with lifestyle: a cross-sectional online survey of adolescents/young adults in 7 European countries","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.3390/cells10061439","key":"2025012411205513100_ljae352-B34","year":"2021","issue":null,"author":"Rao","volume":"10","first-page":"1439","unstructured":null,"article-title":"Endocrine disrupting chemicals, hormone receptors, and acne vulgaris: a connecting hypothesis","journal-title":"Cells","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2021.17633","key":"2025012411205513100_ljae352-B35","year":"2021","issue":null,"author":"Eichenfield","volume":"326","first-page":"2055","unstructured":null,"article-title":"Management of acne vulgaris: a review","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2022.04.021","key":"2025012411205513100_ljae352-B36","year":"2024","issue":null,"author":"Jennings","volume":"90","first-page":"1123","unstructured":null,"article-title":"Acne scarring-pathophysiology, diagnosis, prevention and education: part I","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.2147/CCID.S406235","key":"2025012411205513100_ljae352-B37","year":"2023","issue":null,"author":"Zhou","volume":"16","first-page":"731","unstructured":null,"article-title":"Beyond the surface: a deeper look at the psychosocial impacts of acne scarring","journal-title":"Clin Cosmet Investig Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.16067","key":"2025012411205513100_ljae352-B38","year":"2020","issue":null,"author":"Claudel","volume":"34","first-page":"942","unstructured":null,"article-title":"Acne from the young patient’s perspective","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.2340/00015555-1164","key":"2025012411205513100_ljae352-B39","year":"2012","issue":null,"author":"Shen","volume":"92","first-page":"40","unstructured":null,"article-title":"Prevalence of acne vulgaris in Chinese adolescents and adults: a community-based study of 17,345 subjects in six cities","journal-title":"Acta Derm Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2019.4818","key":"2025012411205513100_ljae352-B40","year":"2020","issue":null,"author":"Barbieri","volume":"156","first-page":"312","unstructured":null,"article-title":"Association of race/ethnicity and sex with differences in health care use and treatment for acne","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1468-3083.2010.03907.x","key":"2025012411205513100_ljae352-B41","year":"2011","issue":null,"author":"Berg","volume":"25","first-page":"969","unstructured":null,"article-title":"Possible gender differences in the quality of life and choice of therapy in acne","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025012411205513100_ljae352-B42","year":"2014","issue":null,"author":"Yang","volume":"2014","first-page":"504279","unstructured":null,"article-title":"Female gender and acne disease are jointly and independently associated with the risk of major depression and suicide: a national population-based study","journal-title":"Biomed Res Int","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2023.12.017","key":"2025012411205513100_ljae352-B43","year":"2024","issue":null,"author":"Reynolds","volume":"90","first-page":"1006.e1","unstructured":null,"article-title":"Guidelines of care for the management of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,24]]},"published-online":{"date-parts":[[2024,9,13]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["British Journal of Dermatology"],"published-other":{"date-parts":[[2025,2]]},"published-print":{"date-parts":[[2025,1,24]]},"reference-count":43,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2024,9,13]]},"references-count":43,"short-container-title":[],"is-referenced-by-count":18},"unpaywall":{"doi":"10.1093/bjd/ljae352","is_oa":false,"title":"Global, regional and national burdens of acne vulgaris in adolescents and young adults aged 10–24 years from 1990 to 2021: a trend analysis","updated":"2025-05-22T18:42:22+00:00","published_date":"2024-09-13","best_oa_location":null}},"created_at":"2025-09-20T06:38:14.492Z","updated_at":"2025-09-20T06:43:47.272Z","tags":[{"paper_doi":"10.1093/bjd/ljae352","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1093/bjd/ljae352","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/bjd/ljae352","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1093/bjd/ljae352","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1093/bjd/ljae352","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1093/bjd/ljae352","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/bjd/ljae352","tag_type":"study_design","value":"Cross-Sectional","value_numeric":null},{"paper_doi":"10.1093/bjd/ljae352","tag_type":"warning","value":"Incidence and DALY increases are reported without absolute figures in the provided text.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljae352","tag_type":"warning","value":"Study design label is approximate; this is a GBD 2021 modeled trend analysis using secondary data across 204 countries.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljae352","tag_type":"warning","value":"The provided text does not describe methodological limitations or data sources in detail.","value_numeric":null}],"summaries":{"what_studied":"A Global Burden of Disease 2021 trend analysis of acne vulgaris in people aged 10–24 years across 204 countries from 1990–2021, assessing age-standardized prevalence, incidence, DALYs, and average annual percentage change by age, sex, region, and Sociodemographic Index.","key_result":"Global age-standardized prevalence rose from 8563.4 to 9790.5 per 100 000 between 1990 and 2021 (AAPC 0.43, 95% CI 0.41–0.46); 2021 prevalence was ~25% higher in young women vs young men (10 911.8 vs 8727.8 per 100 000). Teens 15–19 years had the highest prevalence, 10–14 years had the largest increase (AAPC 0.50, 95% CI 0.48–0.52); Western Europe had the highest rates, and North Africa/Middle East the greatest increases; high SDI regions had the highest burden while low-middle SDI had the lowest but fastest growth; incidence and DALY rates also increased.","practice_takeaway":"Acne burden in youths is rising worldwide, with higher rates in young women and the fastest growth in ages 10–14, underscoring the need to prioritize early adolescent care and targeted management. Regional and SDI differences suggest tailoring resources to local trends."}},{"doi":"10.1111/jocd.16434","pmid":"38982829","title":"Exploring the potential of omega‐3 fatty acids in acne patients: A prospective intervention study","journal_title":"Journal of Cosmetic Dermatology","journal_issn":"1473-2130","published_at":"2024-07-10T00:00:00.000Z","url":"https://doi.org/10.1111/jocd.16434","source_score":495,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2024-07-15","doi":"10.1111/jocd.16434","days":"30","issn":"1473-2130","rank":"1","field":"Clinical Medicine","score":"495","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jocd.16434","title":"Exploring the potential of omega-3 fatty acids in acne patients: A prospective intervention study.","journal":"Journal of cosmetic dermatology","methods":"","results":"At baseline, 98.3% of patients had an EPA/DHA deficit, with the mean HS-omega 3 index® rising from 4.9% at V1 to 8.3% at V4 (p < 0.001). AC showed significantly higher indices than AP at V4 (p = 0.035). Objective improvements in both inflammatory and non-inflammatory lesions were observed (p < 0.001). While self-reported appearance worsened in four patients, overall quality of life improved (p < 0.001), particularly in AP. Dietary triggers were more clearly defined than beneficial foods. Intake of cow's milk and dairy products reduced (p < 0.001). Compliance was good; no adverse events were reported.","abstract":"$3d","keywords":["Mediterranean diet","exposome factors","nutraceuticals","nutrition","supplementation"],"pubmed_id":"38982829","conclusions":"Many acne patients have a ω-3 FA deficit. The HS-omega 3 index® can be increased by a Mediterranean diet and oral supplementation with algae-derived ω-3 FA. Acne severity improved significantly in patients with target ω-3 FA levels.","publication_date":"2024-07-10T00:00:00"},"crossref":{"DOI":"10.1111/jocd.16434","URL":"https://doi.org/10.1111/jocd.16434","ISSN":["1473-2130","1473-2165"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jocd.16434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"3295-3304","type":"journal-article","issue":"10","score":1,"title":["Exploring the potential of omega‐3 fatty acids in acne patients: A prospective intervention study"],"author":[{"given":"Anne","family":"Guertler","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital LMU Munich Munich Germany"}]},{"given":"Katharina","family":"Neu","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital LMU Munich Munich Germany"}]},{"given":"Diana","family":"Lill","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital LMU Munich Munich Germany"}]},{"given":"Benjamin","family":"Clanner‐Engelshofen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital LMU Munich Munich Germany"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital LMU Munich Munich Germany"},{"name":"Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine University of Miami Coral Gables USA"}]},{"given":"Markus","family":"Reinholz","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital LMU Munich Munich Germany"}]}],"issued":{"date-parts":[[2024,7,10]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"23","archive":["Portico"],"created":{"date-time":"2024-07-10T07:02:43Z","timestamp":1720594963000,"date-parts":[[2024,7,10]]},"indexed":{"date-time":"2025-08-27T15:44:45Z","timestamp":1756309485562,"date-parts":[[2025,8,27]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000,"date-parts":[[2024,7,10]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$3e","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.16434"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2024-03-26"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2024-06-11"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2024-07-10"}],"deposited":{"date-time":"2024-09-27T01:16:14Z","timestamp":1727399774000,"date-parts":[[2024,9,27]]},"issn-type":[{"type":"print","value":"1473-2130"},{"type":"electronic","value":"1473-2165"}],"published":{"date-parts":[[2024,7,10]]},"publisher":"Wiley","reference":[{"DOI":"10.1111/ced.14239","key":"e_1_2_12_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clindermatol.2022.04.001","key":"e_1_2_12_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1684/ejd.2022.4306","key":"e_1_2_12_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.16614","key":"e_1_2_12_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.14820","key":"e_1_2_12_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.21739","key":"e_1_2_12_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jocd.15726","key":"e_1_2_12_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-020-00542-y","key":"e_1_2_12_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/exd.12898","key":"e_1_2_12_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/CCID.S69135","key":"e_1_2_12_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.15862","key":"e_1_2_12_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-1802","key":"e_1_2_12_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ddg.14779","key":"e_1_2_12_14_1","year":"2022","issue":null,"author":"Guertler A","volume":"20","first-page":"1023","unstructured":null,"article-title":"Clinical effects of omega‐3 fatty acids on acne vulgaris","journal-title":"J Dtsch Dermatol Ges","doi-asserted-by":"crossref"},{"DOI":"10.3390/nu12040898","key":"e_1_2_12_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_12_16_1","year":"2023","issue":null,"author":"Krupa K","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.3390/nu8030128","key":"e_1_2_12_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms22136965","key":"e_1_2_12_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/openhrt-2015-000385","key":"e_1_2_12_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000492116","key":"e_1_2_12_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ddg.14683","key":"e_1_2_12_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu10111662","key":"e_1_2_12_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.5021/ad.2017.29.1.20","key":"e_1_2_12_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1359/jbmr.1999.14.7.1153","key":"e_1_2_12_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4049/jimmunol.1300298","key":"e_1_2_12_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms21030741","key":"e_1_2_12_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bbrc.2008.01.062","key":"e_1_2_12_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/jid.2013.505","key":"e_1_2_12_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.immuni.2013.05.015","key":"e_1_2_12_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.14374","key":"e_1_2_12_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/1476-511X-7-36","key":"e_1_2_12_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/1476-511X-11-165","key":"e_1_2_12_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_12_33_1","year":"2019","issue":null,"author":"Schacky C","volume":"60","first-page":"1319","unstructured":null,"article-title":"Confusion about the effects of omega‐3 fatty acids: contemplation of study data taking the omega‐3 index into consideration","journal-title":"Internist (Berl)","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_12_34_1","year":"2021","issue":null,"author":"Zainab Z","volume":"33","first-page":"60","unstructured":null,"article-title":"Effectiveness of oral omega 3 in reducing mucocutaneous side effects of oral isotretinoin in patients with acne vulgaris","journal-title":"J Ayub Med Coll Abbottabad","doi-asserted-by":null},{"DOI":"10.3390/nu7115459","key":"e_1_2_12_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2903/j.efsa.2021.6344","key":"e_1_2_12_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ypmed.2004.02.030","key":"e_1_2_12_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1017/S0029665120006989","key":"e_1_2_12_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1610-0387.2010.07466.x","key":"e_1_2_12_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ics.12258","key":"e_1_2_12_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/1475-2891-9-36","key":"e_1_2_12_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1017/S0007114516000544","key":"e_1_2_12_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2230.1994.tb01167.x","key":"e_1_2_12_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu9090930","key":"e_1_2_12_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.13776","key":"e_1_2_12_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.12788/cutis.0273","key":"e_1_2_12_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-021-00680-z","key":"e_1_2_12_47_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.atherosclerosis.2015.03.043","key":"e_1_2_12_48_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4236/wjcd.2012.21003","key":"e_1_2_12_49_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jcmm.17546","key":"e_1_2_12_50_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.plefa.2017.01.009","key":"e_1_2_12_51_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.14475","key":"e_1_2_12_52_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.5826/dpc.0602a05","key":"e_1_2_12_53_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu14245293","key":"e_1_2_12_54_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jocd.16434"],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Cosmetic Dermatology"],"published-print":{"date-parts":[[2024,10]]},"reference-count":53,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2024,7,10]]},"references-count":53,"short-container-title":["J of Cosmetic Dermatology"],"is-referenced-by-count":5},"unpaywall":{"doi":"10.1111/jocd.16434","is_oa":true,"title":"Exploring the potential of omega‐3 fatty acids in acne patients: A prospective intervention study","updated":"2025-09-06T02:51:56+00:00","published_date":"2024-07-10","best_oa_location":{"url":"https://doi.org/10.1111/jocd.16434","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1111/jocd.16434"}}},"created_at":"2025-09-20T07:38:03.516Z","updated_at":"2025-09-20T07:53:53.397Z","tags":[{"paper_doi":"10.1111/jocd.16434","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"modality","value":"Omega-3 Fatty Acid","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"sample_size","value":"n=60","value_numeric":60},{"paper_doi":"10.1111/jocd.16434","tag_type":"study_design","value":"Single-Arm Interventional Study","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"warning","value":"Clinical improvements were reported without absolute lesion count or QoL changes.","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"warning","value":"Diet and supplementation were combined, and dairy intake fell, so effects of omega‑3 alone are unclear.","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"warning","value":"No comparator arm; study design classification is approximate.","value_numeric":null}],"summaries":{"what_studied":"A 16-week prospective, single-arm study in 60 acne patients not on prescription medication tested a Mediterranean diet plus algae-derived omega-3 supplementation (weeks 1–8: 600 mg DHA/300 mg EPA; weeks 8–16: 800 mg DHA/400 mg EPA), tracking HS‑Omega‑3 Index and clinical acne measures at four visits.","key_result":"At baseline, 98.3% had an EPA/DHA deficit; the mean HS‑Omega‑3 Index increased from 4.9% at V1 to 8.3% at V4 (p<0.001), with higher indices in comedonal than papulopustular acne at V4 (p=0.035). Objective improvements in inflammatory and non‑inflammatory lesions (p<0.001) and quality of life (p<0.001) were observed; dairy intake decreased (p<0.001), compliance was good, and no adverse events were reported.","limitations":"No control group and the combined intervention (diet plus supplementation with reduced dairy) prevent attributing effects to omega‑3 alone. The report provides p‑values without absolute changes in lesion counts or quality‑of‑life scores.","practice_takeaway":"Raising the HS‑Omega‑3 Index via a Mediterranean diet plus algae‑derived DHA/EPA to around 8% over 16 weeks was associated with improved acne severity and quality of life, with no reported harms; interpret as preliminary due to the uncontrolled design."}},{"doi":"10.1016/j.jaad.2023.12.017","pmid":"38300170","title":"Guidelines of care for the management of acne vulgaris","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2024-02-01T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2023.12.017","source_score":374,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2024-04-16","doi":"10.1016/j.jaad.2023.12.017","days":"30","issn":"0190-9622","rank":"1","field":"Clinical Medicine","score":"374","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1016/j.jaad.2023.12.017","title":"Guidelines of care for the management of acne vulgaris.","journal":"Journal of the American Academy of Dermatology","methods":"","results":"This guideline presents 18 evidence-based recommendations and 5 good practice statements. Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. Oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy. Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Combining topical therapies with multiple mechanisms of action, limiting systemic antibiotic use, combining systemic antibiotics with topical therapies, and adding intralesional corticosteroid injections for larger acne lesions are recommended as good practice statements.","abstract":"$3f","keywords":["Acne","Cutibacterium acnes","acne vulgaris","adapalene","antiandrogens","antibiotics","azelaic acid","azithromycin","benzoyl peroxide","clascoterone","clindamycin","contraceptives","corticosteroids","diet and acne","doxycycline","erythromycin","grading and classification of acne","guidelines","hormonal therapy","isotretinoin","light therapies","microbiological and endocrine testing","minocycline","retinoids","salicylic acid","sarecycline","spironolactone","tazarotene","treatment","tretinoin","trifarotene"],"pubmed_id":"38300170","conclusions":"","publication_date":"2024-02-01T00:00:00"},"crossref":{"DOI":"10.1016/j.jaad.2023.12.017","URL":"https://doi.org/10.1016/j.jaad.2023.12.017","ISSN":["0190-9622"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0190962223033893?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0190962223033893?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"1006.e1-1006.e30","type":"journal-article","issue":"5","score":1,"title":["Guidelines of care for the management of acne vulgaris"],"author":[{"given":"Rachel V.","family":"Reynolds","sequence":"first","affiliation":[]},{"given":"Howa","family":"Yeung","sequence":"additional","affiliation":[]},{"given":"Carol E.","family":"Cheng","sequence":"additional","affiliation":[]},{"given":"Fran","family":"Cook-Bolden","sequence":"additional","affiliation":[]},{"given":"Seemal R.","family":"Desai","sequence":"additional","affiliation":[]},{"given":"Kelly M.","family":"Druby","sequence":"additional","affiliation":[]},{"given":"Esther E.","family":"Freeman","sequence":"additional","affiliation":[]},{"given":"Jonette E.","family":"Keri","sequence":"additional","affiliation":[]},{"given":"Linda F.","family":"Stein Gold","sequence":"additional","affiliation":[]},{"given":"Jerry K.L.","family":"Tan","sequence":"additional","affiliation":[]},{"given":"Megha M.","family":"Tollefson","sequence":"additional","affiliation":[]},{"given":"Jonathan S.","family":"Weiss","sequence":"additional","affiliation":[]},{"given":"Peggy A.","family":"Wu","sequence":"additional","affiliation":[]},{"given":"Andrea L.","family":"Zaenglein","sequence":"additional","affiliation":[]},{"given":"Jung Min","family":"Han","sequence":"additional","affiliation":[]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/100001934","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100001934","name":"American Academy of Dermatology","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2024,5]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"90","created":{"date-time":"2024-01-30T08:25:55Z","timestamp":1706603155000,"date-parts":[[2024,1,30]]},"indexed":{"date-time":"2025-09-20T07:51:25Z","timestamp":1758354685137,"date-parts":[[2025,9,20]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000,"date-parts":[[2024,5,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000,"date-parts":[[2024,5,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0190962223033893"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Guidelines of care for the management of acne vulgaris"},{"name":"journaltitle","label":"Journal Title","value":"Journal of the American Academy of Dermatology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jaad.2023.12.017"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2024 by the American Academy of Dermatology, Inc."}],"deposited":{"date-time":"2024-06-05T21:02:34Z","timestamp":1717621354000,"date-parts":[[2024,6,5]]},"issn-type":[{"type":"print","value":"0190-9622"}],"published":{"date-parts":[[2024,5]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1016/j.jaad.2016.12.043","key":"10.1016/j.jaad.2023.12.017_bib1","year":"2017","issue":null,"author":"Lim","volume":"76","first-page":"958","unstructured":null,"article-title":"The burden of skin disease in the United States","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.20882","key":"10.1016/j.jaad.2023.12.017_bib2","year":"2022","issue":null,"author":"Chen","volume":"186","first-page":"673","unstructured":null,"article-title":"Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the global burden of disease study 2019","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2015.12.037","key":"10.1016/j.jaad.2023.12.017_bib3","year":"2016","issue":null,"author":"Zaenglein","volume":"74","first-page":"945","unstructured":null,"article-title":"Guidelines of care for the management of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2013-0490B","key":"10.1016/j.jaad.2023.12.017_bib4","year":"2013","issue":"Suppl 3","author":"Eichenfield","volume":"131","first-page":"S163","unstructured":null,"article-title":"Evidence-based recommendations for the diagnosis and treatment of pediatric acne","journal-title":"Pediatrics","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jclinepi.2012.03.013","key":"10.1016/j.jaad.2023.12.017_bib5","year":"2013","issue":null,"author":"Andrews","volume":"66","first-page":"719","unstructured":null,"article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","journal-title":"J Clin Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jclinepi.2013.02.003","key":"10.1016/j.jaad.2023.12.017_bib6","year":"2013","issue":null,"author":"Andrews","volume":"66","first-page":"726","unstructured":null,"article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength","journal-title":"J Clin Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jclinepi.2016.07.006","key":"10.1016/j.jaad.2023.12.017_bib7","year":"2016","issue":null,"author":"Guyatt","volume":"80","first-page":"3","unstructured":null,"article-title":"Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group","journal-title":"J Clin Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2021.17633","key":"10.1016/j.jaad.2023.12.017_bib8","year":"2021","issue":null,"author":"Eichenfield","volume":"326","first-page":"2055","unstructured":null,"article-title":"Management of acne vulgaris: a review","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1038/jid.2013.446","key":"10.1016/j.jaad.2023.12.017_bib9","year":"2014","issue":null,"author":"Hay","volume":"134","first-page":"1527","unstructured":null,"article-title":"The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.12149","key":"10.1016/j.jaad.2023.12.017_bib10","year":"2013","issue":null,"author":"Bhate","volume":"168","first-page":"474","unstructured":null,"article-title":"Epidemiology of acne vulgaris","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2016.5538","key":"10.1016/j.jaad.2023.12.017_bib11","year":"2017","issue":null,"author":"Karimkhani","volume":"153","first-page":"406","unstructured":null,"article-title":"Global skin disease morbidity and mortality: an update from the global burden of disease study 2013","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(98)70442-6","key":"10.1016/j.jaad.2023.12.017_bib12","year":"1998","issue":null,"author":"White","volume":"39","first-page":"S34","unstructured":null,"article-title":"Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s13555-018-0224-7","key":"10.1016/j.jaad.2023.12.017_bib13","year":"2018","issue":null,"author":"Fabbrocini","volume":"8","first-page":"85","unstructured":null,"article-title":"A qualitative investigation of the impact of acne on health-related quality of life (HRQL): development of a conceptual model","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2021.2185","key":"10.1016/j.jaad.2023.12.017_bib14","year":"2021","issue":null,"author":"Barbieri","volume":"157","first-page":"1040","unstructured":null,"article-title":"Patient perspectives on the lived experience of acne and its treatment among adult women with acne: a qualitative study","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1046/j.1365-2133.1999.02768.x","key":"10.1016/j.jaad.2023.12.017_bib15","year":"1999","issue":null,"author":"Mallon","volume":"140","first-page":"672","unstructured":null,"article-title":"The quality of life in acne: a comparison with general medical conditions using generic questionnaires","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib16","year":"2014","issue":null,"author":"Cresce","volume":"13","first-page":"692","unstructured":null,"article-title":"The quality of life impact of acne and rosacea compared to other major medical conditions","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1046/j.1365-2133.1998.02511.x","key":"10.1016/j.jaad.2023.12.017_bib17","year":"1998","issue":null,"author":"Gupta","volume":"139","first-page":"846","unstructured":null,"article-title":"Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1471-6712.2007.00547.x","key":"10.1016/j.jaad.2023.12.017_bib18","year":"2008","issue":null,"author":"Magin","volume":"22","first-page":"430","unstructured":null,"article-title":"Experiences of appearance-related teasing and bullying in skin diseases and their psychological sequelae: results of a qualitative study","journal-title":"Scand J Caring Sci","doi-asserted-by":"crossref"},{"DOI":"10.1186/1751-0759-5-11","key":"10.1016/j.jaad.2023.12.017_bib19","year":"2011","issue":null,"author":"Ritvo","volume":"5","first-page":"11","unstructured":null,"article-title":"Psychosocial judgements and perceptions of adolescents with acne vulgaris: a blinded, controlled comparison of adult and peer evaluations","journal-title":"Biopsychosoc Med","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1440-1754.2006.00979.x","key":"10.1016/j.jaad.2023.12.017_bib20","year":"2006","issue":null,"author":"Purvis","volume":"42","first-page":"793","unstructured":null,"article-title":"Acne, anxiety, depression and suicide in teenagers: a cross-sectional survey of New Zealand secondary school students","journal-title":"J Paediatr Child Health","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41598-020-62715-3","key":"10.1016/j.jaad.2023.12.017_bib21","year":"2020","issue":null,"author":"Heng","volume":"10","first-page":"5754","unstructured":null,"article-title":"Systematic review of the epidemiology of acne vulgaris","journal-title":"Sci Rep","doi-asserted-by":"crossref"},{"DOI":"10.1111/jebm.12249","key":"10.1016/j.jaad.2023.12.017_bib22","year":"2017","issue":null,"author":"Layton","volume":"10","first-page":"163","unstructured":null,"article-title":"Prioritizing treatment outcomes: how people with acne vulgaris decide if their treatment is working","journal-title":"J Evid Based Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib23","year":"2005","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.3109/09546639809160698","key":"10.1016/j.jaad.2023.12.017_bib24","year":"1998","issue":null,"author":"O'Brien","volume":"9","first-page":"215","unstructured":null,"article-title":"The Leeds revised acne grading system","journal-title":"J Dermatol Treat","doi-asserted-by":"crossref"},{"DOI":"10.1046/j.1365-4362.1997.00099.x","key":"10.1016/j.jaad.2023.12.017_bib25","year":"1997","issue":null,"author":"Doshi","volume":"36","first-page":"416","unstructured":null,"article-title":"A comparison of current acne grading systems and proposal of a novel system","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1468-3083.2010.03685.x","key":"10.1016/j.jaad.2023.12.017_bib26","year":"2011","issue":null,"author":"Dreno","volume":"25","first-page":"43","unstructured":null,"article-title":"Development and evaluation of a global acne severity scale (GEA scale) suitable for France and Europe","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.2310/7750.2007.00037","key":"10.1016/j.jaad.2023.12.017_bib27","year":"2007","issue":null,"author":"Tan","volume":"11","first-page":"211","unstructured":null,"article-title":"Development and validation of a comprehensive acne severity scale","journal-title":"J Cutan Med Surg","doi-asserted-by":"crossref"},{"DOI":"10.1111/pde.13262","key":"10.1016/j.jaad.2023.12.017_bib28","year":"2017","issue":null,"author":"Patel","volume":"34","first-page":"656","unstructured":null,"article-title":"The patient-centered acne severity scale study","journal-title":"Pediatr Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2019.4668","key":"10.1016/j.jaad.2023.12.017_bib29","year":"2020","issue":null,"author":"Bernardis","volume":"156","first-page":"296","unstructured":null,"article-title":"Development and initial validation of a multidimensional acne global grading system integrating primary lesions and secondary changes","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/1346-8138.15613","key":"10.1016/j.jaad.2023.12.017_bib30","year":"2021","issue":null,"author":"Cho","volume":"48","first-page":"42","unstructured":null,"article-title":"Analysis of trends and status of physician-based evaluation methods in acne vulgaris from 2000 to 2019","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib31","year":"2016","issue":null,"author":"Stein Gold","volume":"15","first-page":"79","unstructured":null,"article-title":"Evolution of acne assessments and impact on acne medications: an evolving, imperfect paradigm","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2013.07.029","key":"10.1016/j.jaad.2023.12.017_bib32","year":"2013","issue":null,"author":"Tan","volume":"69","first-page":"754","unstructured":null,"article-title":"Evaluation of essential clinical components and features of current acne global grading scales","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2011.09.005","key":"10.1016/j.jaad.2023.12.017_bib33","year":"2012","issue":null,"author":"Tan","volume":"67","first-page":"187","unstructured":null,"article-title":"Acne severity grading: determining essential clinical components and features using a Delphi consensus","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2018.09.017","key":"10.1016/j.jaad.2023.12.017_bib34","year":"2019","issue":null,"author":"Gottlieb","volume":"80","first-page":"823","unstructured":null,"article-title":"A provider global assessment quality measure for clinical practice for inflammatory skin disorders","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.clindermatol.2016.10.006","key":"10.1016/j.jaad.2023.12.017_bib35","year":"2017","issue":null,"author":"Becker","volume":"35","first-page":"147","unstructured":null,"article-title":"Objective assessment of acne","journal-title":"Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.14585","key":"10.1016/j.jaad.2023.12.017_bib36","year":"2018","issue":null,"author":"Chernyshov","volume":"32","first-page":"194","unstructured":null,"article-title":"Quality of life measurement in acne. Position paper of the European Academy of Dermatology and Venereology task forces on quality of life and patient oriented outcomes and acne, rosacea and hidradenitis suppurativa","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s40257-019-00438-6","key":"10.1016/j.jaad.2023.12.017_bib37","year":"2019","issue":null,"author":"Marron","volume":"20","first-page":"527","unstructured":null,"article-title":"Quality-of-Life research in acne vulgaris: current status and future directions","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2022.2260","key":"10.1016/j.jaad.2023.12.017_bib38","year":"2022","issue":null,"author":"Hopkins","volume":"158","first-page":"900","unstructured":null,"article-title":"Patient-reported outcome measures for health-related quality of life in patients with acne vulgaris: a systematic review of measure development and measurement properties","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/jid.2013.21","key":"10.1016/j.jaad.2023.12.017_bib39","year":"2013","issue":null,"author":"Fitz-Gibbon","volume":"133","first-page":"2152","unstructured":null,"article-title":"Propionibacterium acnes strain populations in the human skin microbiome associated with acne","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib40","year":"2010","issue":null,"author":"Miura","volume":"57","first-page":"65","unstructured":null,"article-title":"Quantitative PCR of Propionibacterium acnes DNA in samples aspirated from sebaceous follicles on the normal skin of subjects with or without acne","journal-title":"J Med Dent Sci","doi-asserted-by":null},{"DOI":"10.1111/1346-8138.13245","key":"10.1016/j.jaad.2023.12.017_bib41","year":"2016","issue":null,"author":"Akaza","volume":"43","first-page":"906","unstructured":null,"article-title":"Microorganisms inhabiting follicular contents of facial acne are not only Propionibacterium but also Malassezia spp","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib42","year":"2020","issue":null,"author":"Jusuf","volume":"13","first-page":"773","unstructured":null,"article-title":"Differences of microbiomes found in non-inflammatory and inflammatory lesions of acne vulgaris","journal-title":"Clin Cosmet Investig Dermatol","doi-asserted-by":null},{"DOI":"10.1111/exd.13296","key":"10.1016/j.jaad.2023.12.017_bib43","year":"2017","issue":null,"author":"Dreno","volume":"26","first-page":"798","unstructured":null,"article-title":"Skin microbiome and acne vulgaris: staphylococcus, a new actor in acne","journal-title":"Exp Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s12275-021-0647-1","key":"10.1016/j.jaad.2023.12.017_bib44","year":"2021","issue":null,"author":"Kim","volume":"59","first-page":"369","unstructured":null,"article-title":"Inferences in microbial structural signatures of acne microbiome and mycobiome","journal-title":"J Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1159/000356777","key":"10.1016/j.jaad.2023.12.017_bib45","year":"2014","issue":null,"author":"Numata","volume":"228","first-page":"86","unstructured":null,"article-title":"Analysis of facial skin-resident microbiota in Japanese acne patients","journal-title":"Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1346-8138.2006.00206.x","key":"10.1016/j.jaad.2023.12.017_bib46","year":"2006","issue":null,"author":"Ergin","volume":"33","first-page":"899","unstructured":null,"article-title":"Nasal antibiotic-resistant Propionibacterium acnes carriage in acne vulgaris patients in Turkey","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-4632.2011.05371.x","key":"10.1016/j.jaad.2023.12.017_bib47","year":"2013","issue":null,"author":"Schafer","volume":"52","first-page":"418","unstructured":null,"article-title":"Antimicrobial susceptibility and genetic characteristics of Propionibacterium acnes isolated from patients with acne","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib48","year":"2018","issue":null,"author":"Franik","volume":"22","first-page":"4411","unstructured":null,"article-title":"Hormonal and metabolic aspects of acne vulgaris in women with polycystic ovary syndrome","journal-title":"Eur Rev Med Pharmacol Sci","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib49","year":"2016","issue":null,"author":"Kiayani","volume":"28","first-page":"357","unstructured":null,"article-title":"Association of serum testosterone and sex hormone binding globulin levels in females with acne based on its severity","journal-title":"J Ayub Med Coll Abbottabad","doi-asserted-by":null},{"DOI":"10.1210/jc.2018-00241","key":"10.1016/j.jaad.2023.12.017_bib50","year":"2018","issue":null,"author":"Martin","volume":"103","first-page":"1233","unstructured":null,"article-title":"Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline","journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-4632.2007.03411.x","key":"10.1016/j.jaad.2023.12.017_bib51","year":"2007","issue":null,"author":"Seirafi","volume":"46","first-page":"1188","unstructured":null,"article-title":"Assessment of androgens in women with adult-onset acne","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib52","year":"1990","issue":null,"author":"Schmidt","volume":"24","first-page":"457","unstructured":null,"article-title":"Endocrine parameters in acne vulgaris","journal-title":"Endocrinol Exp","doi-asserted-by":null},{"DOI":"10.1111/1523-1747.ep12539043","key":"10.1016/j.jaad.2023.12.017_bib53","year":"1983","issue":null,"author":"Lucky","volume":"81","first-page":"70","unstructured":null,"article-title":"Plasma androgens in women with acne vulgaris","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1346-8138.1997.tb02778.x","key":"10.1016/j.jaad.2023.12.017_bib54","year":"1997","issue":null,"author":"Timpatanapong","volume":"24","first-page":"223","unstructured":null,"article-title":"Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.clinbiochem.2010.09.010","key":"10.1016/j.jaad.2023.12.017_bib55","year":"2010","issue":null,"author":"Arora","volume":"43","first-page":"1415","unstructured":null,"article-title":"The relationship of lipid profile and menstrual cycle with acne vulgaris","journal-title":"Clin Biochem","doi-asserted-by":"crossref"},{"DOI":"10.1590/S0100-879X2009000600005","key":"10.1016/j.jaad.2023.12.017_bib56","year":"2009","issue":null,"author":"Abulnaja","volume":"42","first-page":"501","unstructured":null,"article-title":"Changes in the hormone and lipid profile of obese adolescent Saudi females with acne vulgaris","journal-title":"Braz J Med Biol Res","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib57","year":"2012","issue":null,"author":"Saleh","volume":"33","first-page":"1196","unstructured":null,"article-title":"Role of growth hormone and insulin-like growth factor-I in hyperandrogenism and the severity of acne vulgaris in young males","journal-title":"Saudi Med J","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib58","year":"2018","issue":"10","author":"Tyring","volume":"17","first-page":"1084","unstructured":null,"article-title":"Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older","journal-title":"J Drugs Dermatol JDD","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2004.10.879","key":"10.1016/j.jaad.2023.12.017_bib59","year":"2006","issue":null,"author":"Thiboutot","volume":"54","first-page":"242","unstructured":null,"article-title":"Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib60","year":"1999","issue":null,"author":"Shalita","volume":"63","first-page":"349","unstructured":null,"article-title":"Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.36849/JDD.2020.3977","key":"10.1016/j.jaad.2023.12.017_bib61","year":"2020","issue":null,"author":"Tanghetti","volume":"19","first-page":"70","unstructured":null,"article-title":"Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials","journal-title":"J Drugs Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2019.02.044","key":"10.1016/j.jaad.2023.12.017_bib62","year":"2019","issue":"6","author":"Tan","volume":"80","first-page":"1691","unstructured":null,"article-title":"Randomized phase 3 evaluation of trifarotene 50 mug/g cream treatment of moderate facial and truncal acne","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib63","year":"2020","issue":"6","author":"Webster","volume":"18","first-page":"343","unstructured":null,"article-title":"Microencapsulated benzoyl peroxide and tretinoin for the treatment of acne vulgaris: results from a phase 2 multicenter, double-blind, randomized, vehicle-controlled study","journal-title":"Skinmed","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2133.2009.09209.x","key":"10.1016/j.jaad.2023.12.017_bib64","year":"2009","issue":null,"author":"Gollnick","volume":"161","first-page":"1180","unstructured":null,"article-title":"Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/1346-8138.12580","key":"10.1016/j.jaad.2023.12.017_bib65","year":"2014","issue":"9","author":"Kawashima","volume":"41","first-page":"795","unstructured":null,"article-title":"Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double-blind, vehicle-controlled, parallel-group study","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib66","year":"2011","issue":null,"author":"Eichenfield","volume":"10","first-page":"1382","unstructured":null,"article-title":"Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib67","year":"1980","issue":null,"author":"Smith","volume":"25","first-page":"90","unstructured":null,"article-title":"Benzoyl peroxide lotion (20 percent) in acne","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/S0190-9622(83)70211-2","key":"10.1016/j.jaad.2023.12.017_bib68","year":"1983","issue":null,"author":"Chalker","volume":"9","first-page":"933","unstructured":null,"article-title":"A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(97)70177-4","key":"10.1016/j.jaad.2023.12.017_bib69","year":"1997","issue":null,"author":"Lookingbill","volume":"37","first-page":"590","unstructured":null,"article-title":"Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2230.1992.tb00196.x","key":"10.1016/j.jaad.2023.12.017_bib70","year":"1992","issue":null,"author":"Hughes","volume":"17","first-page":"165","unstructured":null,"article-title":"A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne","journal-title":"Clin Exp Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib71","year":"2012","issue":null,"author":"Jarratt","volume":"11","first-page":"318","unstructured":null,"article-title":"Efficacy and safety of clindamycin-tretinoin gel versus clindamycin or tretinoin alone in acne vulgaris: a randomized, double-blind, vehicle-controlled study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2133.2011.10332.x","key":"10.1016/j.jaad.2023.12.017_bib72","year":"2011","issue":null,"author":"Trifu","volume":"165","first-page":"177","unstructured":null,"article-title":"Cortexolone 17alpha-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib73","year":"2021","issue":null,"author":"Baldwin","volume":"14","first-page":"E53","unstructured":null,"article-title":"Tazarotene 0.045% lotion for moderate-to-severe acne in male and female participants: a phase II post-hoc analysis","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib74","year":"2019","issue":"11","author":"Lain","volume":"18","first-page":"1128","unstructured":null,"article-title":"Tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: impact of gender and Race on efficacy and safety","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib75","year":"2021","issue":"6","author":"Green","volume":"20","first-page":"608","unstructured":null,"article-title":"Tazarotene 0.045% lotion for moderate-to-severe acne patients: pooled phase 3 analysis by age and sex","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib76","year":"2019","issue":"12","author":"Stein Gold","volume":"18","first-page":"1218","unstructured":null,"article-title":"Tretinoin 0.05% lotion for the once-daily treatment of moderate and severe acne vulgaris in females: effect of age on efficacy and tolerability","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib77","year":"2020","issue":"2","author":"Paracha","volume":"34","first-page":"134","unstructured":null,"article-title":"Efficacy and safety of short term use of 0.1% tazarotene gel in the treatment of mild to moderate acne vulgaris: a randomized-vehicle controlled trial","journal-title":"J Postgrad Med Inst","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib78","year":"2007","issue":null,"author":"Alirezai","volume":"17","first-page":"45","unstructured":null,"article-title":"Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline","journal-title":"Eur J Dermatol","doi-asserted-by":null},{"DOI":"10.1159/000018255","key":"10.1016/j.jaad.2023.12.017_bib79","year":"1999","issue":null,"author":"Glass","volume":"199","first-page":"242","unstructured":null,"article-title":"A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris","journal-title":"Dermatology (Basel, Switzerland)","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib80","year":"2019","issue":"6","author":"Tanghetti","volume":"18","first-page":"542","unstructured":null,"article-title":"A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/S0190-9622(87)70200-X","key":"10.1016/j.jaad.2023.12.017_bib81","year":"1987","issue":null,"author":"Chalker","volume":"17","first-page":"251","unstructured":null,"article-title":"Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib82","year":"2019","issue":"11","author":"Harper","volume":"18","first-page":"1147","unstructured":null,"article-title":"Efficacy and tolerability of a novel tretinoin 0.05% lotion for the once-daily treatment of moderate or severe acne vulgaris in adult females","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib83","year":"2007","issue":null,"author":"Lucky","volume":"6","first-page":"981","unstructured":null,"article-title":"Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib84","year":"2016","issue":"8","author":"Eichenfield","volume":"15","first-page":"962","unstructured":null,"article-title":"Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib85","year":"2016","issue":"5","author":"Stein Gold","volume":"15","first-page":"553","unstructured":null,"article-title":"Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle-controlled trials","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib86","year":"2018","issue":"11","author":"Alexis","volume":"11","first-page":"25","unstructured":null,"article-title":"BPX-01 minocycline topical gel shows promise for the treatment of moderate-tosevere inflammatory acne vulgaris","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2019.05.078","key":"10.1016/j.jaad.2023.12.017_bib87","year":"2020","issue":"4","author":"Raoof","volume":"82","first-page":"832","unstructured":null,"article-title":"Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: a phase 3 study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib88","year":"1988","issue":null,"author":"Pochi","volume":"41","first-page":"132","unstructured":null,"article-title":"Erythromycin 2 percent gel in the treatment of acne vulgaris","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/S0190-9622(80)80113-7","key":"10.1016/j.jaad.2023.12.017_bib89","year":"1980","issue":null,"author":"Dobson","volume":"3","first-page":"478","unstructured":null,"article-title":"Topical erythromycin solution in acne: results of a multiclinic trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(80)80044-2","key":"10.1016/j.jaad.2023.12.017_bib90","year":"1980","issue":null,"author":"Bernstein","volume":"2","first-page":"318","unstructured":null,"article-title":"Topically applied erythromycin in inflammatory acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(85)70074-6","key":"10.1016/j.jaad.2023.12.017_bib91","year":"1985","issue":null,"author":"Lesher","volume":"12","first-page":"526","unstructured":null,"article-title":"An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.1981.01650080036024","key":"10.1016/j.jaad.2023.12.017_bib92","year":"1981","issue":null,"author":"Becker","volume":"117","first-page":"482","unstructured":null,"article-title":"Topical clindamycin therapy for acne vulgaris. A cooperative clinical study","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2020.0465","key":"10.1016/j.jaad.2023.12.017_bib93","year":"2020","issue":"6","author":"Hebert","volume":"156","first-page":"621","unstructured":null,"article-title":"Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials","journal-title":"JAMA Dermatology","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib94","year":"2019","issue":null,"author":"Mazzetti","volume":"1","first-page":"570","unstructured":null,"article-title":"A phase 2b, randomized, double-blind vehicle controlled, dose escalation study evaluating clascoterone 0.1%, 0.5%, and 1% topical cream in subjects with facial","journal-title":"Acne","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib95","year":"1981","issue":null,"author":"Shalita","volume":"28","first-page":"556","unstructured":null,"article-title":"Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib96","year":"1989","issue":null,"author":"Cunliffe","volume":"143","first-page":"31","unstructured":null,"article-title":"Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne","journal-title":"Acta Derm Venereol Suppl","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib97","year":"1989","issue":null,"author":"Katsambas","volume":"143","first-page":"35","unstructured":null,"article-title":"Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin","journal-title":"Acta Derm Venereol Suppl","doi-asserted-by":null},{"DOI":"10.4103/0378-6323.31892","key":"10.1016/j.jaad.2023.12.017_bib98","year":"2007","issue":null,"author":"Iraji","volume":"73","first-page":"94","unstructured":null,"article-title":"Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris","journal-title":"Indian J Dermatol Venereol Leprol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s40257-021-00650-3","key":"10.1016/j.jaad.2023.12.017_bib99","year":"2022","issue":"1","author":"Stein Gold","volume":"23","first-page":"93","unstructured":null,"article-title":"Efficacy and safety of a fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: a randomized phase II study of the first triple-combination drug","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib100","year":"2015","issue":"4","author":"Harper","volume":"14","first-page":"381","unstructured":null,"article-title":"The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib101","year":"2014","issue":"9","author":"Pariser","volume":"13","first-page":"1083","unstructured":null,"article-title":"An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib102","year":"2015","issue":"5","author":"Cook-Bolden","volume":"8","first-page":"28","unstructured":null,"article-title":"Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib103","year":"2015","issue":"12","author":"Gold","volume":"8","first-page":"22","unstructured":null,"article-title":"Sub-group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate-to-severe acne vulgaris","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib104","year":"2015","issue":"9","author":"Stein Gold","volume":"14","first-page":"969","unstructured":null,"article-title":"Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib105","year":"2012","issue":null,"author":"Guerra-Tapia","volume":"11","first-page":"714","unstructured":null,"article-title":"Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single-blind study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2133.2007.08308.x","key":"10.1016/j.jaad.2023.12.017_bib106","year":"2008","issue":null,"author":"Langner","volume":"158","first-page":"122","unstructured":null,"article-title":"A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/09546634.2020.1720579","key":"10.1016/j.jaad.2023.12.017_bib107","year":"2021","issue":"8","author":"Dogra","volume":"32","first-page":"925","unstructured":null,"article-title":"Efficacy and safety comparison of combination of 0.04% tretinoin microspheres plus 1% clindamycin versus their monotherapy in patients with acne vulgaris: a phase 3, randomized, double-blind study","journal-title":"J Dermatolog Treat","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib108","year":"2011","issue":null,"author":"Tanghetti","volume":"10","first-page":"783","unstructured":null,"article-title":"Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1007/s40257-018-0352-y","key":"10.1016/j.jaad.2023.12.017_bib109","year":"2018","issue":"2","author":"Dreno","volume":"19","first-page":"275","unstructured":null,"article-title":"Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6-month randomized, vehicle-controlled trial using intra-individual comparison","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib110","year":"2015","issue":"12","author":"Weiss","volume":"14","first-page":"1427","unstructured":null,"article-title":"Customized single-agent therapy management of severe inflammatory acne: a randomized, double-blind, parallel-group, controlled study of a new treatment - adapalene 0.3%-benzoyl peroxide 2.5% gel","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1007/s40257-016-0178-4","key":"10.1016/j.jaad.2023.12.017_bib111","year":"2016","issue":"3","author":"Stein Gold","volume":"17","first-page":"293","unstructured":null,"article-title":"Moderate and severe inflammatory acne vulgaris effectively treated with single-agent therapy by a new fixed-dose combination adapalene 0.3 %/benzoyl peroxide 2.5 % gel: a randomized, double-blind, parallel-group, controlled study","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib112","year":"2017","issue":"6","author":"Stein Gold","volume":"16","first-page":"582","unstructured":null,"article-title":"Adapalene/benzoyl peroxide gel 0.3%/2.5%: effective acne therapy regardless of age or gender","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1111/1346-8138.12979","key":"10.1016/j.jaad.2023.12.017_bib113","year":"2015","issue":"11","author":"Kwon","volume":"42","first-page":"1058","unstructured":null,"article-title":"Do tutorials on application method enhance adapalene-benzoyl peroxide combination gel tolerability in the treatment of acne?","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2010.303","key":"10.1016/j.jaad.2023.12.017_bib114","year":"2010","issue":null,"author":"Margolis","volume":"105","first-page":"2610","unstructured":null,"article-title":"Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.139.4.459","key":"10.1016/j.jaad.2023.12.017_bib115","year":"2003","issue":null,"author":"Skidmore","volume":"139","first-page":"459","unstructured":null,"article-title":"Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib116","year":"2013","issue":null,"author":"Leyden","volume":"12","first-page":"658","unstructured":null,"article-title":"A randomized, phase 2, dose-ranging study in the treatment of moderate to severe inflammatory facial acne vulgaris with doxycycline calcium","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib117","year":"2015","issue":null,"author":"Moore","volume":"14","first-page":"581","unstructured":null,"article-title":"Efficacy and safety of subantimicrobial dose, modified-release doxycycline 40 mg versus doxycycline 100 mg versus placebo for the treatment of inflammatory lesions in moderate and severe acne: a randomized, double-blinded, controlled study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1001/archderm.1970.04000040057011","key":"10.1016/j.jaad.2023.12.017_bib118","year":"1970","issue":null,"author":"Plewig","volume":"101","first-page":"435","unstructured":null,"article-title":"Double-blind study of doxycycline in acne vulgaris","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib119","year":"2006","issue":null,"author":"Fleischer","volume":"78","first-page":"21","unstructured":null,"article-title":"Safety and efficacy of a new extended-release formulation of minocycline","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib120","year":"2006","issue":null,"author":"Stewart","volume":"78","first-page":"11","unstructured":null,"article-title":"Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2003.07.021","key":"10.1016/j.jaad.2023.12.017_bib121","year":"2004","issue":null,"author":"Leyden","volume":"50","first-page":"443","unstructured":null,"article-title":"A systemic type 15-reductase inhibitor is ineffective in the treatment of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib122","year":"1976","issue":null,"author":"Hersle","volume":"19","first-page":"339","unstructured":null,"article-title":"Minocycline in acne vulgaris: a double-blind study","journal-title":"Curr Ther Res Clin Exp","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib123","year":"2018","issue":null,"author":"Moore","volume":"17","first-page":"987","unstructured":null,"article-title":"Once-daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib124","year":"2018","issue":null,"author":"Leyden","volume":"17","first-page":"333","unstructured":null,"article-title":"Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib125","year":"2019","issue":null,"author":"Pariser","volume":"12","first-page":"E53","unstructured":null,"article-title":"Safety and tolerability of sarecycline for the treatment of acne vulgaris: results from a phase III, multicenter, open-Label study and a phase I phototoxicity study","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib126","year":"2011","issue":null,"author":"Maleszka","volume":"9","first-page":"86","unstructured":null,"article-title":"Pulsed azithromycin treatment is as effective and safe as 2-week-longer daily doxycycline treatment of acne vulgaris: a randomized, double-blind, noninferiority study","journal-title":"Skinmed","doi-asserted-by":null},{"DOI":"10.3109/09546631003762639","key":"10.1016/j.jaad.2023.12.017_bib127","year":"2011","issue":null,"author":"Babaeinejad","volume":"22","first-page":"206","unstructured":null,"article-title":"Comparison of therapeutic effects of oral doxycycline and azithromycin in patients with moderate acne vulgaris: what is the role of age?","journal-title":"J Dermatol Treat","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib128","year":"2014","issue":null,"author":"Ullah","volume":"26","first-page":"64","unstructured":null,"article-title":"Comparison of oral azithromycin with oral doxycycline in the treatment of acne vulgaris","journal-title":"J Ayub Med Coll Abbottabad","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2230.2005.01769.x","key":"10.1016/j.jaad.2023.12.017_bib129","year":"2005","issue":null,"author":"Kus","volume":"30","first-page":"215","unstructured":null,"article-title":"Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris","journal-title":"Clin Exp Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0b013e318187e1c5","key":"10.1016/j.jaad.2023.12.017_bib130","year":"2008","issue":null,"author":"Maloney","volume":"112","first-page":"773","unstructured":null,"article-title":"Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0015-0282(01)01938-0","key":"10.1016/j.jaad.2023.12.017_bib131","year":"2001","issue":null,"author":"Thiboutot","volume":"76","first-page":"461","unstructured":null,"article-title":"A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment","journal-title":"Fertil Steril","doi-asserted-by":"crossref"},{"DOI":"10.1067/mjd.2002.122192","key":"10.1016/j.jaad.2023.12.017_bib132","year":"2002","issue":null,"author":"Leyden","volume":"47","first-page":"399","unstructured":null,"article-title":"Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: a randomized, placebo-controlled trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0029-7844(97)00059-8","key":"10.1016/j.jaad.2023.12.017_bib133","year":"1997","issue":null,"author":"Redmond","volume":"89","first-page":"615","unstructured":null,"article-title":"Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(97)70112-9","key":"10.1016/j.jaad.2023.12.017_bib134","year":"1997","issue":null,"author":"Lucky","volume":"37","first-page":"746","unstructured":null,"article-title":"Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2008.10.010","key":"10.1016/j.jaad.2023.12.017_bib135","year":"2009","issue":null,"author":"Palombo-Kinne","volume":"79","first-page":"282","unstructured":null,"article-title":"Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1053/cjwh.2001.25638","key":"10.1016/j.jaad.2023.12.017_bib136","year":"2001","issue":null,"author":"Maloney JM Arbit","volume":"1","first-page":"123","unstructured":null,"article-title":"Use of low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris","journal-title":"Clin J Wom Health","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2007.11.003","key":"10.1016/j.jaad.2023.12.017_bib137","year":"2008","issue":null,"author":"Koltun","volume":"77","first-page":"249","unstructured":null,"article-title":"Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2009.02.016","key":"10.1016/j.jaad.2023.12.017_bib138","year":"2009","issue":null,"author":"Plewig","volume":"80","first-page":"25","unstructured":null,"article-title":"Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1080/13625180008500411","key":"10.1016/j.jaad.2023.12.017_bib139","year":"2000","issue":null,"author":"Katz","volume":"5","first-page":"248","unstructured":null,"article-title":"Effect of a desogestrel-containing oral contraceptive on the skin","journal-title":"Eur J Contracept Reprod Health Care","doi-asserted-by":"crossref"},{"DOI":"10.1111/1346-8138.15559","key":"10.1016/j.jaad.2023.12.017_bib140","year":"2020","issue":null,"author":"Patiyasikunt","volume":"47","first-page":"1411","unstructured":null,"article-title":"Efficacy and tolerability of low-dose spironolactone and topical benzoyl peroxide in adult female acne: a randomized, double-blind, placebo-controlled trial","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1984.tb04045.x","key":"10.1016/j.jaad.2023.12.017_bib141","year":"1984","issue":null,"author":"Goodfellow","volume":"111","first-page":"209","unstructured":null,"article-title":"Oral spironolactone improves acne vulgaris and reduces sebum excretion","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1986.tb05722.x","key":"10.1016/j.jaad.2023.12.017_bib142","year":"1986","issue":null,"author":"Muhlemann","volume":"115","first-page":"227","unstructured":null,"article-title":"Oral spironolactone: an effective treatment for acne vulgaris in women","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2020.5468","key":"10.1016/j.jaad.2023.12.017_bib143","year":"2021","issue":null,"author":"Barbieri","volume":"157","first-page":"296","unstructured":null,"article-title":"Temporal trends and clinician variability in potassium monitoring of healthy young women treated for acne with spironolactone","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1159/000471799","key":"10.1016/j.jaad.2023.12.017_bib144","year":"2017","issue":null,"author":"Grandhi","volume":"233","first-page":"141","unstructured":null,"article-title":"Spironolactone for the treatment of acne: a 4-year retrospective study","journal-title":"Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2015.34","key":"10.1016/j.jaad.2023.12.017_bib145","year":"2015","issue":null,"author":"Plovanich","volume":"151","first-page":"941","unstructured":null,"article-title":"Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00266-006-0081-0","key":"10.1016/j.jaad.2023.12.017_bib146","year":"2006","issue":null,"author":"Sato","volume":"30","first-page":"689","unstructured":null,"article-title":"Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians","journal-title":"Aesthetic Plast Surg","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijwd.2019.04.024","key":"10.1016/j.jaad.2023.12.017_bib147","year":"2019","issue":null,"author":"Thiede","volume":"5","first-page":"155","unstructured":null,"article-title":"Hyperkalemia in women with acne exposed to oral spironolactone: a retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program","journal-title":"Int J Womens Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.4103/0378-6323.86482","key":"10.1016/j.jaad.2023.12.017_bib148","year":"2011","issue":null,"author":"Agarwal","volume":"77","first-page":"688","unstructured":null,"article-title":"Oral isotretinoin in different dose regimens for acne vulgaris: a randomized comparative trial","journal-title":"Indian J Dermatol Venereol Leprol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00403-007-0777-2","key":"10.1016/j.jaad.2023.12.017_bib149","year":"2007","issue":null,"author":"Akman","volume":"299","first-page":"467","unstructured":null,"article-title":"Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study","journal-title":"Arch Dermatol Res","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.2010.10152.x","key":"10.1016/j.jaad.2023.12.017_bib150","year":"2011","issue":null,"author":"Lee","volume":"164","first-page":"1369","unstructured":null,"article-title":"Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib151","year":"2014","issue":null,"author":"Webster","volume":"13","first-page":"665","unstructured":null,"article-title":"Results of a phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib152","year":"2016","issue":"1","author":"Tangjaturonrusamee","volume":"98","first-page":"56","unstructured":null,"article-title":"Comparison of pneumatic broadband light plus adapalene gel 0.3% versus adapalene gel 0.3% monotherapy in the treatment of mild to moderate acne","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/S0190-9622(96)90443-0","key":"10.1016/j.jaad.2023.12.017_bib153","year":"1996","issue":null,"author":"Shalita","volume":"34","first-page":"482","unstructured":null,"article-title":"A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(98)70141-0","key":"10.1016/j.jaad.2023.12.017_bib154","year":"1998","issue":null,"author":"Lucky","volume":"38","first-page":"S17","unstructured":null,"article-title":"Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter, double-blind, parallel study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/09546634.2019.1587884","key":"10.1016/j.jaad.2023.12.017_bib155","year":"2020","issue":"2","author":"Harper","volume":"31","first-page":"160","unstructured":null,"article-title":"Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups","journal-title":"J Dermatol Treat","doi-asserted-by":"crossref"},{"DOI":"10.1046/j.1365-2133.1998.1390s2017.x","key":"10.1016/j.jaad.2023.12.017_bib156","year":"1998","issue":"Suppl 52","author":"Dunlap","volume":"139","first-page":"17","unstructured":null,"article-title":"Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1067/mjd.2000.108322","key":"10.1016/j.jaad.2023.12.017_bib157","year":"2000","issue":null,"author":"Kakita","volume":"43","first-page":"S51","unstructured":null,"article-title":"Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib158","year":"2001","issue":null,"author":"Webster","volume":"67","first-page":"4","unstructured":null,"article-title":"Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1046/j.1365-2133.1998.1390s2034.x","key":"10.1016/j.jaad.2023.12.017_bib159","year":"1998","issue":"Suppl 52","author":"Galvin","volume":"139","first-page":"34","unstructured":null,"article-title":"Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1971.tb02533.x","key":"10.1016/j.jaad.2023.12.017_bib160","year":"1971","issue":null,"author":"Pedace","volume":"84","first-page":"465","unstructured":null,"article-title":"Topical retinoic acid in acne vulgaris","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1159/000251602","key":"10.1016/j.jaad.2023.12.017_bib161","year":"1974","issue":null,"author":"Christiansen","volume":"148","first-page":"82","unstructured":null,"article-title":"Topical tretinoin, vitamin A acid (Airol) in acne vulgaris. A controlled clinical trial","journal-title":"Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(97)70056-2","key":"10.1016/j.jaad.2023.12.017_bib162","year":"1997","issue":null,"author":"Cunliffe","volume":"36","first-page":"S126","unstructured":null,"article-title":"Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib163","year":"1976","issue":null,"author":"Krishnan","volume":"216","first-page":"106","unstructured":null,"article-title":"Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris","journal-title":"Practitioner","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib164","year":"1978","issue":null,"author":"Cunliffe","volume":"220","first-page":"479","unstructured":null,"article-title":"Benzoyl peroxide in acne","journal-title":"Practitioner","doi-asserted-by":null},{"DOI":"10.1111/j.1600-0560.1974.tb00628.x","key":"10.1016/j.jaad.2023.12.017_bib165","year":"1974","issue":null,"author":"Fulton","volume":"1","first-page":"191","unstructured":null,"article-title":"Studies on the mechanism of action to topical benzoyl peroxide and vitamin A acid in acne vulgaris","journal-title":"J Cutan Pathol","doi-asserted-by":"crossref"},{"DOI":"10.1159/000249352","key":"10.1016/j.jaad.2023.12.017_bib166","year":"1986","issue":null,"author":"Fyrand","volume":"172","first-page":"263","unstructured":null,"article-title":"Water-based versus alcohol-based benzoyl peroxide preparations in the treatment of acne vulgaris","journal-title":"Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-4362.1986.tb04534.x","key":"10.1016/j.jaad.2023.12.017_bib167","year":"1986","issue":null,"author":"Mills","volume":"25","first-page":"664","unstructured":null,"article-title":"Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/000155502320323216","key":"10.1016/j.jaad.2023.12.017_bib168","year":"2002","issue":null,"author":"Mills","volume":"82","first-page":"260","unstructured":null,"article-title":"Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle","journal-title":"Acta Derm Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archdermatol.2009.186","key":"10.1016/j.jaad.2023.12.017_bib169","year":"2009","issue":null,"author":"Dubina","volume":"145","first-page":"1027","unstructured":null,"article-title":"Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.1986.01660170113031","key":"10.1016/j.jaad.2023.12.017_bib170","year":"1986","issue":null,"author":"Parry","volume":"122","first-page":"583","unstructured":null,"article-title":"Pseudomembranous colitis caused by topical clindamycin phosphate","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib171","year":"2010","issue":null,"author":"Yentzer","volume":"86","first-page":"103","unstructured":null,"article-title":"Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib172","year":"2019","issue":null,"author":"Rosette","volume":"18","first-page":"412","unstructured":null,"article-title":"Cortexolone 17alpha-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib173","year":"2011","issue":null,"author":"Kircik","volume":"10","first-page":"586","unstructured":null,"article-title":"Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2013.09.010","key":"10.1016/j.jaad.2023.12.017_bib174","year":"2014","issue":null,"author":"Murase","volume":"70","first-page":"401.e1","unstructured":null,"article-title":"Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s13555-022-00854-3","key":"10.1016/j.jaad.2023.12.017_bib175","year":"2023","issue":null,"author":"Ly","volume":"13","first-page":"115","unstructured":null,"article-title":"Treatment of acne vulgaris during pregnancy and lactation: a Narrative review","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1111/ajd.12075","key":"10.1016/j.jaad.2023.12.017_bib176","year":"2014","issue":null,"author":"Perret","volume":"55","first-page":"111","unstructured":null,"article-title":"Non-antibiotic properties of tetracyclines and their clinical application in dermatology","journal-title":"Australas J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2018.4944","key":"10.1016/j.jaad.2023.12.017_bib177","year":"2019","issue":null,"author":"Barbieri","volume":"155","first-page":"290","unstructured":null,"article-title":"Trends in oral antibiotic prescription in dermatology, 2008 to 2016","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib178","year":"2025","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1001/archdermatol.2011.355","key":"10.1016/j.jaad.2023.12.017_bib179","year":"2012","issue":null,"author":"Margolis","volume":"148","first-page":"326","unstructured":null,"article-title":"Association of pharyngitis with oral antibiotic use for the treatment of acne: a cross-sectional and prospective cohort study","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJM197803092981003","key":"10.1016/j.jaad.2023.12.017_bib180","year":"1978","issue":null,"author":"Bartlett","volume":"298","first-page":"531","unstructured":null,"article-title":"Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1146/annurev-micro-090110-102824","key":"10.1016/j.jaad.2023.12.017_bib181","year":"2011","issue":null,"author":"Carroll","volume":"65","first-page":"501","unstructured":null,"article-title":"Biology of Clostridium difficile: implications for epidemiology and diagnosis","journal-title":"Annu Rev Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.15585/mmwr.rr6506a1","key":"10.1016/j.jaad.2023.12.017_bib312","year":"2016","issue":"6","author":"Sanchez","volume":"65","first-page":"1","unstructured":null,"article-title":"Core elements of outpatient antibiotic stewardship","journal-title":"MMWR Recomm Rep","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.13776","key":"10.1016/j.jaad.2023.12.017_bib182","year":"2016","issue":null,"author":"Nast","volume":"30","first-page":"1261","unstructured":null,"article-title":"European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib183","year":"2019","issue":null,"author":"Oon","volume":"12","first-page":"34","unstructured":null,"article-title":"Acne management guidelines by the Dermatological Society of Singapore","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib184","year":"2010","issue":null,"author":"Gold","volume":"85","first-page":"94","unstructured":null,"article-title":"Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1001/archderm.142.5.605","key":"10.1016/j.jaad.2023.12.017_bib185","year":"2006","issue":null,"author":"Leyden","volume":"142","first-page":"605","unstructured":null,"article-title":"Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib186","year":"2012","issue":null,"author":"Tan","volume":"11","first-page":"174","unstructured":null,"article-title":"Short-term combination therapy and long-term relapse prevention in the treatment of severe acne vulgaris","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1001/archderm.142.5.597","key":"10.1016/j.jaad.2023.12.017_bib187","year":"2006","issue":null,"author":"Thiboutot","volume":"142","first-page":"597","unstructured":null,"article-title":"Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1346-8138.2012.01626.x","key":"10.1016/j.jaad.2023.12.017_bib188","year":"2012","issue":null,"author":"Moon","volume":"39","first-page":"833","unstructured":null,"article-title":"Antibiotic resistance of microbial strains isolated from Korean acne patients","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib189","year":"2008","issue":null,"author":"Toossi","volume":"7","first-page":"1149","unstructured":null,"article-title":"Subantimicrobial-dose doxycycline in the treatment of moderate facial acne","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/S0140-6736(04)17591-0","key":"10.1016/j.jaad.2023.12.017_bib190","year":"2004","issue":null,"author":"Ozolins","volume":"364","first-page":"2188","unstructured":null,"article-title":"Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1002/14651858.CD004425.pub5","key":"10.1016/j.jaad.2023.12.017_bib191","year":"2012","issue":null,"author":"Arowojolu","volume":"6","first-page":null,"unstructured":null,"article-title":"Combined oral contraceptive pills for treatment of acne","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib192","year":"2012","issue":null,"author":"Arrington","volume":"90","first-page":"83","unstructured":null,"article-title":"Combined oral contraceptives for the treatment of acne: a practical guide","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1111/j.1529-8019.2009.01261.x","key":"10.1016/j.jaad.2023.12.017_bib193","year":"2009","issue":null,"author":"Harper","volume":"22","first-page":"452","unstructured":null,"article-title":"Should dermatologists prescribe hormonal contraceptives for acne?","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":"10.3109/09513590009167685","key":"10.1016/j.jaad.2023.12.017_bib194","year":"2000","issue":null,"author":"Rabe","volume":"14","first-page":"223","unstructured":null,"article-title":"Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro","journal-title":"Gynecol Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0000000000003880","key":"10.1016/j.jaad.2023.12.017_bib195","year":"2020","issue":null,"author":"Barbieri","volume":"135","first-page":"1306","unstructured":null,"article-title":"Influence of contraception class on incidence and severity of acne vulgaris","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib196","year":"2016","issue":null,"author":"Lortscher","volume":"15","first-page":"670","unstructured":null,"article-title":"Hormonal contraceptives and acne: a retrospective analysis of 2147 patients","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib197","year":"2012","issue":null,"author":"Davtyan","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.2165/11535450-000000000-00000","key":"10.1016/j.jaad.2023.12.017_bib198","year":"2010","issue":null,"author":"Kelly","volume":"30","first-page":"325","unstructured":null,"article-title":"Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study","journal-title":"Clin Drug Investig","doi-asserted-by":"crossref"},{"DOI":"10.2340/0001555564517523","key":"10.1016/j.jaad.2023.12.017_bib199","year":"1984","issue":null,"author":"Palatsi","volume":"64","first-page":"517","unstructured":null,"article-title":"Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives","journal-title":"Acta Derm Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1067/mob.2003.294","key":"10.1016/j.jaad.2023.12.017_bib200","year":"2003","issue":null,"author":"Rosen","volume":"188","first-page":"1158","unstructured":null,"article-title":"A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2003.12.017","key":"10.1016/j.jaad.2023.12.017_bib201","year":"2004","issue":null,"author":"Winkler","volume":"69","first-page":"469","unstructured":null,"article-title":"Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2014.06.002","key":"10.1016/j.jaad.2023.12.017_bib202","year":"2014","issue":null,"author":"Jaisamrarn","volume":"90","first-page":"535","unstructured":null,"article-title":"A comparison of multiphasic oral contraceptives containing norgestimate or desogestrel in acne treatment: a randomized trial","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib203","year":"2004","issue":null,"author":"Thorneycroft","volume":"74","first-page":"123","unstructured":null,"article-title":"Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/S0010-7824(99)00093-1","key":"10.1016/j.jaad.2023.12.017_bib204","year":"1999","issue":null,"author":"Thorneycroft","volume":"60","first-page":"255","unstructured":null,"article-title":"Effect of low-dose oral contraceptives on androgenic markers and acne","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.285.17.2232","key":"10.1016/j.jaad.2023.12.017_bib205","year":"2001","issue":null,"author":"Stewart","volume":"285","first-page":"2232","unstructured":null,"article-title":"Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib206","year":"2016","issue":null,"author":"Curtis","volume":"65","first-page":"1","unstructured":null,"article-title":"U.S. Selected practice recommendations for contraceptive use, 2016","journal-title":"MMWR Recomm Rep","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib207","year":"2012","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib208","year":"2016","issue":null,"author":"Curtis","volume":"65","first-page":"1","unstructured":null,"article-title":"U.S. Medical eligibility criteria for contraceptive use, 2016","journal-title":"MMWR Recomm Rep","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib209","year":"2011","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.clindermatol.2009.03.006","key":"10.1016/j.jaad.2023.12.017_bib210","year":"2010","issue":null,"author":"Katsambas","volume":"28","first-page":"17","unstructured":null,"article-title":"Hormonal therapy for acne: why not as first line therapy? facts and controversies","journal-title":"Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1158/1055-9965.EPI-13-0298","key":"10.1016/j.jaad.2023.12.017_bib211","year":"2013","issue":null,"author":"Gierisch","volume":"22","first-page":"1931","unstructured":null,"article-title":"Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review","journal-title":"Cancer Epidemiol Biomarkers Prev","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0b013e318291c235","key":"10.1016/j.jaad.2023.12.017_bib212","year":"2013","issue":null,"author":"Havrilesky","volume":"122","first-page":"139","unstructured":null,"article-title":"Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ajog.2017.02.002","key":"10.1016/j.jaad.2023.12.017_bib213","year":"2017","issue":null,"author":"Iversen","volume":"216","first-page":"580.e1","unstructured":null,"article-title":"Lifetime cancer risk and combined oral contraceptives: the Royal College of general practitioners' oral contraception study","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(07)61684-5","key":"10.1016/j.jaad.2023.12.017_bib214","year":"2007","issue":null,"author":"Appleby","volume":"370","first-page":"1609","unstructured":null,"article-title":"Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib215","year":"2016","issue":null,"author":"Roura","volume":"11","first-page":null,"unstructured":null,"article-title":"The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort","journal-title":"PLoS One","doi-asserted-by":null},{"DOI":"10.1097/AOG.0b013e3181cb50b5","key":"10.1016/j.jaad.2023.12.017_bib216","year":"2010","issue":null,"author":null,"volume":"115","first-page":"206","unstructured":null,"article-title":"ACOG practice bulletin no. 110: noncontraceptive uses of hormonal contraceptives","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0000000000004659","key":"10.1016/j.jaad.2023.12.017_bib217","year":"2022","issue":null,"author":null,"volume":"139","first-page":"350","unstructured":null,"article-title":"Patient-centered contraceptive counseling: ACOG Committee statement number 1","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(97)80322-2","key":"10.1016/j.jaad.2023.12.017_bib218","year":"1997","issue":null,"author":"Helms","volume":"36","first-page":"705","unstructured":null,"article-title":"Oral contraceptive failure rates and oral antibiotics","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.1994.01690030128027","key":"10.1016/j.jaad.2023.12.017_bib219","year":"1994","issue":null,"author":"London","volume":"130","first-page":"392","unstructured":null,"article-title":"Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1097/00006250-200606000-00055","key":"10.1016/j.jaad.2023.12.017_bib220","year":"2006","issue":null,"author":null,"volume":"107","first-page":"1453","unstructured":null,"article-title":"ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2007.09.024","key":"10.1016/j.jaad.2023.12.017_bib221","year":"2008","issue":null,"author":"Krunic","volume":"58","first-page":"60","unstructured":null,"article-title":"Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1186/1472-6904-11-23","key":"10.1016/j.jaad.2023.12.017_bib222","year":"2011","issue":null,"author":"Bird","volume":"11","first-page":"23","unstructured":null,"article-title":"The association between drospirenone and hyperkalemia: a comparative-safety study","journal-title":"BMC Clin Pharmacol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2021.05.002","key":"10.1016/j.jaad.2023.12.017_bib223","year":"2021","issue":null,"author":"Creinin","volume":"104","first-page":"222","unstructured":null,"article-title":"Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1139/o79-131","key":"10.1016/j.jaad.2023.12.017_bib224","year":"1979","issue":null,"author":"Boisselle","volume":"57","first-page":"1042","unstructured":null,"article-title":"Interaction of spironolactone with rat skin androgen receptor","journal-title":"Can J Biochem","doi-asserted-by":"crossref"},{"DOI":"10.1016/0024-3205(74)90330-0","key":"10.1016/j.jaad.2023.12.017_bib225","year":"1974","issue":null,"author":"Menard","volume":"15","first-page":"1639","unstructured":null,"article-title":"Spironolactone and cytochrome P-450: impairment of steroid hydroxylation in the adrenal cortex","journal-title":"Life Sci","doi-asserted-by":"crossref"},{"DOI":"10.1210/endo-94-6-1628","key":"10.1016/j.jaad.2023.12.017_bib226","year":"1974","issue":null,"author":"Menard","volume":"94","first-page":"1628","unstructured":null,"article-title":"Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism","journal-title":"Endocrinology","doi-asserted-by":"crossref"},{"DOI":"10.1210/jcem-46-2-338","key":"10.1016/j.jaad.2023.12.017_bib227","year":"1978","issue":null,"author":"Rifka","volume":"46","first-page":"338","unstructured":null,"article-title":"Interaction of digitalis and spironolactone with human sex steroid receptors","journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1159/000211271","key":"10.1016/j.jaad.2023.12.017_bib228","year":"1994","issue":null,"author":"Zouboulis","volume":"7","first-page":"33","unstructured":null,"article-title":"Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone","journal-title":"Skin Pharmacol","doi-asserted-by":"crossref"},{"DOI":"10.1016/0022-4731(85)90236-5","key":"10.1016/j.jaad.2023.12.017_bib229","year":"1985","issue":null,"author":"Serafini","volume":"23","first-page":"191","unstructured":null,"article-title":"The effect of spironolactone on genital skin 5 alpha-reductase activity","journal-title":"J Steroid Biochem","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib230","year":"2018","issue":null,"author":"Barbieri","volume":"17","first-page":"632","unstructured":null,"article-title":"Frequency of treatment switching for spironolactone compared to oral tetracycline-class antibiotics for women with acne: a retrospective cohort study 2010-2016","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1007/s40257-016-0245-x","key":"10.1016/j.jaad.2023.12.017_bib231","year":"2017","issue":null,"author":"Layton","volume":"18","first-page":"169","unstructured":null,"article-title":"Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2020.12.071","key":"10.1016/j.jaad.2023.12.017_bib232","year":"2021","issue":null,"author":"Garg","volume":"84","first-page":"1348","unstructured":null,"article-title":"Long-term use of spironolactone for acne in women: a case series of 403 patients","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1177/120347540200600604","key":"10.1016/j.jaad.2023.12.017_bib233","year":"2002","issue":null,"author":"Shaw","volume":"6","first-page":"541","unstructured":null,"article-title":"Long-term safety of spironolactone in acne: results of an 8-year followup study","journal-title":"J Cutan Med Surg","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib234","year":"2023","issue":null,"author":"Santer","volume":"381","first-page":null,"unstructured":null,"article-title":"Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial","journal-title":"BMJ","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib235","year":"2013","issue":null,"author":"Zeichner","volume":"12","first-page":"1416","unstructured":null,"article-title":"Evaluating and treating the adult female patient with acne","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2018.10.023","key":"10.1016/j.jaad.2023.12.017_bib236","year":"2019","issue":null,"author":"Liszewski","volume":"80","first-page":"1147","unstructured":null,"article-title":"Lack of evidence for feminization of males exposed to spironolactone in utero: a systematic review","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2021.5866","key":"10.1016/j.jaad.2023.12.017_bib237","year":"2022","issue":null,"author":"Bommareddy","volume":"158","first-page":"275","unstructured":null,"article-title":"Association of spironolactone use with risk of cancer: a systematic review and meta-analysis","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.1983.01650300034012","key":"10.1016/j.jaad.2023.12.017_bib238","year":"1983","issue":null,"author":"Levine","volume":"119","first-page":"480","unstructured":null,"article-title":"Intralesional corticosteroids in the treatment of nodulocystic acne","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2019.02.067","key":"10.1016/j.jaad.2023.12.017_bib239","year":"2019","issue":null,"author":"Alikhan","volume":"81","first-page":"76","unstructured":null,"article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00266-008-9152-8","key":"10.1016/j.jaad.2023.12.017_bib240","year":"2008","issue":null,"author":"Hochman","volume":"32","first-page":"705","unstructured":null,"article-title":"Intralesional triamcinolone acetonide for keloid treatment: a systematic review","journal-title":"Aesthetic Plast Surg","doi-asserted-by":"crossref"},{"DOI":"10.1080/02844310500430003","key":"10.1016/j.jaad.2023.12.017_bib241","year":"2006","issue":null,"author":"Muneuchi","volume":"40","first-page":"111","unstructured":null,"article-title":"Long-term outcome of intralesional injection of triamcinolone acetonide for the treatment of keloid scars in Asian patients","journal-title":"Scand J Plast ReConstr Surg Hand Surg","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2016.06.049","key":"10.1016/j.jaad.2023.12.017_bib242","year":"2016","issue":null,"author":"Riis","volume":"75","first-page":"1151","unstructured":null,"article-title":"Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib243","year":"1962","issue":null,"author":"Seif-El-Nasr","volume":"45","first-page":"105","unstructured":null,"article-title":"Granuloma annulare. Report of a case treated successfully by intralesional triamcinolone injection","journal-title":"J Egypt Med Assoc","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2133.1975.tb06481.x","key":"10.1016/j.jaad.2023.12.017_bib244","year":"1975","issue":null,"author":"Sparrow","volume":"93","first-page":"85","unstructured":null,"article-title":"Granuloma annulare and necrobiosis lipoidica treated by jet injector","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.15233","key":"10.1016/j.jaad.2023.12.017_bib245","year":"2019","issue":null,"author":"Zouboulis","volume":"33","first-page":"19","unstructured":null,"article-title":"Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.2340/00015555-1346","key":"10.1016/j.jaad.2023.12.017_bib246","year":"2012","issue":null,"author":"Kwon","volume":"92","first-page":"241","unstructured":null,"article-title":"Clinical and histological effect of a low glycaemic load diet in treatment of acne vulgaris in Korean patients: a randomized, controlled trial","journal-title":"Acta Derm Venereol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib247","year":"2020","issue":null,"author":"Gallagher","volume":"13","first-page":"41","unstructured":null,"article-title":"Dermatologist use of intralesional triamcinolone in the treatment of acne","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1046/j.1365-4362.1998.00443.x","key":"10.1016/j.jaad.2023.12.017_bib248","year":"1998","issue":null,"author":"Jansen","volume":"37","first-page":"254","unstructured":null,"article-title":"Acne fulminans","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/0190-9622(93)70076-6","key":"10.1016/j.jaad.2023.12.017_bib249","year":"1993","issue":null,"author":"Karvonen","volume":"28","first-page":"572","unstructured":null,"article-title":"Acne fulminans: report of clinical findings and treatment of twenty-four patients","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/14740338.2022.2102605","key":"10.1016/j.jaad.2023.12.017_bib250","year":"2022","issue":null,"author":"Villani","volume":"21","first-page":"1027","unstructured":null,"article-title":"Oral isotretinoin for acne: a complete overview","journal-title":"Expert Opin Drug Saf","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(82)70063-5","key":"10.1016/j.jaad.2023.12.017_bib251","year":"1982","issue":null,"author":"Peck","volume":"6","first-page":"735","unstructured":null,"article-title":"Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(80)80074-0","key":"10.1016/j.jaad.2023.12.017_bib252","year":"1980","issue":null,"author":"Farrell","volume":"3","first-page":"602","unstructured":null,"article-title":"The treatment of severe cystic acne with 13-cis-retinoic acid: evaluation of sebum production and the clinical response in a multiple-dose trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1982.tb00410.x","key":"10.1016/j.jaad.2023.12.017_bib253","year":"1982","issue":null,"author":"King","volume":"107","first-page":"583","unstructured":null,"article-title":"A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(84)80100-0","key":"10.1016/j.jaad.2023.12.017_bib254","year":"1984","issue":null,"author":"Strauss","volume":"10","first-page":"490","unstructured":null,"article-title":"Isotretinoin therapy for acne: results of a multicenter dose-response study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.12170","key":"10.1016/j.jaad.2023.12.017_bib255","year":"2014","issue":null,"author":"Rademaker","volume":"28","first-page":"747","unstructured":null,"article-title":"Isotretinoin 5 mg daily for low-grade adult acne vulgaris--a placebo-controlled, randomized double-blind study","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1503/cmaj.140665","key":"10.1016/j.jaad.2023.12.017_bib256","year":"2016","issue":null,"author":"Asai","volume":"188","first-page":"118","unstructured":null,"article-title":"Management of acne: Canadian clinical practice guideline","journal-title":"CMAJ","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.13675","key":"10.1016/j.jaad.2023.12.017_bib257","year":"2016","issue":null,"author":"Gollnick","volume":"30","first-page":"1480","unstructured":null,"article-title":"A consensus-based practical and daily guide for the treatment of acne patients","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.15843","key":"10.1016/j.jaad.2023.12.017_bib258","year":"2017","issue":null,"author":"Le Cleach","volume":"177","first-page":"908","unstructured":null,"article-title":"Guidelines for the management of acne: recommendations from a French multidisciplinary group","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2017.09.078","key":"10.1016/j.jaad.2023.12.017_bib259","year":"2018","issue":null,"author":"Thiboutot","volume":"78","first-page":"S1","unstructured":null,"article-title":"Practical management of acne for clinicians: an international consensus from the global alliance to improve outcomes in acne","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib260","year":"2019","issue":null,"author":"Gómez-Flores","volume":"56","first-page":"441","unstructured":null,"article-title":"[Second joint position paper: use of isotretinoin in severe acne]","journal-title":"Rev Med Inst Mex Seguro Soc","doi-asserted-by":null},{"DOI":"10.1016/j.abd.2020.09.001","key":"10.1016/j.jaad.2023.12.017_bib261","year":"2020","issue":"Suppl 1","author":"Bagatin","volume":"95","first-page":"19","unstructured":null,"article-title":"Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology","journal-title":"An Bras Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/dth.15974","key":"10.1016/j.jaad.2023.12.017_bib262","year":"2022","issue":null,"author":"Kassem","volume":"35","first-page":null,"unstructured":null,"article-title":"Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: randomized, controlled, comparative study","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1468-3083.2010.03933.x","key":"10.1016/j.jaad.2023.12.017_bib263","year":"2011","issue":null,"author":"Borghi","volume":"25","first-page":"1094","unstructured":null,"article-title":"Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1468-3083.2006.01784.x","key":"10.1016/j.jaad.2023.12.017_bib264","year":"2006","issue":null,"author":"Kaymak","volume":"20","first-page":"1256","unstructured":null,"article-title":"The effectiveness of intermittent isotretinoin treatment in mild or moderate acne","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2005.11.1061","key":"10.1016/j.jaad.2023.12.017_bib265","year":"2006","issue":null,"author":"Amichai","volume":"54","first-page":"644","unstructured":null,"article-title":"Low-dose isotretinoin in the treatment of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib266","year":"2014","issue":null,"author":"Kızılyel","volume":"94","first-page":"234","unstructured":null,"article-title":"Effects of oral isotretinoin on lipids and liver enzymes in acne patients","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib267","year":"2006","issue":null,"author":"Ghaffarpour","volume":"5","first-page":"878","unstructured":null,"article-title":"Oral isotretinoin for acne, adjusting treatment according to patient's response","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1590/1516-3180.2018.054405072019","key":"10.1016/j.jaad.2023.12.017_bib268","year":"2019","issue":null,"author":"Evaristo","volume":"137","first-page":"363","unstructured":null,"article-title":"Use of oral isotretinoin to treat acne in the public system: a hospital-based retrospective cohort","journal-title":"Sao Paulo Med J","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2019.06.025","key":"10.1016/j.jaad.2023.12.017_bib269","year":"2020","issue":null,"author":"Barbieri","volume":"82","first-page":"72","unstructured":null,"article-title":"The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jocd.12268","key":"10.1016/j.jaad.2023.12.017_bib270","year":"2017","issue":null,"author":"Yap","volume":"16","first-page":"348","unstructured":null,"article-title":"Safety and efficacy of fixed-dose 10 mg daily isotretinoin treatment for acne vulgaris in Malaysia","journal-title":"J Cosmet Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2015.3091","key":"10.1016/j.jaad.2023.12.017_bib271","year":"2016","issue":null,"author":"Lee","volume":"152","first-page":"35","unstructured":null,"article-title":"Laboratory monitoring during isotretinoin therapy for acne: a systematic review and meta-analysis","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2022.2044","key":"10.1016/j.jaad.2023.12.017_bib272","year":"2022","issue":null,"author":"Xia","volume":"158","first-page":"942","unstructured":null,"article-title":"Isotretinoin laboratory monitoring in acne treatment: a Delphi consensus study","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.21840","key":"10.1016/j.jaad.2023.12.017_bib273","year":"2022","issue":null,"author":"Affleck","volume":"187","first-page":"857","unstructured":null,"article-title":"Is routine laboratory testing in healthy young patients taking isotretinoin necessary: a critically appraised topic","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/0190-9622(92)70088-W","key":"10.1016/j.jaad.2023.12.017_bib274","year":"1992","issue":null,"author":"Dai","volume":"26","first-page":"599","unstructured":null,"article-title":"Epidemiology of isotretinoin exposure during pregnancy","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2010.09.017","key":"10.1016/j.jaad.2023.12.017_bib275","year":"2011","issue":null,"author":"Shin","volume":"65","first-page":"1117","unstructured":null,"article-title":"The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2013.08.034","key":"10.1016/j.jaad.2023.12.017_bib276","year":"2014","issue":null,"author":"Collins","volume":"70","first-page":"55","unstructured":null,"article-title":"Compliance with pregnancy prevention measures during isotretinoin therapy","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib277","year":"2017","issue":null,"author":null,"volume":"130","first-page":"e251","unstructured":null,"article-title":"Practice bulletin No. 186: long-acting reversible contraception: implants and intrauterine devices","journal-title":"Obstet Gynecol","doi-asserted-by":null},{"DOI":"10.1038/jid.2012.387","key":"10.1016/j.jaad.2023.12.017_bib278","year":"2013","issue":null,"author":"Alhusayen","volume":"133","first-page":"907","unstructured":null,"article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2009.417","key":"10.1016/j.jaad.2023.12.017_bib279","year":"2009","issue":null,"author":"Bernstein","volume":"104","first-page":"2774","unstructured":null,"article-title":"Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2010.124","key":"10.1016/j.jaad.2023.12.017_bib280","year":"2010","issue":null,"author":"Crockett","volume":"105","first-page":"1986","unstructured":null,"article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a case-control study","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2013.1344","key":"10.1016/j.jaad.2023.12.017_bib281","year":"2013","issue":null,"author":"Etminan","volume":"149","first-page":"216","unstructured":null,"article-title":"Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2014.8","key":"10.1016/j.jaad.2023.12.017_bib282","year":"2014","issue":null,"author":"Racine","volume":"109","first-page":"563","unstructured":null,"article-title":"Isotretinoin and risk of inflammatory bowel disease: a French nationwide study","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2020.07.042","key":"10.1016/j.jaad.2023.12.017_bib283","year":"2021","issue":null,"author":"Wright","volume":"84","first-page":"41","unstructured":null,"article-title":"Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2014.1540","key":"10.1016/j.jaad.2023.12.017_bib284","year":"2014","issue":null,"author":"Rashtak","volume":"150","first-page":"1322","unstructured":null,"article-title":"Isotretinoin exposure and risk of inflammatory bowel disease","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.sder.2005.04.003","key":"10.1016/j.jaad.2023.12.017_bib285","year":"2005","issue":null,"author":"Marqueling","volume":"24","first-page":"92","unstructured":null,"article-title":"Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review","journal-title":"Semin Cutan Med Surg","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.c5812","key":"10.1016/j.jaad.2023.12.017_bib286","year":"2010","issue":null,"author":"Sundstrom","volume":"341","first-page":null,"unstructured":null,"article-title":"Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jad.2021.09.055","key":"10.1016/j.jaad.2023.12.017_bib287","year":"2022","issue":null,"author":"Chen","volume":"296","first-page":"277","unstructured":null,"article-title":"Risk of psychiatric disorders in patients taking isotretinoin: a nationwide, population-based, cohort study in Taiwan","journal-title":"J Affect Disord","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2021.01.107","key":"10.1016/j.jaad.2023.12.017_bib288","year":"2021","issue":null,"author":"Ugonabo","volume":"85","first-page":"878","unstructured":null,"article-title":"Psychiatric disorders and suicidal behavior in patients with acne prescribed oral antibiotics versus isotretinoin: analysis of a large commercial insurance claims database","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.136.10.1231","key":"10.1016/j.jaad.2023.12.017_bib289","year":"2000","issue":null,"author":"Jick","volume":"136","first-page":"1231","unstructured":null,"article-title":"Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2015.18392","key":"10.1016/j.jaad.2023.12.017_bib290","year":"2016","issue":null,"author":"Siu","volume":"315","first-page":"380","unstructured":null,"article-title":"Screening for depression in adults: US preventive services task force recommendation statement","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2020.2330","key":"10.1016/j.jaad.2023.12.017_bib291","year":"2020","issue":null,"author":"Secrest","volume":"156","first-page":"1098","unstructured":null,"article-title":"Quality of life assessed using Skindex-16 scores among patients with acne receiving isotretinoin treatment","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/09546634.2019.1577545","key":"10.1016/j.jaad.2023.12.017_bib292","year":"2019","issue":null,"author":"Bray","volume":"30","first-page":"796","unstructured":null,"article-title":"Is there an association between isotretinoin therapy and adverse mood changes? A prospective study in a cohort of acne patients","journal-title":"J Dermatolog Treat","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.21049","key":"10.1016/j.jaad.2023.12.017_bib293","year":"2022","issue":null,"author":"Paljarvi","volume":"187","first-page":"64","unstructured":null,"article-title":"Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2022.16946","key":"10.1016/j.jaad.2023.12.017_bib294","year":"2022","issue":null,"author":"Mangione","volume":"328","first-page":"1534","unstructured":null,"article-title":"Screening for depression and suicide risk in children and adolescents: US preventive services task force recommendation statement","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2022.16936","key":"10.1016/j.jaad.2023.12.017_bib295","year":"2022","issue":null,"author":"Mangione","volume":"328","first-page":"1438","unstructured":null,"article-title":"Screening for anxiety in children and adolescents: US preventive services task force recommendation statement","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2016.02.1148","key":"10.1016/j.jaad.2023.12.017_bib296","year":"2016","issue":null,"author":"Schrom","volume":"75","first-page":"237","unstructured":null,"article-title":"Depression screening using health questionnaires in patients receiving oral isotretinoin for acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1097/DSS.0000000000001166","key":"10.1016/j.jaad.2023.12.017_bib297","year":"2017","issue":null,"author":"Waldman","volume":"43","first-page":"1249","unstructured":null,"article-title":"ASDS guidelines task force: consensus recommendations regarding the safety of lasers, dermabrasion, chemical peels, Energy devices, and skin surgery during and after isotretinoin use","journal-title":"Dermatol Surg","doi-asserted-by":"crossref"},{"DOI":"10.1007/s10103-022-03645-6","key":"10.1016/j.jaad.2023.12.017_bib298","year":"2022","issue":null,"author":"Scopelliti","volume":"37","first-page":"3639","unstructured":null,"article-title":"A novel 1726-nm laser system for safe and effective treatment of acne vulgaris","journal-title":"Lasers Med Sci","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2023.05.085","key":"10.1016/j.jaad.2023.12.017_bib299","year":"2023","issue":"4","author":"Alexiades","volume":"89","first-page":"703","unstructured":null,"article-title":"Novel 1726 nm laser demonstrates durable therapeutic outcomes and tolerability for moderate-to-severe acne across skin types","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.3390/nu2101060","key":"10.1016/j.jaad.2023.12.017_bib300","year":"2010","issue":null,"author":"Reynolds","volume":"2","first-page":"1060","unstructured":null,"article-title":"Effect of the glycemic index of carbohydrates on Acne vulgaris","journal-title":"Nutrients","doi-asserted-by":"crossref"},{"DOI":"10.1093/ajcn/86.1.107","key":"10.1016/j.jaad.2023.12.017_bib301","year":"2007","issue":null,"author":"Smith","volume":"86","first-page":"107","unstructured":null,"article-title":"A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial","journal-title":"Am J Clin Nutr","doi-asserted-by":"crossref"},{"DOI":"10.4103/ijdvl.IJDVL_109_17","key":"10.1016/j.jaad.2023.12.017_bib302","year":"2019","issue":null,"author":"Pavithra","volume":"85","first-page":"486","unstructured":null,"article-title":"A randomized controlled trial of topical benzoyl peroxide 2.5% gel with a low glycemic load diet versus topical benzoyl peroxide 2.5% gel with a normal diet in acne (grades 1-3)","journal-title":"Indian J Dermatol Venereol Leprol","doi-asserted-by":"crossref"},{"DOI":"10.12788/cutis.0067","key":"10.1016/j.jaad.2023.12.017_bib303","year":"2020","issue":null,"author":"Barbieri","volume":"106","first-page":"E4","unstructured":null,"article-title":"Active comparator trial designs used to promote development of innovative new medications","journal-title":"Cutis","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2021.0356","key":"10.1016/j.jaad.2023.12.017_bib304","year":"2021","issue":null,"author":"Miller","volume":"157","first-page":"597","unstructured":null,"article-title":"Use of active comparator trials for topical medications in dermatology","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2017.06.004","key":"10.1016/j.jaad.2023.12.017_bib305","year":"2017","issue":null,"author":"Gao","volume":"77","first-page":"971","unstructured":null,"article-title":"Acne, sexual orientation, and mental health among young adults in the United States: a population-based, cross-sectional study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib306","year":"2022","issue":null,"author":"Pathmarajah","volume":"15","first-page":"43","unstructured":null,"article-title":"Acne vulgaris in skin of color: a systematic review of the effectiveness and tolerability of current treatments","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1001/jamadermatol.2020.5353","key":"10.1016/j.jaad.2023.12.017_bib307","year":"2021","issue":null,"author":"Braun","volume":"157","first-page":"344","unstructured":null,"article-title":"Moderate-to-severe acne and mental health symptoms in Transmasculine persons who have received testosterone","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jid.2020.05.086","key":"10.1016/j.jaad.2023.12.017_bib308","year":"2021","issue":null,"author":"DeGrazia","volume":"141","first-page":"189","unstructured":null,"article-title":"Eligibility criteria related to hormone therapy in acne clinical trials: a systematic review","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib309","year":"2022","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2018.02.042","key":"10.1016/j.jaad.2023.12.017_bib310","year":"2019","issue":null,"author":"Yeung","volume":"80","first-page":"581","unstructured":null,"article-title":"Dermatologic care for lesbian, gay, bisexual, and transgender persons: terminology, demographics, health disparities, and approaches to care","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2013.09.009","key":"10.1016/j.jaad.2023.12.017_bib311","year":"2014","issue":null,"author":"Butler","volume":"70","first-page":"417.e1","unstructured":null,"article-title":"Safety of dermatologic medications in pregnancy and lactation: part II. Lactation","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0190962223033893"],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,5]]},"reference-count":312,"published-online":null,"references-count":312,"short-container-title":["Journal of the American Academy of Dermatology"],"is-referenced-by-count":189},"unpaywall":{"doi":"10.1016/j.jaad.2023.12.017","is_oa":true,"title":"Guidelines of care for the management of acne vulgaris","updated":"2025-08-17T18:46:03+00:00","published_date":"2024-01-30","best_oa_location":{"url":"http://www.jaad.org/article/S0190962223033893/pdf","pmh_id":null,"url_for_pdf":"http://www.jaad.org/article/S0190962223033893/pdf","url_for_landing_page":"https://doi.org/10.1016/j.jaad.2023.12.017"}}},"created_at":"2025-09-20T08:37:26.392Z","updated_at":"2025-09-20T08:53:46.685Z","tags":[{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"azelaic acid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"clascoterone","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"isotretinoin","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"minocycline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"salicylic acid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"sarecycline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"spironolactone","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Androgen Receptor Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Hormonal Therapy","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Intralesional Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Oral Retinoid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Oral Tetracycline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Topical Antibiotic","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Topical Keratolytic","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Topical Retinoid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"warning","value":"Design classification noted as a clinical practice guideline based on a systematic review with GRADE; taxonomy may vary across sources.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"warning","value":"Only high-level recommendations are available in the provided text; quantitative outcomes and dosing details are not included here.","value_numeric":null}],"summaries":{"what_studied":"An evidence-based clinical guideline for acne vulgaris, developed via systematic review using GRADE, covering management in preadolescents (≥9 years), adolescents, and adults.","key_result":"The guideline issues 18 recommendations and 5 good practice statements: strong recommendations for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline; strong for oral isotretinoin in severe, scarring/psychosocial burden, or refractory acne; conditional for topical clascoterone, salicylic acid, and azelaic acid, and for oral minocycline, sarecycline, combined oral contraceptives, and spironolactone; good practice to combine topical agents with different mechanisms, limit systemic antibiotic use, pair systemic antibiotics with topicals, and add intralesional corticosteroids for larger lesions.","practice_takeaway":"Use benzoyl peroxide and a topical retinoid (± topical antibiotic) as core therapy; add oral doxycycline when needed, and reserve isotretinoin for severe, scarring/psychosocial burden, or refractory cases. Consider clascoterone, salicylic or azelaic acid, minocycline or sarecycline, combined oral contraceptives, or spironolactone as conditionally recommended options; combine topicals, minimize systemic antibiotic exposure, and use intralesional corticosteroids for large lesions."}},{"doi":"10.1016/j.jaad.2024.01.033","pmid":"38290620","title":"Medicaid formularies for acne treatments are difficult to access and reflect inconsistent coverage policies","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2024-01-31T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2024.01.033","source_score":72,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2024-02-11","doi":"10.1016/j.jaad.2024.01.033","days":"30","issn":"0190-9622","rank":"5","field":"Clinical Medicine","score":"72","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1016/j.jaad.2024.01.033","title":"Medicaid formularies for acne treatments are difficult to access and reflect inconsistent coverage policies.","journal":"Journal of the American Academy of Dermatology","methods":"","results":"","abstract":"","keywords":["accessibility","acne","antibiotics","clascoterone","coverage","formulary","isotretinoin","retinoids"],"pubmed_id":"38290620","conclusions":"","publication_date":"2024-01-31T00:00:00"},"crossref":{"DOI":"10.1016/j.jaad.2024.01.033","URL":"https://doi.org/10.1016/j.jaad.2024.01.033","ISSN":["0190-9622"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0190962224001336?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0190962224001336?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"1074-1076","type":"journal-article","issue":"5","score":1,"title":["Medicaid formularies for acne treatments are difficult to access and reflect inconsistent coverage policies"],"author":[{"given":"Sherry","family":"Ershadi","sequence":"first","affiliation":[]},{"given":"James","family":"Choe","sequence":"additional","affiliation":[]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2024,5]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"90","created":{"date-time":"2024-01-28T15:00:23Z","timestamp":1706454023000,"date-parts":[[2024,1,28]]},"indexed":{"date-time":"2025-05-13T19:07:22Z","timestamp":1747163242337,"date-parts":[[2025,5,13]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000,"date-parts":[[2024,5,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000,"date-parts":[[2024,5,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0190962224001336"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Medicaid formularies for acne treatments are difficult to access and reflect inconsistent coverage policies"},{"name":"journaltitle","label":"Journal Title","value":"Journal of the American Academy of Dermatology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jaad.2024.01.033"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2024 by the American Academy of Dermatology, Inc."}],"deposited":{"date-time":"2024-06-05T21:01:19Z","timestamp":1717621279000,"date-parts":[[2024,6,5]]},"issn-type":[{"type":"print","value":"0190-9622"}],"published":{"date-parts":[[2024,5]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1001/jamadermatol.2021.2185","key":"10.1016/j.jaad.2024.01.033_bib1","year":"2021","issue":"9","author":"Barbieri","volume":"157","first-page":"1040","unstructured":null,"article-title":"Patient perspectives on the lived experience of acne and its treatment among adult women with acne: a qualitative study","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2022.6322","key":"10.1016/j.jaad.2024.01.033_bib2","year":"2023","issue":"3","author":"Barbieri","volume":"159","first-page":"245","unstructured":null,"article-title":"Double standards and inconsistencies in access to care-what constitutes a cosmetic treatment?","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.3109/09546634.2013.814758","key":"10.1016/j.jaad.2024.01.033_bib3","year":"2014","issue":"2","author":"Tan","volume":"25","first-page":"110","unstructured":null,"article-title":"Factors associated with topical retinoid prescriptions for acne","journal-title":"J Dermatolog Treat","doi-asserted-by":"crossref"},{"DOI":"10.12788/cutis.0844","key":"10.1016/j.jaad.2024.01.033_bib4","year":"2023","issue":"2","author":"Shields","volume":"112","first-page":"E24","unstructured":null,"article-title":"From breakouts to bargains: Strategies for patient-centered, cost-effective acne care","journal-title":"Cutis","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2017.6144","key":"10.1016/j.jaad.2024.01.033_bib5","year":"2018","issue":"4","author":"Ryskina","volume":"154","first-page":"456","unstructured":null,"article-title":"The role of the physician in patient perceptions of barriers to primary adherence with acne medications","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0190962224001336"],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,5]]},"reference-count":5,"published-online":null,"references-count":5,"short-container-title":["Journal of the American Academy of Dermatology"],"is-referenced-by-count":2},"unpaywall":{"doi":"10.1016/j.jaad.2024.01.033","is_oa":false,"title":"Medicaid formularies for acne treatments are difficult to access and reflect inconsistent coverage policies","updated":"2025-08-17T18:46:03+00:00","published_date":"2024-01-28","best_oa_location":null}},"created_at":"2025-09-20T09:30:19.732Z","updated_at":"2025-09-20T13:06:15.900Z","tags":[{"paper_doi":"10.1016/j.jaad.2024.01.033","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2024.01.033","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2024.01.033","tag_type":"warning","value":"No quantitative outcomes are reported in the provided text.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2024.01.033","tag_type":"warning","value":"Only the title was available; no abstract or data were provided.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2024.01.033","tag_type":"warning","value":"Study design and sample size are unclear.","value_numeric":null}],"summaries":{"what_studied":"Assessed how accessible Medicaid formularies are for acne treatments and whether coverage policies are consistent.","key_result":"Reported that Medicaid formularies for acne treatments are difficult to access and show inconsistent coverage policies."}},{"doi":"10.1001/jamadermatol.2023.4487","pmid":"38055249","title":"Evaluation of Stigma Toward Individuals With Acne","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2023-12-06T00:00:00.000Z","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10701660","source_score":112,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2023-12-09","doi":"10.1001/jamadermatol.2023.4487","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"112","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2023.4487","title":"Evaluation of Stigma Toward Individuals With Acne.","journal":"JAMA dermatology","methods":"","results":"$40","abstract":"$41","keywords":[],"pubmed_id":"38055249","conclusions":"","publication_date":"2023-12-06T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2023.4487","URL":"https://doi.org/10.1001/jamadermatol.2023.4487","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2812215/jamadermatology_shields_2023_br_230019_1705092763.49105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"93","type":"journal-article","issue":"1","score":1,"title":["Evaluation of Stigma Toward Individuals With Acne"],"author":[{"given":"Ali","family":"Shields","sequence":"first","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania"},{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"}]},{"given":"Michael R.","family":"Nock","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}]},{"given":"Sophia","family":"Ly","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"College of Medicine, University of Arkansas for Medical Sciences, Little Rock"}]},{"given":"Priya","family":"Manjaly","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"Boston University School of Medicine, Boston, Massachusetts"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Associate Editor and Evidence-Based Practice Editor, JAMA Dermatology"}]}],"issued":{"date-parts":[[2024,1,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"160","created":{"date-time":"2023-12-06T16:02:21Z","timestamp":1701878541000,"date-parts":[[2023,12,6]]},"indexed":{"date-time":"2025-08-24T01:44:49Z","timestamp":1755999889770,"date-parts":[[2025,8,24]]},"subject":[],"abstract":"$42","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2812215"}},"subtitle":[],"deposited":{"date-time":"2024-01-17T17:54:33Z","timestamp":1705514073000,"date-parts":[[2024,1,17]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2024,1,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.2310/7750.2010.09053","key":"dbr230019r1","year":"2010","issue":"6","author":"Roosta","volume":"14","first-page":"285","unstructured":null,"article-title":"Skin disease and stigma in emerging adulthood: impact on healthy development.","journal-title":"J Cutan Med Surg","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0205009","key":"dbr230019r2","year":"2018","issue":"9","author":"Davern","volume":"13","first-page":null,"unstructured":null,"article-title":"Stigma predicts health-related quality of life impairment, psychological distress, and somatic symptoms in acne sufferers.","journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.20737","key":"dbr230019r3","year":"2022","issue":"1","author":"Ra","volume":"186","first-page":"191","unstructured":null,"article-title":"More than skin deep: a survey of real-life experiences of acne vulgaris.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.08.014","key":"dbr230019r6","year":"2019","issue":"6","author":"Pearl","volume":"80","first-page":"1556","unstructured":null,"article-title":"Stigmatizing attitudes toward persons with psoriasis among laypersons and medical students.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.5732","key":"dbr230019r7","year":"2021","issue":"4","author":"Creadore","volume":"157","first-page":"392","unstructured":null,"article-title":"Evaluation of stigma toward individuals with alopecia.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-016-0113-x","key":"dbr230019r9","year":"2016","issue":"2","author":"Dréno","volume":"6","first-page":"207","unstructured":null,"article-title":"How people with facial acne scars are perceived in society: an online survey.","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2022.6322","key":"dbr230019r10","year":"2023","issue":"3","author":"Barbieri","volume":"159","first-page":"245","unstructured":null,"article-title":"Double standards and inconsistencies in access to care—what constitutes a cosmetic treatment?","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2019.4818","key":"dbr230019r11","year":"2020","issue":"3","author":"Barbieri","volume":"156","first-page":"312","unstructured":null,"article-title":"Association of race/ethnicity and sex with differences in health care use and treatment for acne.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2022.09.054","key":"dbr230019r12","year":"2023","issue":"3","author":"Nock","volume":"88","first-page":"568","unstructured":null,"article-title":"Racial and ethnic differences in barriers to care among US adults with chronic inflammatory skin diseases: a cross-sectional study of the All of Us Research Program.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"dbr230019r4","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Karras? T. This person does not exist. NVIDIA Research. Accessed July 5, 2019. https://www.thispersondoesnotexist.com","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"dbr230019r5","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Morillo? C. Man wearing blue button up sweater. Accessed May 14, 2019. https://www.pexels.com/photo/man-wearing-blue-button-up-sweater-1181391/","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"dbr230019r8","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Disclosure standards. American Association for Public Opinion Research. Updated April 2021. Accessed August 12, 2023. https://aapor.org/standards-and-ethics/disclosure-standards/#1667933142550-55785157-2071","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2024,1,1]]},"reference-count":12,"published-online":null,"references-count":12,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":9},"unpaywall":{"doi":"10.1001/jamadermatol.2023.4487","is_oa":true,"title":"Evaluation of Stigma Toward Individuals With Acne","updated":"2025-07-30T00:59:52+00:00","published_date":"2023-12-06","best_oa_location":{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10701660","pmh_id":"oai:pubmedcentral.nih.gov:10701660","url_for_pdf":null,"url_for_landing_page":"https://www.ncbi.nlm.nih.gov/pmc/articles/10701660"}}},"created_at":"2025-09-20T13:03:59.836Z","updated_at":"2025-09-20T18:09:19.489Z","tags":[{"paper_doi":"10.1001/jamadermatol.2023.4487","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4487","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4487","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4487","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4487","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4487","tag_type":"sample_size","value":"n=1357","value_numeric":1357},{"paper_doi":"10.1001/jamadermatol.2023.4487","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4487","tag_type":"study_design","value":"Cross-Sectional","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4487","tag_type":"warning","value":"Adjusted coefficients are reported, but the underlying scale meaning and clinical thresholds are not specified in the abstract.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4487","tag_type":"warning","value":"Internet convenience sample (ResearchMatch) may not represent the general US population.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4487","tag_type":"warning","value":"No single primary outcome is specified.","value_numeric":null}],"summaries":{"what_studied":"A cross-sectional internet survey of 1,357 US adults randomized to view one of 12 adult portraits varying by sex, skin tone, and acne severity (none/mild/severe) and then rate social distance and stereotype attitudes toward the pictured person.","key_result":"Compared with no acne, severe acne was associated with lower comfort across scenarios—friendship (adjusted coefficient −0.28; 95% CI −0.47 to −0.10), hiring (−0.33; −0.51 to −0.15), physical contact (−0.26; −0.45 to −0.08), dating (−0.44; −0.74 to −0.14), and posting on social media (−0.50; −0.70 to −0.30)—and with more negative stereotypes (e.g., poorer hygiene −1.04; −1.46 to −0.82; unattractive −0.89; −1.12 to −0.67; unintelligent −0.42; −0.63 to −0.22). Effects on social distance were larger for darker skin.","limitations":"Convenience sample of ResearchMatch volunteers in an internet survey limits generalizability; stimuli were digitally altered stock portraits; outcomes were self-reported attitudes in a cross-sectional design.","practice_takeaway":"Public stigma toward acne—especially when severe and in darker skin—was measurable across social and professional contexts; discuss stigma with patients and support timely access to acne care."}}],"initialOffset":18,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Acne Vulgaris"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Acne Vulgaris"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Acne Vulgaris"}}}]]

Papers